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ABSTRACT 
 
Sujey Carro-Mojica: Gaps in Butadiene Biomarkers of Exposure and Effect  
 (Under the direction of James A. Swenberg) 
 
1,3-Butadiene (BD) is a well-characterized carcinogen that is both an occupational and an 
environmental hazard. BD is metabolized mainly by CYP4502E1 into epoxides, 1,2-
epoxybutene (EB), 1,2:3,4-diepoxybutane (DEB) and 3,4-epoxy-1,2-butanediol (EB-diol). These 
reactive epoxides can react with and form adducts with both hemoglobin (Hb) and DNA. Tumor 
formation in rodents shows species and gender differences, with mice being much more sensitive 
than rats, and female mice being more sensitive than male mice. The weight of evidence 
presented across rodent species suggests there are sex specific differences in BD-DNA 
crosslinks, tumor formation, and mutagenicity and supports the hypothesis that DNA repair 
processes rather than differences in BD metabolism drive tumor formation in a sex dependent 
manner. Combining metabolic biomarkers data with tumor formation presented interspecies 
differences that were difficult to understand. Some of the questions that remained unclear were 
how BD was acting as a carcinogen, how we could use this data, and what these findings meant 
for human risk assessment. To help answer these questions, we looked at BD metabolic 
activation in male and female mice, rats and humans and BD-epoxide induced DNA repair.  
 
 
 iv 
 
 
 
ACKNOWLEDGEMENTS 
 
I extend my gratitude and thanks to my advisor, Dr. James Swenberg, for his continuous 
guidance and encouragement during all these years. I would like to acknowledge all of my 
committee members Drs. Louis Ball, Wanda Bodnar, Avram Gold, and Vernon Walker for their 
active involvement, time, and patience. We are incredibly thankful to Dr. Vernon Walker 
(Lovelace Respiratory Research Institute-Albuquerque, NM and BioMosaics-Burlington, VT) for 
performing animal exposures and facilitating our access to blood samples. Financial support 
provided by HEI, NIH, and the American Chemistry Council was key for the execution and 
completion of this investigation.  As a late bloomer, I want to extend my deepest thanks to the 
entire group of the Swenberg lab. First, Nadia Georgieva and Gunnar Boysen, whom both 
introduced me to the essentials and basics of this project; specially Immunoaffinty enrichment 
coupled to UPLC-ESI+ MS/MS. Second, Narisa Bordeerat and Lina Gao, for investing 
numerous hours, patience, guidance, teaching, project brainstorming and most important, their 
friendships. Third, Wanda Bodnar, Patricia Upton, Leonard Collins and Valerie Afonin, whom 
always found the time and were essential in every step of the way; from sample preparation, 
method development to writing and revision, love and moral support. Patricia Upton, mother of 
all, thank you for everything! Both Dr. Bodnar and Leonard were actively involved in the 
improvement, method development and troubleshooting for HPLC and MS training. Fourth, Jun 
Nakamura whom trained me and taught me invaluable assets and techniques during the DNA 
 v 
 
Damage Response portion of this work. Fifth, I want to extend my warmest thanks to Esra 
Mutlu, April Luke, Jack Ridpath, Irene Abraham, Mitch Troutman, Ben Moeller and Kun Lu. 
Spending so much time together made us family. My eternal love and thanks to both my parents: 
Carmen and Roberto, whom have never given up on me, my ideas or my projects. My greatest 
thanks to Arayoán Vergara-Mojica and Stephanie Vergara-Mojica. They are my brick wall of 
love, support, and inspiration. During this project, they have reminded me every day, with their 
own accomplishments, that we have exerted a positive influence on each other in both our 
careers and lives. Ultimately, I want to dedicate this thesis to my grandfather Feliciano Mojica-
Oferral; this one is for you. I’m sure you will have plenty of time to read it in heaven, just like 
we use to read the newspapers together, every morning, with a really good cup coffee.  
 
 
 
 
 
 
 
 
 
 
 vi 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES……………………………………………………….………………..……xiii 
LIST OF FIGURES………………………………………………………….……...…………..xvi 
LIST OF ABBREVIATIONS……………………………………………………………………xx 
CHAPTER I: BUTADIENE LITERATURE REVIEW…………………………………..………1 
1.0 BACKGROUND……………………………………………………………………………...1 
1.1 History Sources and Exposure……………………………………………...…………1 
1.2 Butadiene Metabolism and Epoxide Generation……………………………………...2 
1.2.1 Mutagenicity of Butadiene Epoxides………………………………………..3 
1.3 Butadiene as a Carcinogen…………………………………………………………….3 
1.3.1 Rodent Carcinogen…………………………………………………………..4 
1.3.2 Human Carcinogen………………………………………………………….5 
1.3.3 Exposure Limits……………………………………………………………11 
 vii 
 
1.4 Butadiene Biomarkers………………………………………………………………..12 
1.4.1 Butadiene Biomarkers of Exposure………………………………………..13 
1.5 Single Immunoaffinity Enrichment Method…………………………………………27 
1.6 Simultaneous Immunoaffinity Enrichment Method…………………………………28 
1.6.1 THB-Val Peptide Standards……………………………...………………..29 
1.6.2 Quantitative Analysis of N-terminal Valine Adducts  
in Mice Exposed to 1,3-Butadiene, Internal Blood Dose  
Formation, and EB-equivalency…………………………………………………30 
1.7 Butadiene DNA Adducts…………………………………………………………….31 
1.7.1 DNA Adducts Introduction………………………………………..…..…...31 
1.7.2 Butadiene Epoxide Specific Guanine Adducts…………………………….32 
1.7.3 Integration of Hemoglobin and DNA Adducts…………………………….33 
1.8 Biomarkers of Effect…………………………………………………………………34 
1.8.1 DNA Adducts and DNA Repair………………….………………………..34 
1.8.2 Damage Induced by DNA Adducts……………………………………..…34 
1.8.3 DNA Damage Response Pathways  
and Butadiene DNA Adducts…………………………………………………….35 
1.8.4 DNA Damage Response and Butadiene Epoxides………………………...40 
 viii 
 
1.8.5 DNA Damage Response and DT40/XTT System…………………………42 
1.9 Research goal and specific aims……………………………………………………..43 
1.10 TABLES……………..…………………………………………...…………….......45 
1.11 FIGURES……………..…………...…………………………………….....…….....48 
REFERENCES…………………………………………………………………………………..51 
CHAPTER II: DIRECT ALKYLATION, CHARACTERIZATION,  
AND QUANTITATION OF BUTADIENE SPECIFIC  
α (1-11) N-TERMINAL THB-VAL HEMOGLOBIN PEPTIDE STANDARDS………………59 
2.1 OVERVIEW………………………..………………………………………………..59 
2.2 INTRODUCTION………………....………………………………………………...60 
2.3 METHODS…………………………………………………………………………..63 
2.3.1 Materials.…………………………………………………………………..63 
2.3.2 Methods.…………………………………………………………………...63 
2.4 RESULTS……………………………………………………………………………66 
2.4.1 Direct alkylation of Hb α (1-11) peptide sequences for 
(1-11) THB-Val peptide standards……………………………………………….67 
2.4.2 Purification of (1-11) THB-Val by LC-ESI+ MS/MS………………..……67 
2.4.3 Characterization of NTV Alkylation by MS/MS  
(b and y fragments)………………………………………………………………68 
 ix 
 
2.4.4 Quantitation of 1-11-THB-Val peptide standards 
by UPLC MS/MS………………………………….......…………………………68 
 
2.5 CONCLUSIONS…………………………………………………………………….69 
2.5.1 THB-Val peptide standards………………………………………………...69 
2.5.2 Incorporation and Application of peptide standards……………………….70 
2.5.3 Achievements………………………………………………………………70 
2.6 ACKNOWLEDGEMENTS………………………………………………………….71 
2.7 TABLES………………..…………………………………………...…………….....72 
2.8 FIGURES……………..…………...……………………………………...…….........80 
REFERENCES…………………………………………………………………………………..86 
CHAPTER III: SIMULTANEOUS QUANTITATIVE ANALYSIS 
OF ALL BUTADIENE N-TERMINAL VALINE ADDUCTS  
IN MICE EXPOSED TO 1,3-BUTADIENE (10 DAYS)  
WITH A RECENTLY IMPROVED METHOD…………………………………………..…….89 
3.1 OVERVIEW……………...................………………………………………….........89 
3.2 INTRODUCTION ...……………….……………………………………………......90 
3.3 MATERIALS AND METHODS………………………………….………..…….….93 
3.3.1 Materials.…………………………………………….……………...……..93 
3.3.2 Methods………………………………………….…………….……..…….94 
 x 
 
3.3.3 Animal and Exposures………………………………..……….……….…..95 
3.3.4 Globin extraction and trypsin hydrolysis…………………………………..96 
3.3.5 Immunoaffinity (IA) enrichment…………………………………………..96 
3.3.6 Liquid chromatography mass spectrometry…………………………….….97 
3.3.7 Method validation………………………………………………………….98 
3.3.8. Mice Internal Blood Dose Formation and EB-Equivalency……………....99 
3.4 RESULTS AND DISCUSSION……………………………………………………101 
3.4.1 A simultaneous IA-UPLC-MS/MS method………………………………102 
3.4.2 Method validation………………………………………………………...102 
3.4.3 Simultaneous Butadiene Hemoglobin  
Adducts in Samples……………………………………………………..............104 
3.5 CONCLUSION……………………………………………………………………..109 
3.6 ADDITIONAL NOTES…………………………………………………………….111 
3.7 ACKNOWLEDGEMENTS………………………………………………………...111 
3.8 TABLES………………..…………………………………………...……………...112 
3.9 FIGURES……………..…………...……………..………………………...…….....121 
REFERENCES…………………………………………………………………………………134 
 xi 
 
CHAPTER IV: IN VITRO ASSESSMENT OF DNA DAMAGE RESPONSE 
TO BUTADIENE EPOXIDES…………………………………………………………………137 
 
4.1 OVERVIEW………………………………………………………………………..137 
4.2 INTRODUCTION………………………………………………………………….138 
4.2.1 Butadiene Epoxides………………………………………………………138 
4.2.2 BD-Epoxide DNA-Adducts………………………………………………138 
4.2.3 BD-Epoxides Genotoxicity……………………………………………….140 
4.2.4 Gaps in Knowledge in DNA Repair……………………………………...141 
4.2.5 DNA Damage Response XTT-DT40 System…………………………….142 
4.3 MATERIALS AND METHODS…………………………………………………...143 
4.3.1 Materials………………………………………………………………….143 
4.3.2 Methods…………………………………………………………………...144 
4.4 RESULTS AND DISCUSSION……………………………………………………146 
4.4.1 EB-diol Isomers [Limitations]……………………………………………146 
4.4.2 Butadiene Epoxides DNA Damage Response……………………………147 
4.5 CONCLUSIONS…………………………………………………………………...164 
 xii 
 
4.6 ACKNOWLEDGEMENTS………………………………………………………...167 
4.7 TABLES………………..…………………………………………...……………...168 
4.8 FIGURES……………..……………...……………………………………...……...175 
REFERENCES…………………………………………………………………………………193 
CHAPTER V: CONCLUSIONS AND FUTURE DIRECTIONS……………………………..200 
5.1 CONCLUSIONS…………………………………………………………………...200 
5.1.1 Introduction……………………………………………………………….200 
5.1.2 Contribution of this Thesis………………………………………………..201 
5.1.3 Thesis Chapters…………………………………………………………...202 
5.2 FUTURE DIRECTIONS…………………………………………………………...209 
REFERENCES…………………………………………………………………………………210 
 
 
 
 
 
 
 
 xiii 
 
LIST OF TABLES 
 
Table [1.1]: Albertini et al 2001 (Albertini I):  
Analysis for urine metabolites by group in occupationally exposed workers to BD………….…45 
Table [1.2]: Albertini et al 2007 (Albertini II): 
Urine metabolites by group in occupationally exposed workers to BD……………...……….....46 
Table [1.3]: DT40 wt and DT40 mutant cells……………………………………………………47 
Table [2.1]: Observed EB-diol + (1-11) Peptide reaction                                                                             
mixture products for all three species and their m/z.………………..….…………………..……72 
Table [2.2]: (1-11) THB-Val Peptide Standards                                                              
Chromatographic Purification Conditions……………………………………………………….73 
Table [2.3]: Protein Prospector b and y fragments for                                                                       
Mouse α (1-11) peptide and Mouse α (1-11) THB-Val peptide standard..…………..………….74 
Table [2.4]: Protein Prospector b and y fragments for                                                                             
Rat α (1-11) peptide and Rat α (1-11) THB-Val peptide standard…...….………………………75 
Table [2.5]: Protein Prospector b and y fragments for                                                                                    
Human α (1-11) peptide and Human α (1-11) THB-Val peptide standard...…………………….76 
Table [2.6]: Amino acids Used for Peptide Standard Quantitation………………………...…....77 
Table [2.7]: UPLC-MS/MS Reference Table for CID energy [eV]                                                       
and MS/MS transitions of selected amino acids used for peptide standard                                                   
quantitation of Human, Mice, and Rat Hb α (1-11) THB-Val peptide standards                                        
using Norleucine as Internal Standard…………………………………………………………...78 
Table [2.8]: (1-11) THB-Val peptide standards Amino acids                                                       
Reference Factors (RF) used for Quantitation and                                                                                
Final Measured Concentrations………………………………………………………………….79 
 xiv 
 
Table [3.1]: Molecular weights and m/z (1-11) BD-NTV                                                               
peptide standards: pyr-Val, HB-Val and THB-Val…………………………………………..…112 
Table [3.2]: Mice NTV Neat Peptide Standard Recovery                                                                 
on BD Triple IA Columns………………………………………………………………………113 
Table [3.3]: Hemoglobin Adducts (pmol/g) of B6C3F1 Mice                                                       
Exposed to Butadiene for 10 days……………………………………………………………...114 
Table [3.4]: Hemoglobin Adduct Formation Ratio                                                         
(Adducts/ppmBD) in B6C3F1 Mice Exposed to Butadiene for 10 days……………………….115 
Table [3.5]: Hemoglobin Adducts (pmol/g) of F344 Rats                                                               
Exposed to Butadiene for 10 days……………………………………………………………...116 
Table [3.6]: Hemoglobin Adduct Formation Ratio                                                         
(Adducts/ppmBD) in F344 Rats Exposed to Butadiene for 10 days…………………………...117 
Table [3.7]: Hemoglobin Adducts (pmol/g) and Fold Differences                                                            
in BD-adducts in B6C3F1 Mice Exposed to Butadiene for 10 days…………………………...118 
Table [3.8]: Hemoglobin Adducts Formation Ratio                                                         
(Adducts/ppmBD) and Fold Difference in B6C3F1 Mice vs F344 Rats                                              
Exposed to Butadiene for 10 days……………………………………………………………...119 
Table [3.9]: Individual estimated Butadiene-epoxides                                                                          
doses in blood [nMh/ppmh] and the EB-equivalency for                                                                            
Female and Male B6C3F1 Mice exposed to Butadiene (10 days)……………………………...120 
Table [4.1]: Relative LD50 of EB-diol in DT40 wt and DT40 mutants………………………..168 
Table [4.2] Relative LD50 Sensitivity Ranges…………………………………………………169 
Table [4.3] Relative Sensitivity of (a) Base Excision Repair                                                                     
and (b) Nucleotide Excision Repair to Butadiene Epoxides……………………………………170 
Table [4.4] Relative Sensitivity of (a) Mismatch Repair                                                                           
and (b) Translesion Synthesis to Butadiene Epoxide…………………………………………..171 
 xv 
 
Table [4.5] Relative Sensitivity of (a) Fanconi Anemia                                                                         
and (b) Homologous Recombination to Butadiene Epoxides…………………………………..172 
Table [4.6] Relative Sensitivity of (a) Non-Homologous End Joining                                                   
and (b) Sensors and Cell Cycle Check Points to Butadiene Epoxides…………………………173 
Table [4.7] DNA Damage Response in DT40 Cells                                                                                                            
with a Relative LD50 < 0.50……………………………………………………………………174 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi 
 
LIST OF FIGURES 
 
Figure [1.1]: Butadiene Metabolism and Fate……………………………………………...……48 
Figure [1.2]: Survival Adjusted Tumor Rates of Neoplasms  
in Female and Male B6C3F1 Mice Exposed to 1,3 Butadiene via  
Inhalation (adapted from Melnick, 1993)………………………………………………………..49 
Figure [1.3]: Butadiene Hemoglobin Adducts; Metabolism  
and NTV Adducts………………………………………………………………………………..50 
Figure [2.1]: BD metabolism and formation of N-terminal valine adducts……………………...80 
Figure [2.2]: Schematic representation of 1-11 THB-Val  
standard peptides. (1-11) NTV Peptides sequences were mixed  
with EB-diol in a 1:20 ratio……………………………………………………………………...81 
Figure [2.3]: MS/MS of Purified (1-11) NTV Mouse labeled  
peptide from Reaction Mixture…………………………………………………………………..82 
Figure [2.4]: Full Scan Spectrum of (1-11) NTV Mouse labeled  
peptide by EB-diol in a 1:20 ratio………………………………………………………………..83 
Figure [2.5]: Schemes of b and y fragments and Fragmentation  
Spectrum of Rat THB-Val Internal Standard…………………………………………………….84 
Figure [2.6]: Schematic Representations of Amino-acid Quantitation…………………………..85 
Figure [3.1]: BD metabolic activation and formation of BD reactive 
epoxides…………………………………………………………………………..…………….121 
Figure [3.2]: BD metabolism and formation of N-terminal valine adducts…………….………122 
Figure [3.3]: Calibration Curve for N-terminal valine adduct THB-Val……………………….123 
 xvii 
 
Figure [3.4]: Ion chromatogram of THB-Val adduct in  
B6C3F1 Mice exposed to BD and its corresponding internal standard………………..……….124 
Figure [3.5]: Exposure response curves of THB-Val adducts  
formation (pmol/g) in B6C3F1 mice exposed to BD for 10 days……………...……………….125 
Figure [3.6]: Exposure response curves of THB-Val adducts  
formation (pmol/g) in F344 rats exposed to BD for 10 days…………………….……………..126 
Figure [3.7]: Exposure response curves of THB-Val adducts  
formation (pmol/g) in Rodents exposed to BD for 10 days………………………………...…..127 
Figure [3.8]: Exposure response curves of HB-Val, pyr-Val  
and THB-Val adducts formation (pmol/g) in B6C3F1 mice exposed  
to BD for 10 days…………………………………………………………………...…………..128 
Figure [3.9]: Exposure response curves of HB-Val, pyr-Val,  
and THB-Val adducts formation (pmol/g) in F344 rats exposed 
to BD for 10 days………………………………………………………………………….……129 
Figure [3.10]: THB-Val Adduct Formation Ratio ([pmol/g]/[ppmBD])  
in Rodents Exposed to BD for 10 days…………………………………………………………130 
Figure [3.11]: Hemoglobin Adducts Formation Ratio ([pmol/g]/[ppmBD])  
in Rodents Exposed to BD (10 days)…………………………………………………….……..131 
Figure [3.12]: IBD: Internal Blood Doses Formation [nMh/ppmh]  
in Female and Male Mice Exposed to Butadiene by Inhalation (10 days)……………………..132 
Figure [3.13]: EB-equivalency of Male and Female Mice  
Exposed to Butadiene (10 Days)…………………………………………………………….….133 
Figure [4.1] Schematic Representations of the DT40/XTT Method:  
(a) Schematic representation of 24-well plate format for doses, controls and blanks.  
(b) Schematic representation of the general method: exposures  
of DT40wt and DT40 mutants, and XTT dye incubation/quantitation…………………....……175 
 
 xviii 
 
Figure [4.2] Cytotoxicity of Butadiene epoxide  
EB-diol isomers (2R,3S, 2S,3R, 2S, 3S and 2R,3R) in both  
(a) DT40wt cells and (b) TK6 cells………………………………………….…………………176 
Figure [4.3] Sample Graphs from Dose-Response Curves for  
EB-diol exposures of DT40wt against DT40 mutants: 
(a) Sensors: R17-/- and R9-/-  
(b) Translesion Synthesis: Polη-/-, Polк-/-, and REV1-/- 
(c) BRCA proteins: BRCA1-/- and BRCA2-/-…………………………………………….....…...177 
Figure [4.4]: EB-diol Relative LD50 in BER Repair DT40 mutants…………………………..178 
Figure [4.5]: EB-diol Relative LD50 in NER Repair DT40 mutants…………………………..179 
Figure [4.6]: EB-diol Relative LD50 in MMR Repair DT40 mutants…………………………180 
Figure [4.7]: EB-diol Relative LD50 in TLS Repair DT40 mutants………...…………………181 
Figure [4.8]: EB-diol Relative LD50 in HR Repair DT40 mutants…………………………….182 
Figure [4.9]: EB-diol Relative LD50 in FA Repair DT40 mutants…………………………….183 
Figure [4.10]: EB-diol Relative LD50 in NHEJ Repair DT40 mutants………………………..184 
Figure [4.11]: EB-diol Relative LD50 in Cells and Cell Cycle  
Checkpoints and Sensor DT40 mutants………………………………………………………...185 
Figure [4.12]: EB-diol DNA Damage Response as the  
Relative LD50 of DT40 mutants to DT40 wt…………………………………………………..186 
Figure [4.13]: EB, DEB and EB-diol monoadducts or AP-sites  
DDR via TLS bypass…………………………………………………………………………...187 
Figure [4.14]: DEB and EB-diol crosslink DDR of FA  
ICL recognition, and ICL un-hooking………………………………………………………….188 
 
 xix 
 
Figure [4.15]: DEB and EB-diol crosslink DDR of FA and  
TLS proteins convergence into FA-TLS coupled repair………………………………………..189 
Figure [4.16]: DEB and EB-diol crosslink DDR of TLS proteins from  
FA-TLS coupled repair bypassing the ICL left over lesion…………………………………….190 
Figure [4.17]: EB-diol crosslink DDR of NER proteins participating  
in the excision of the ICL left over………………………………………………..……………191 
Figure [4.18] Diagram of HR in the Repair of DSB created  
by FA repair in EB-diol crosslinks……………………………………………………………..192 
 
 
 
 
 
 
 
 
 
 
 
 xx 
 
LIST OF ABBREVIATIONS 
 
Ade   Adenine 
ADH   Alcoholdehydrogenase 
ADP   Adenosine diphosphate 
AGT   O6-alkylguanine DNA alkyltransferase 
AP-site  apurinic/apyrimidinic site or abasic site. 
ATP   Adenosine triphosphate 
BD   1,3-Butadiene 
BDM   Butadiene monomer  
BER   Base Excision Repair 
BLM   Bloom Syndrome RecQ Like Helicase 
BRCA   Breast Cancer Protein: 
BRCA1  Breast Cancer 1 
BRCA2  Breast Cancer 2 
CML   Chronic myelocytic leukemia 
CLL   Chronic lymphocytic leukemia 
CSA & CSB  Cockayne syndrome factors A and B 
CtIP   C terminal interacting protein 
DBS   Double strand breaks 
DDB   DNA Damage Binding Protein: 
DDB1   Component 1 
DDB2   Component 2 
 xxi 
 
DDR   DNA damage response 
DEB   1,2:3,4-diepoxybutane 
DNA2   DNA 2 Nuclease 
DPC   DNA Protein-crosslink 
DT40   Chicken B-lymphocyte cell line 
EB   1,2-epoxybutene 
EB-diol  3,4-epoxy-1,2-butanediol 
EH   Epoxide hydrolase 
ERCC    Excision Repair Cross Complementation Group 
EXO1   Exonuclease 1 
GADPH  glyceraldehyde 3-phosphate dehydrogenase 
GG-NER  Global Genome Nucleotide Excision Repair 
GSH   Glutathione 
GST   Glutathione-S-transferase 
Gua   Guanine 
Hb   Hemoglobin 
HB-Val  N-(2-hydroxy-3-butenyl)-valine 
HB-Ade:  
HB-Ade I  N-1-(2-hydroxy-3-buten-1-yl) adenine 
HB-Ade II  N-1-(1-hydroxy-3-buten-2-yl) adenine 
HB-Ade III  N-3-(2-hydroxy-3-buten-1-yl) adenine 
HB-Ade IV  N-3-(1-hydroxy-3-buten-2-yl) adenine 
 
 xxii 
 
HB-Gua: 
HB-Gua I   N-7-(2-hydroxy-3-buten-1-yl)guanine 
HB-Gua II  N-7-(1-hydroxy-3- buten-2-yl)guanine 
HMVK  Hydroxymethylvinylketone 
HPLC   High pressure liquid chromatography 
HR   Homologous Recombination 
hHR23B  Human Homolog Rad23 B 
IA   Immunoaffinity 
IARC   International Agency for Research on Cancer 
IBD   Internal Blood Dose 
ICL   Interstrand crosslinks 
IDLs   Insertion/deletion loops 
LC-MS/MS  Liquid chromatography tandem mass spectrometry 
LD50   Lethal Dose 50% 
LOD   Limit of Detection 
LOQ   Limit of Quantitation 
M1   1,2-dihydroxy-4-(N-acetylcysteinyl)-butane 
M2   1-(N-acetylcysteinyl)-2-hydroxy-3-butene 
M3   1,3,4-trihydroxy-2-(N-acetylcysteinyl)-butane 
MMR   Mismatch Repair  
MF   Mutant frequencies 
MOA   Mode of Action 
MPG   Methyl purine glycosylase 
 xxiii 
 
MRN complex Mre11/Rad50/Nbs1: 
Mre11   Miotic Recombination 11 Protein 
Nbs1   Nijmegen Breakage Syndrome-1 Protein 
MS/MS  Tandem mass spectrometry 
MSH   Mut S Homolog 
N1-THB-A  N1-(2,3,4-trihydroxybut-1-yl)adenine 
NER   Nucleotide Excision Repair 
NHEJ   Non Homologous End Joining 
NIOSH  National Institute for Occupational Safety and Health 
NTP   National Toxicology Program 
NTV   N terminal Valine 
OSHA   United States Occupational Safety and Health Administration 
PARP-1  Poly [ADP-ribose] polymerase 1 
PCNA   Proliferating Cell Nuclear Antigen  
PEL   Permissible exposure limit 
PFPTH  Pentafluorophenylthiohydantoin 
Pol    Polymerase  
pyr-Val  N, N-(2, 3-dihydroxy-1, 4-butadiyl)-valine 
RFC   Replication Factor C 
RNAP2  Ribonucleic Acid Polymerase II 
RPA   Replication Protein A 
SBR    Styrene-butadiene rubber 
STEL   Short-term exposure limit 
 xxiv 
 
TC-NER  Transcription Coupled Nucleotide Excision Repair 
TFIIH   Transcription Factor II Human 
THB-Ade:  
N3 THB-Ade   N-3-(2ʹ,3ʹ,4ʹ-trihydroxybut-1ʹ-yl)-adenine 
N6 THB-Ade   N-6-(2ʹ,3ʹ,4ʹ-trihydroxybut-1ʹ-yl)-adenine 
THB-Gua  N-7-(2’,3’,4’-trihydroxybut-1’-yl)guanine 
THB-Val  N-(2,3,4-trihydroxybutyl) valine 
TLS   Translesion Synthesis 
TWA   Time-weighted average 
U.S. EPA  U.S. Environmental Protection Agency 
UV-DDB  Ultra-Violet Damage Deoxyribonucleic Acid Binding Protein B 
WHO   World Health Organization 
XPC   Xeroderma pigmentosum Complementation Group 
XPG   Xeroderma pigmentosum Group  
XRCC   X-Ray Repair Cross Complementing Protein  
XTT   sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-   
   [(phenylamino)-carbonyl]-2H-tetrazolium inner salt 
 
1 
 
 
 
CHAPTER I: BUTADIENE LITERATURE REVIEW 
1.0 BACKGROUND 
1.1 History Sources and Exposure 
1,3 Butadiene (BD) was first isolated in 1863 by the French chemist Caventou, but not 
identified until 1886, by Armstrong, and finally polymerized by Lebedev in 1910. Initially, the 
industry of BD was mainly controlled by the British government and primarily derived from 
natural rubber. BD production dependence on its natural source became apparent, propelling its 
synthetic production worldwide. In 1930, the Soviet Union had the first pilot BD production 
plant, using ethanol from potatoes. In 1936, its manufacture evolved, using petroleum as a 
source, and producing poly-butadiene (PBD). It was not until 1940, that the Soviet Union turned 
into the largest producer of BD, followed by Germany and the US. As of today, BD continues its 
production for several uses that include car and truck tires in its majority, as well as an additive 
in the manufacture of plastics, synthetic rubbers, resins, and a small portion designated to the 
production of nylon. BD is also indirectly generated as a by-product of ethylene manufacture, as 
a component of cigarette smoke, and also found as part of vehicle exhaust emissions. 
Alternatively, in nature, BD may also be released from the burning of natural wood in forest fires 
and or homes that depend on wood stove burners.  
BD is a volatile organic compound (VOC), whether the source is natural or 
anthropogenic, its properties are the same. BD is a flammable gas with gasoline like odor, 
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composed of 4 carbons in the form of [CH2=CH-CH=CH2]. It has a molecular mass of 54.09 and 
Chemical Abstracts Service (CAS) number. 106-99-0. Because BD is a gas, the primary route of 
exposure is via inhalation with the general population exposed to it, at different levels. For 
instance, BD has been identified to be present at 0.001-0.01 ppm in urban air, 0.02-0.06 ppm 
from motor vehicle emissions, and ~2 ppm BD in occupational settings. Also, BD is a major 
component of cigarette smoke  with 0.4mg per cigarette and with the highest cancer risk index. 
The two largest groups of anthropogenic BD exposure are occupationally exposed workers, and 
cigarette smokers. 
1.2 Butadiene Metabolism and Epoxide Generation 
BD is inhaled into the lungs and enters the bloodstream through passive diffusion. Those 
organs actively involved in BD metabolism include liver, lungs, and kidneys. BD absorption, 
distribution, and metabolic activation have been shown to lead to the generation of three reactive 
epoxides, which can ultimately covalently bind and modify both proteins and DNA or be 
excreted in urine. 
The first step of BD activation is the oxidation of BD into the first monoepoxide, 1, 2-
epoxy-3-butene (EB) by enzymes CYP2E1 and CYP2A6. The second step is further oxidation of 
EB, into the diepoxide: 1,2;3,4 diepoxybutene (DEB) by enzymes CYP2E1 or CYP3A4. Both 
EB and DEB can undergo hydrolysis and form butene-diol (BD-diol) from EB or lead to the 
formation of the second mono epoxide, 1,2-epoxy-3,4-butanediol (EB-diol) from DEB, by the 
enzyme epoxyhydrolaze (EH). Ultimately BD-diol can be further oxidized into more EB-diol. 
[Figure 1.1] 
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1.2.1 Mutagenicity of Butadiene Epoxides  
In human lymphoblastoid Tk6 cells, and rats and mice T-cells individual mutagenic potency 
for each of these BD-epoxides can vary up to 200-fold (Walker, 2009, Meng, 2007, Meng, 
2007b). Results from T-cloning assay from mice and rats exposed to BD showed that BD 
expoxides were most to least mutagenic, in the following order DEB > EB > EB-diol (Walker, 
2009). There is also an inversely proportional relationship across BD-epoxides with respect to 
mutagenicity and thier abundance of generation. The most mutagenic epoxides are the least 
abundant (DEB > EB > EB-diol) and the least mutagenic epoxides are the most abundant (EB-
diol > EB > DEB) both in vitro and in vivo (Swenberg 2011, Meng, 2010). When looking closer 
at gender and species, Meng has shown that the mutagenic response in T-cells to BD is highest in 
female followed by male mice then female rats and male rats (Meng 2007b) supporting BD as a 
stronger carcinogen for mice than rats. These observations are consistent with EB, DEB and EB-
diol alkylations in both DNA, and more specifically, the N-terminal Valine (NTV) of 
hemoglobin (Hb) upon BD exposure (Moll 1999). When looking at biomarkers of exposure and 
effect, earlier reports have identified species differences in the formation of DNA and Hb 
adducts endpoints; ultimately indicating that BD metabolic activation is species dependent as 
evidenced by biomarkers of exposure. When considering biomarkers of effect, the biggest 
difference in mutagenicity lies between DEB and EB-diol with DEB being almost 200 times 
more mutagenic.  
1.3 Butadiene as a Carcinogen  
BD has been classified as “known human carcinogen” by IARC, NTP and EPA. 
Exposure to BD results in multi-site carcinogenesis in rodents (Melnick, 1993, Owen, 1987) and 
an increased incidence of leukemia and lymphoma in occupationally exposed workers (IARC, 
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2008, NTP, 2005). Cumulative evidence has been presented from both multi-species/multi-site 
tumor studies and human occupational epidemiological data (IARC, 2008, U.S. EPA, 2002, 
NTP, 2005, ASTDR, 1993). BD induces genotoxic effects through its epoxides, and this has 
been associated with cancer induction by a mutagenic mode of action (MOA) (Walker, 2009, 
Kirman, 2010), ultimately resulting in multi-species carcinogenicity. 
1.3.1 Rodent Carcinogen 
1.3.1.1 Acute Studies  
One of the earlier studies was performed by Carpenter in 1944. Here, he examined the 
lethality of BD. Acute exposure data in humans was limited, however, men exposed for 6-8 
hours at 8,000 ppm presented no effects. Shugaev performed experiments in laboratory animals 
and humans in 1968 and 1969. Humans exposed to 10,000 ppm BD for 5 minutes presented 
effects that ranged from irritation and dryness of the upper respiratory tract to increased heart 
rate without affecting blood pressure of respiration (Shugaev, 1968). In rabbits exposed to 
250,000 ppm BD via inhalation death was noted after 30 minutes. At almost half the exposure 
concentration used on rabbits, (122,000 and 129,000 ppm), BD caused 50% lethality (LC50) in 
rats and mice exposed for 4 and 2 hours respectively (Shugaev, 1969). Acute exposures in the 
literature are observed to drop from being performed above 10,000 ppm, to become below this 
concentration.   
Several experiments followed these acute exposures, particularly in rodents, and these 
studies were important in identifying organ targets of toxicity. However, the historical acute 
exposure data indicated that dose-response assessment for inhalation exposures needed to be 
considered, placing particular importance on long term exposure at even lower levels. Most of 
these acute experiments did not provide evidence that the observed differences were attributable 
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to species differences in the metabolism of BD. Therefore subsequent studies focused  on the 
evaluation of chronic BD-exposures at lower levels. 
1.3.1.2 Chronic Studies  
NTP and EPA presented three different long-term exposure BD inhalation rodent studies 
that have served as proof that BD is a rodent carcinogen (NTP, 1984, Melnick, 1990, NTP, 1993, 
U.S. EPA, 1985, Owen, 1990). Levels of BD exposure via inhalation in B6C3F1 mice studies 
include the following concentrations (1st  study): 62.5ppm, 625ppm and 1,250ppm (NTP, 1984), 
and (2nd study): 6.25ppm, 20ppm, 200ppm and 625ppm (NTP, 1993). F344 rats have only one 
study to which exposure was at high concentrations (3rd study) at 1,000ppm and 8,000pppm (U. 
S. EPA, 1985). The first study with BD-exposed mice had to be terminated early due to observed 
tumor formations at higher exposure levels (625ppm and 1250ppm). Accounting for survival 
adjusted tumor rates of neoplasms, results indicated that the organ with the higher tumor rates 
was the lungs.  However, when comparing lung to liver tumor rate, there was a significant 
difference in those BD levels of exposure that induced tumors. The lowest levels that presented 
increased tumors rates of neoplasms at more than one site were between BD exposures of 
6.25ppm for female mice and 20ppm for male mice. Particularly, female mice had tumors in lung 
and livers at both 6.25ppm and 20ppm respectively, whereas, in male mice, the same tumors 
were formed but at 62.5 ppm and 200ppm. Overall, this represents a 10-fold sex-related 
difference amongst tumor formation on the same organs for the same species. The only other 
parallel 2 year long-term study in rodent exposure tested BD via inhalation in rats but did not 
consider those lower range levels of exposure as those performed for mice. In rats, the increase 
in tumor formation was only present when exposed to BD at 1,000 ppm. The first general 
observation from these 2 year rodent bioassays for carcinogenicity was that BD demonstrated to 
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be a tumorigen of weak influence in rats and strong influence in mice. [Figure 1.2]  
1.3.2 Human Carcinogen 
BD classification as a carcinogen is extensively documented by epidemiologic studies of 
workers in the BD rubber industry exposed to both the BD monomer (BMD) or co-exposed to 
styrene (styrene butadiene rubber; SBR). The following discussion summarizes those key 
findings as well as any limitations in studies that need to be considered when interpreting the 
data. 
The first study that considered BD co-exposure was performed in Texas (Meinhardt 
1982). Two SBR plants A and B, measured exposure levels at 1.2ppm and 13.5ppm respectively. 
The ratio of mortality amongst workers to the average US value (standardized mortality ratios or 
SMR) was the highest for Lymphosarcoma (1.7 SMR) but the mortality rate from all cancers was 
not elevated. Because there were two leukemia deaths reported from employees of these plants, 
BD and mortality from lymphohematopoietic cancers (LHC) became a highlight then. Results, 
however, showed that LHC was only elevated for plant A, which had the lowest BD exposure. In 
addition, the period from which these workers were employed until they developed Leukemia (3-
4 years) was too short to be solely attributed to BD exposure.  
In 1987, Downs et al. recognized that in previous studies, those workers from SBR had 
multisite cancer excess, but it was still inconclusive if BD was the etiological culprit; giving rise 
to the first BMD specific cohort. Here, cause-specific mortality was examined across 2,586 male 
workers employed for at least six months between 1943 and 1979. Findings suggested that BD 
was associated but not solely responsible for the increases in the SMRs, for Lymphosarcoma and 
Reticulum cell sarcoma (SMR 2.4). One limitation merits mentioning however, subjects were 
divided into routine, non-routine and low-exposure groups, the SMRs were inconsistent when 
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compared amongst each other. The authors couldn’t conclude that BD exposure was directly 
responsible for this increase in deaths (Downs, 1987).  
Divine and Hartman examined the same BMD facility that now employed 2,800 male 
workers, again for a minimum of 6 months in an aging cohort that extended from 1943 until 
1996, with a final follow up in 2001. A total of three analysis of this cohort (Divine, 1990, 
Divine, 1993 and Divine & Hartman, 1996) showed no increase in most cancers (SMR 0.9). The 
most striking difference was a significant elevation for deaths from LHC’s (SMR 1.5) due to an 
increase in deaths from Lymphosarcoma (SMR 1.9), Leukemia (SMR 1.1) and Non-Hodgkin’s 
Lymphoma (SMR 1.7). The last and fourth study published by the same authors in 2001 included 
an additional five-year follow-up after the plant closed due to its sale in 1996 (Divine & 
Hartman, 2001).  Similar results were found confirming no increase in most cancers (SMR 0.9). 
A similar observation found an increase in deaths from LHC (SMR 1.4), Leukemia (SMR 1.3) 
and Non-Hodgkin’s Lymphoma (SMR 1.5). In this final follow-up they concluded that for the 
totality of this cohort, LHC were elevated specifically in short-term workers employed before 
1950 (Divine & Hartman, 2001). These findings coincide with observations from all three 
previous cohorts where both SMRs for Leukemia and Lymphosarcomas were specifically found 
to be higher in workers that were employed for less than ten years when compared to those that 
were employed for more than ten years for Leukemia (1.6 fold and 3.3-fold respectively). 
Despite this, the overall Relative Risks (RR) for LHC were 1.0, representing no increase in risk 
with increased BD exposure.  
Epidemiological data on BD co-exposure presented a robust dataset with 12,110 
employees from 8 plants (7 in North America and 1 in Canada) that included subjects from both 
SBR and BMD industries with one or more year of employment. Significant observations for this 
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cohort are here reviewed using a total of four publications:  Matanoski & Schwartz, 1987, 
Matanoski, 1989, Matanoski, 1990, and Santos-Burgoa, 1992. It’s important to note most 
exposure data was obtained from personal monitors.  However, some of this exposure data had 
no values and was therefore estimated from previous exposures obtained from representatives of 
the plant, making some of this exposures relative and not actual.  
Matanoski found that mortality rates for all cancers (SMR 0.8) and LHCs (SMR 1.0) 
were not significantly elevated. Duration of employment and or exposure category subdivision 
by production process did not affect mortality rates. However, when workers were subdivided by 
race, there was a distinct 4.9-fold difference in mortality for leukemia for blacks (SMR 6.6) 
when compared to whites (SMR 1.3). Both Matanoski and Santos-Burgoa then proceeded to 
incorporate the use of a substantial control group from all plants to match them to those exposed 
workers using specific variables. Santos-Burgoa identified risks depending on the intensity of the 
exposure (ranks 0-10) and the duration of employment in an exposed job. It’s noteworthy to 
consider that the cases and controls were not perfectly matched on duration of employment, but 
the periods were similar. The excess risk of Leukemia was associated with BD, even when 
correcting for styrene exposure. Using odds ratio (OR) to compare controls with cancer 
development, they found that the highest correlation between exposure and disease for Leukemia 
was BD (OR 7.6) with a 2.6-fold higher OR than styrene (OR 2.9). Styrene exposure was 
associated with Lymphosarcoma and Myeloma, whereas BD exposure was associated with 
Leukemia and Hodgkin’s disease.  
Delzell and colleagues compiled data from a total of 15,649 workers who were studied in 
1995 and followed up in 1996 in facilities located both in US and Canada (Delzell, 1995, 
Delzell, 1996). To date, this study ranks as the second most comprehensive dataset of 
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occupationally exposed workers to SBR that extended from 1943 to 1992. The cohort includes 
data from previously discussed facilities and from Meindhart, Matanoski, and Santos-Burgoa et 
al. The limitations of the study were incomplete identification of workers who terminated their 
employment before 1950, and lack of medical records that could confirm if the death that was 
certified due to leukemia and/or other lymphopoietic cancers. Mortality rates for all death causes 
and cancers had SMR’s similar to controls irrespective of race (whites or blacks), hourly/salary 
status, duration of employment and/or period since hire. However, when focusing on certain 
parameters of the cohort groups, they found a strong overall positive relationship between 
employment in these SBR plants and leukemia mortality (SMR 1.3). The subgroup with most 
significantly elevated SMR’s were hourly workers with long duration of employment (10 years 
worked and age 20+ years at the time of hire). Lymphosarcoma was elevated in white males who 
died after 1985 (SMR 2.8) whereas other LHC’s were prominent in blacks (SMR 1.4). When 
looking at Leukemia only, the subgroup of hourly black workers had mortality ratios (SMR 2.3) 
1.8-fold greater than that of whites (SMR 1.3). The overall association for Leukemia was even 
more underlined when they worked for 10+ years and had 20 years or more since hire as hourly 
workers (SMR 2.2) and it was here where there was a 2.3 fold difference amongst races (SMR’s 
whites 1.9 and blacks 4.4). The largest Leukemia excess was primarily found in those deaths 
after 1985 (SMR 1.9), in subjects that were 65 years old or younger (SMR 1.8), and in subjects 
that were hired between 1950-1959 (SMR 2.0). Moreover, the greatest increase in Leukemia 
mortality was identified in the group of workers that were 20-29 years since hire and that worked 
for 10+ years (SMR 3.2). This study presented that the strongest association between BD 
exposure and Leukemia was in hourly subjects with long duration of employment and with 20+ 
years when hired, specifically for subjects in process groups of polymerization (SMR 2.5), 
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coagulation (SMR 2.5), labor (SMR 2.2), maintenance labor (SMR 2.7) and laboratory (SMR 
4.3) jobs.  
In 2015 Sathiakumar presented the latest and most updated cohort with 11 years of 
mortality data through 2009 that now includes an update that now includes 16,411 BD exposed 
workers that worked for at least one year from 1944 (Sathiakumar, 2015). Results indicated a 
positive exposure-response relationship between BD cumulative exposure and Leukemia. Using 
Cox regression analyses, 10 models were employed, and for all, the exposure-response trend for 
BD-ppm-years and Leukemia was not only positive but also statistically significant. Also, 
models adjusted only for age had a better fit than models that adjusted for age, year of birth, race 
and plant. When closely looking at the subset group by year of hire, only subjects that were 
employed before 1960 had both positive and statistically significant values in the exposure-
response trend between BD-ppm-years and leukemia. Within the same group, all models also 
identified Non-Hodgkin’s Lymphoma to be positively associated with no statistical significance 
and no association with Multiple Myeloma, however Lymphoma/Lymphosarcoma was not 
evaluated.  
Despite the number of epidemiological exposure studies, the one that presents the most 
consistent data to date, with the largest population of exposed workers reviewed and longer 
terms of BD exposure, was the latter: University of Alabama at Birmingham cohort. When 
summarizing all cohort findings, we agree on the following consistent observations. BD-exposed 
workers present a deficit in overall cancer mortality. In most of the cohorts that analyzed 
exposures before 2000, there was an excess of LHC’s mortality when compared with the average 
population in long term exposed workers. Length of employment and the era in which the 
workers were employed had a strong influence in LHC’s as an outcome, particularly for exposed 
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workers hired at ages that ranged between 20-29 years old that worked around 1950-1960 and 
died after 1985. This suggest that the approximate time for the induction of LHC’s upon 
exposure to BD via monomer or both exposed the BD-styrene is ~35-40 years.  
The observation of increased risk for Leukemia cannot exclude styrene as a cofounding 
factor, since SBR plant employees are exposed to both BD and styrene. In this respect, we must 
consider that although the models that have been applied to those cohorts with workers employed 
in SBR industries presenting a high risk of Leukemia, the exposure to the BD and styrene in SBR 
facilities is not mutually exclusive and the combination does play an influential role in the 
increase of risk for this category. Moreover, we want to reiterate that 
Lymphoma/Lymphosarcoma risk in BDM industries is an exclusive hallmark when looking at 
exposure to the BD monomer. 
1.3.3 Exposure Limits 
All previously discussed epidemiological studies that have analyzed the risk of BD-
exposure in humans as a carcinogen have served as means to shape industrial limits to which 
BD-workers can perform their tasks in these plants. In the publication of Sathiakumar et al. in 
2015 they state that the historical time-weighted averages (TWA) were around 10 ppm in the 
1940s to the early 1970s and declined to about 2 ppm in the 1980s. Currently, there are four 
different set exposure levels for BD-workers and three organizations that regulate them. Levels 
established by OSHA include the Permissible Exposure Limit (PEL) and 15 minute Short-Term 
Exposure Limit (STEL) which are 1ppm and 5ppm respectively. The other two organizations are 
the National Institute for Occupational Safety and Health (NIOSH) and American Conference of 
Governmental and Industrial Hygienist (ACGIH). NIOSH recommends an exposure limit for an 
8 hour shift (TWA) of 1ppm. ACGIH has set a Threshold Limit Value (TLV), or a maximum 
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level of everyday exposure for a lifetime of work at 2ppm.  
1.4 Butadiene Biomarkers  
 Occupational exposure limits and regulations for BD have been shaped by results 
obtained from historical-occupational cohorts. However, one of the main data gaps that remain 
unresolved is the accuracy of retrospective estimation of occupational exposure levels for BD-
workers. Alternatively, biomarkers have proven to be a useful approach not only to document 
exposure-effect relationships but also to internally estimate actual BD-exposure and address this 
gap.  
First, let’s define biomarkers as an objectively measured characteristic on a subject 
(animal or human), as means to evaluate a process or response upon a specific stimulus. A 
thorough review on biomarkers as a risk assessment tool in dose-response relationships was 
presented by Swenberg and colleagues in 2008. They delineated two main types of biomarkers 
for risk assessment: (a) Biomarkers of Exposure and (b) Biomarkers of Effect. Here, we will 
review studies and their key findings from the standpoint of those BD biomarkers of exposure, 
how they relate to biomarkers of effect, how they have improved our understanding on dose-
response relationships, and ultimately how they have allowed us to estimate the “internal-dose” 
in BD-exposed workers. For practical purposes, the first focus will be placed on Biomarkers of 
Exposure including: urinary metabolites and enzymes, and both DNA adducts and hemoglobin 
adducts. The second focus will be directed towards Biomarkers of Effect including: DNA 
Damage response pathways.  
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1.4.1 Butadiene Biomarkers of Exposure  
1.4.1.1 Butadiene Urine Metabolites and Metabolic Enzymes  
BD is metabolized in the human body into its reactive intermediates (EB, EB-diol and 
DEB) and later detoxified via oxidation by CYP’s or aldehyde dehydrogenase (AHD), 
conjugation by glutathione-s-transferase (GST) or hydrolysis via EH [Figure 1.1]. The final 
result is creation of four different BD mercapturic acids (MAs) that are excreted in urine. Initial 
formation of the MAs starts with EB conjugation by GST and excretion as 2-(N-acetyl-L-
cystein-S-yl)-1-hydroxybut-3-ene and 1-(N-acetyl-L-cystein-S-yl)-2-hydroxybut-3-ene 
(MHBMA or M2). The second MA arises from EB hydrolysis by EH into BD-diol that can be 
oxidized into hydroxymethylvinylketone (HMVK) via ADH. Subsequently, HMVK is 
conjugated by GST and excreted as 4-(N-acetyl-L-cystein-S-yl)-1,2-dihydroxybutane (DHBMA 
or M1). The third MA springs from the further oxidation of EB into DEB via CYP oxidation and 
later GST conjugation of DEB into 1,4-bis-(N-acetyl-L-cystein-S-yl)butane-2,3-diol (bis-BDMA 
or M3). BD-diol oxidation by CYP or DEB hydrolysis by EH both generate EB-diol, which 
ultimately is conjugated by GST into 4-(N-acetyl-L-cystein-S-yl)-1,2,3-trihydroxy-butane 
(THBMA). Of all four MA monitored, M1 and M2 have been the most predominantly discussed 
in the literature across species in earlier studies, and have contributed to our understanding of 
those underlining similarities and differences in the metabolism of all 3 specific BD-epoxides. 
The most predominant BD specific biomarker in urine for occupationally exposed 
workers is M1. This is consistent with findings of the higher activity of EH activity in human 
liver when compared to that of rodents. The two most commonly used formulas to evaluate BD 
detoxification are the relative activity of hydrolysis defined as the ratio of MA = M1/(M1 + M2) 
and/or the relative activity of conjugation of MA = M2/(M1 + M2). 
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One of the earlier studies of urinary biomarkers across species was in 1993 by Bechtold, 
who analyzed two BD-specific MA; M1 and M2. He incorporated Csanady’s kinetic constants 
for EH and GST and calculated an enzymatic ratio rate constant [EH/GST] for comparison with 
the relative activity of hydrolysis [M1/(M1 + M2)]. First, it’s very important to recognize that the 
original rate constant of the hepatic clearance of EB via EH hydrolysis as reported by Csanady in 
1992 goes from higher to lower for Humans > Rats > Mice whereas conjugation of EB via GST 
follows the order Rats > Mice > Humans (Csanady, 1992). A higher enzymatic ratio rate 
constant suggests that EB is hydrolyzed into BD-diol in the liver, and conversely, a smaller value 
indicates a predominant conjugation of EB by GST. The difference in this enzymatic ratio rate is 
45-fold in Humans vs Mice, 23-fold in Humans vs Rats and 2-fold in Rats vs Mice. Csanady 
with Bechtold integrated results, found a higher the enzymatic ratio rate, the greater the 
proportion of M1 with respect with M1 + M2. Across species, the order from higher to lower 
ratio of MA was Humans > Rats > Mice. The differences in relative activity of hydrolysis was 
4.9-fold in Humans vs Mice, 1.9-fold in Humans vs Rats and 2.6-fold in Rats vs Mice.  
Two hallmark studies have been performed in occupationally exposed workers in 2001 
(Albertini I) with all male subjects (Albertini, 2001), and 2007 (Albertini II) for both male and 
females subjects employed at a facility in the Czech Republic (Albertini, 2007). In the first study, 
Albertini and colleagues determined MA concentrations in urine for 86 male occupationally 
exposed workers. Air exposures in 8-hour shifts were approximately 0.290 ppm and 0.812 ppm 
in BDM and SBR facilities respectively; with a control group with background concentrations of 
0.010 ppm.  
Net concentrations of BD-specific MA after the work shift resulted in an M1 40-fold 
higher than M2 in BDM workers. In SBR workers, M1 was 32-fold higher than M2. On average, 
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M1 was ~36 times more abundant than M2 in exposed workers to BD, independent of exposure 
to the monomer or polymer [Table 1.1]. They also estimated BD detoxification as the relative 
activity of conjugation = M2/(M1 + M2). Mean values for measurements performed after work 
resulted in BD exposure stimulated conjugation. As BD exposure increased, so did the relative 
activity of conjugation. However, the authors underlined that conjugation accounts for 
approximately 1-2% of the urinary excretion for both MA. In addition, all workers were 
genotyped for a homozygous null GST phenotype (GSTT1). Workers with this phenotype had a 
reduced production of the M2, reflecting a lower ratio activity of conjugation when compared to 
those with GST positive phenotype.  
In the second study (Albertini II) published in 2007, they incorporated some changes to 
the original study. They re-tested males from Albertini I and included 18 females (for a total of 
104 subjects), double-blinded all samples, and monitored exposure as an average of ten 8-hour 
shifts per subject over the course of 4 months. BD-air exposure levels were 0.004 ppm and 0.003 
ppm for control females and males, and 0.180 ppm 0.367 ppm for exposed females and males 
respectively. When examining the average MA, females excreted lower levels than males for 
both M1 and M2. After-work BD-specific MA’s resulted in an M1 22.2-fold higher than M2 for 
all workers. Individually, females exhibited a difference of M1 being 26.5-fold higher than M2 
whereas in males this difference was 17.8-fold higher. Estimated BD detoxification, defined as 
the relative activity of conjugation = M2/(M1 + M2) versus hydrolysis was also calculated. Mean 
values for measurements performed after-work resulted in BD exposure also stimulating overall 
conjugation in females and males when compared to that of controls. The relative activity of 
conjugation was specifically increased by 1.68 fold with BD exposure in all subjects; specifically 
1.54 fold for females and 1.79 fold for males [Table 1.2]. This ratio was maintained considering 
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the units of BD to which they were exposed, suggesting sex-related differences in metabolism 
but not in the pathway, which once again, reflected that hydrolysis is favored over conjugation. 
In his studies, Albertini has clearly shown the overall dominance of hydrolytic detoxification of 
BD epoxides via EH with a distribution of 99% in Humans > 51% in Rats > 23% in Mice. 
Additional endpoints for biomarkers of effect were measured for both Albertini studies 
(Albertini, 2001, Albertini, 2007). These additional endpoints were sister-chromatid exchange 
frequencies, chromosomal aberrations and hprt mutations. None of these endpoints demonstrated 
a significant difference for either study. 
Some studies in occupationally exposed workers have focused on analyzing these key 
enzymes and their genetic sensitivity. For instance, in 2001 Abdel-Rahman and colleagues 
studied 49 non-smoking workers exposed to > 0.15 ppm or < 0.15 ppm in two SBR plants in 
Texas (Abdel-Rahman, 2001). All subjects were genotyped for polymorphic variants in both 
GST (GSTM1 and GSTT1), and microsomal epoxy hydrolase (mEH) and tested for genetic 
sensitivity as measured by hprt Vf.  A particular polymorphic variant in mEH is Tyr113His, 
where tyrosine has been substituted by histidine at residue 113. This polymorphism in mEH has 
been shown to reduce its enzymatic activity by 40%, making this variant an attractive marker for 
human sensitivity. Overall results indicated that exposed workers in the high exposure group > 
0.15 ppm BD had a 2-fold increase in the mutation frequency when compared to those that were 
in the low exposure group < 0.15 ppm BD. Moreover, mEH played a significant role in the 
sensitivity of BD exposure to genetic damage using the HPRT gene mutation assay.  Those 
individuals exposed to > 0.15 ppm, and with at least one His allele (His/Tyr or His/His), had 3-
fold higher mutation frequencies (Vf) than individuals with a normal phenotype for mEH. When 
combining both GST and mEH polymorphisms, they found similar results in the high exposure 
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group > 0.15 ppm BD. The level of genetic damage was highest in individuals with one mEH 
His allele and either GSTM1 and/or GSTT1 null genotypes. Perhaps this implies that exposure 
levels of BD > 0.015ppm represent a significant turning point in occupational settings 
particularly for individuals with sensitive enzymatic polymorphic variants, such as mEH, that 
can ultimately lead to genetic sensitivity.  
The latest publication of BD-MA was released in 2015 by Kotapati and colleagues. A 
total of 72 workers employed at a BDM and SBR production facility near Prague, Czech 
Republic were analyzed for all four BD-MA in their urine (Kotapati, 2015). This study included 
both females and males in both controls (BD at 0.0136 ppm) and exposed (BD at 0.023-0.680 
ppm) workers. Results confirmed that BD metabolism in humans is predominantly via the 
hydrolytic pathway. Concentrations of MHBMA (M2), DHBMA (M1) and THBMA were 
determined in after-work urine samples. The order of predominance of MA metabolites in all 
groups, for both sexes was DHMBA > THBMA > MHBMA. When looking at all MA; 
MHBMA, DHBMA and THBMA levels were greater in both male and female exposed workers 
compared to controls. Only. Females formed less MHBMA per unit dose of BD than males, but 
this sex-specific difference was not significant for DHBMA or THBMA. As a reminder, 
MHBMA is formed by EB conjugation via GST, whereas DHBMA corresponds to EB 
hydrolysis via EH. Using the metabolic ratios as determined by the formula [MHBMA/ 
(MHBMA + DHBMA + THBMA), the authors concluded that in humans, less than ~ 3% of EB 
is detoxified by conjugation via GST, and ~ 97% of EB formed by hydrolysis by EH to EB-diol. 
In addition, HPRT mutation frequencies (Vf) and BD-hemoglobin adducts from Albertini II were 
evaluated for correlations with BD-MA, but no statistical association was found. In contrast, they 
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did find that all three BD-MA were also strongly associated BD-hemoglobin adducts with some 
limitations.  
We therefore summarize all the previous data with the statement that humans 
metabolically favor the hydrolysis of EB and later oxidation into the EB-diol and to a minor 
extent oxidation into DEB. Results in BD-MA and BD-metabolic enzymes on all previously 
presented studies support this statement. M1 is the most predominant biomarker of exposure in 
urine for all species and polymorphic variants in both BD-metabolic enzymes (mEH and GST) 
play an important role in the genetic sensitivity of occupationally exposed subjects. Despite its 
conjugation being the minor pathways in humans, BD has been shown to stimulate the relative 
activity of conjugation in these exposed subjects. Moreover, it has been shown that females 
metabolize less BD than males per unit of exposure (Vacek, 2010).  Other biomarkers, such as 
BD-hemoglobin adducts have been included in these studies and will be discussed in the next 
section.  
1.4.1.2 Butadiene Hemoglobin Adducts: pyr-Val, HB-Val, and   
  THB-Val 
Each BD-epoxide induces a distinctive alkylation at the N-terminal Valine of Hb upon 
exposure (Moll 1999) generating three adducts: N,N-(2,3 dihydroxy-1,4 butadiyl)-valine (pyr-
Val); N-(2-hydroxy-3-butenyl)-valine (HB-Val); and N (2,3,4 trihydroxybutyl)-valine (THB-
Val) (Swenberg, 2000) [Figure 1.3]. The most abundant adduct across species is THB-Val, 
followed by HB-Val and pyr-Val. The THB-Val adducts differ from the other two adducts in that 
they are also formed endogenously from reactions with sugars erythrose and threose (Rydberg, 
1996). HB-Val and pyr-Val have no endogenous sources, but other exogenous sources have been 
implicated to contribute in their formation. Occupationally exposed workers employed in SBR 
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facilities have increased HB-Val adducts due to co-exposure to styrene (Albertini, 2001). 
Smoking status has notably shown to contribute in the formation of both pyr-Val and THB-Val 
adducts.   
Vacek and others reported as evidence when measuring THB-Val adducts amongst BD 
exposed workers. Occupational levels presented a marked difference when considering smoking 
habits in the group. Smokers, had 502 pmol/g globin versus 179 pmol/g globin in non-smokers 
(Vacek, 2010). The significant difference reported on smokers, presents that smoking is a 
cofounding factor in the generation of THB-Val adducts. However, the difference was 
independent from sex, reinforcing that metabolic activation of BD, from sources such as 
cigarette smoking, is not a driving factor that comes into play when looking for sex specific 
differences.  
All three BD-Hb adducts serve as surrogate markers of BD exposure, and they have been 
used to identify underlying differences in metabolism/metabolic activation through the 
estimation of internal dose in blood (IBD) (Fred 2008, Swenberg, 2011). Different from DNA 
adducts, Hb adducts are attractive endpoints due to their abundance in blood, non invasive access 
sampling, chemical stability and persistence due to lack of repair under biological conditions 
(Albertini 2001, Ospina 2005, Tornqvist 1986, Boysen 2004). These adduct levels are useful in 
molecular dosimetry comparisons and correlation analysis with other biomarkers (Booth 2004) 
such as DNA adducts and induced Mutation Frequency (MF) (Georgieva 2010, Swenberg 2011) 
and when comparing the formation of electrophilic intermediates across species in blood, by 
using the Internal Blood Dose (IBD) (Swenberg 2011, Fred 2008). Perhaps the major advantage 
of the measurement of Hb adducts is that they represent the cumulative exposure from 0 to 45, 
60 and 120 days for mice, rat and humans.   
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The structure of hemoglobin is composed of two alpha chains (141 aminoacids) and two 
beta chains (146 aminoacids). Several residues of these sequences have been positively identified 
as locations for Hb adduct formation when incubated with BD. They include Histidine, Lysine, 
Serine, Methionine and Valine (Moll, 2000). Distinctively, the gold standard for the 
measurement of Hb adducts has favored the use of residue 1, the N-terminal valine (NTV). The 
NTV is conserved across species and present in the same position in both alpha and beta chains. 
Therefore, this common residue which is modified as a result of BD exposure is targeted in the 
process of developing methods to isolate and quantify BD-hemoglobin adducts in blood samples.  
1.4.1.3 Quantitation of Butadiene-Hemoglobin Adducts  
1.4.1.3.1 Early Studies   
One of the earlier studies in BD-Hb adducts was performed by Sun in 1989 (Sun, 1989). 
Here, male B6C3F1 mice and Sprague-Dawley rats were injected intraperitoneally with 1, 10, 
100, or 1,000 μmol of radiolabeled [14C]-BD and sacrificed 24 hours later. All BD-Hb adducts 
were measured by liquid scintillation counting of radioactivity. Results showed a linearity with 
increasing doses up to 100 μmol per kilogram body weight for rodents. Adducts were formed 
more efficiently by rats than mice (expressed as pmol of 14C-adducts/mg globin)/(pmol of 
retained [14C]-BD/kg body weight). For the first time, they determined the lifetime of BD-Hb 
adducts to be 24 days for mice and 65 days for rats. They also concluded that BD-Hb adducts 
were formed from metabolites of BD rather than the parent compound. However, they weren’t 
able to distinguish what proportion of those adducts corresponded to which BD-specific 
metabolite. Due to the use of radioactive [14C]-BD for exposures, this assay couldn’t be used in 
the future to evaluate BD-Hb adducts from human occupationally exposed samples.  
21 
 
In 1991, Osterman-Golkar exposed Wistar rats to BD via inhalation at: 0, 250, 500 and 
1000 ppm (6 h/day, 5 days/week, 2 weeks) (Osterman-Golkar, 1991). Samples of blood were 
pooled from 8 rats per exposure level. These authors used different analytical techniques for each 
individual endpoint. HPLC for urine BD-MA and GC-MS for BD-Hb adducts. Both endpoints 
were found to linearly increase in proportion to exposure concentrations. When correlating rats 
BD-Hb adducts to other endpoints, such as the induced SCE frequency it presented to be at its 
highest at 250 ppm. However, between 250 ppm-1000 ppm where BD-Hb’s continued to linearly 
increase, SCE’s decreased. Overall, they found that the current HPLC method used wasn’t 
sensitive enough for the quantitation BD-MA at human occupational levels of exposure, since 
these adducts are considerably lower than that of rats exposed at higher levels. In addition, they 
found two stereo-isomeric derivatives were produced in the analysis HB-Val adducts.  Authors 
suggested that in vivo formation of other reactive intermediates needed to be considered, such as 
DEB, due it being a more effective mutagen. 
Two years later, in 1993, the same authors proceeded to specifically analyze HB-Val 
which is formed by the reaction of EB with Hb. Only male rodents (B6C3F1 mice and Sprague-
Dawley rats) were exposed to BD via inhalation (0, 2, 10 and 100 ppm for 6 h/day, 5 days/week, 
4 weeks) (Osterman-Golkar, 1993). HB-Val increased linearly with BD concentration in mice, 
whereas with rats there was a deviation from linearity. Specifically, for concentrations < 100 
ppm, HB-Val presented no significant difference between rodents however at the 100 ppm level, 
HB-Val adducts were 4-fold greater in mice > than rats. In a preliminary assessment of HB-Val 
in occupationally exposed (~1 ppm BD) non-smokers HB-Val ranged between 1-3 pmol/g of 
globin with smokers having increased HB-Val levels. The authors concluded for the first time 
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that HB-Val was simultaneously detected across species, with humans having the lowest levels 
when compared to rodents.  
The same authors subsequently included additional samples to the previously presented 
human BD-Hb levels in 1993 (Osterman-Golkar, 1993). Subjects were non-smoking workers at a 
SBR plant in the US. TWA 8-hr area samples averaged a BD exposure level of 3.5 ppm, 
however, most samples contained < 1 ppm and thus the authors agreed that average BD 
exposures were < 3.5 ppm. HB-Val was found in exposed workers at adduct levels that ranged 
between 1.1-2.6 pmol/g globin in BD production areas. Controls from non-production areas, and 
external controls exposed to ~ 0.03 ppm BD were evaluated for HB-Val levels, however, 
samples were below the detection limit of 0.5 pmol/g globin. Authors suggested that additional 
research was needed to define the relationship between BD exposure and BD-Hb levels. 
Albrecht and colleagues in 1993 analyzed HB-Val, but this time, in female rodents 
(Albrecht, 1993). Both CB6F1 mice and Wistar rats were exposed to BD (0, 50, 200, 500 or 
1300 ppm, 6h/d, 5d) via inhalation. BD-Hb adducts were analyzed by derivatization of the N-
terminal valine via modified Edman degradation procedure. HB-Val presented to be 5-fold 
higher in mice than in rats (17 and 3.5 nmol/g globin) at 500 ppm. Adducts increased linearly 
with BD exposure in rats, however in mice there was a decrease in formation at 500ppm. At 
higher levels, there was still an increase in HB-Val, but at a slower rate (less steep slope). The 
authors concluded that this sharp decrease in the formation of HB-Val adducts could explain in 
part why in female mice has a greater susceptibility to tumor formation when exposed to BD.  
Authors Van Sittert & Van Vliet, and Richardson measured HB-Val in control and BD-
exposed workers at a plant that produces BD by a naptha cracking process in a chemical plant in 
the Netherlands (Van Sittert & Van Vliet, 1994, Richardson, 1996). The method employed the 
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quantitation of derivatized N-terminal valine using the Edman degradation and later analysis by 
GC-MS. The 1994 study determined by air samples that BD-exposures had a TWA 8h of < 1 
ppm. HB-Val was detected in both smokers and nonsmoking subjects. In the BD-exposed group, 
levels of HB-Val for both smokers and non-smokers had an average of less than < 2 pmol/g 
hemoglobin. Similarly, controls had averages of HB-Val with less than < 4 pmol/g hemoglobin 
in non-smokers and < 3 pmol/g hemoglobin in smokers. There was no apparent increase in HB-
Val adducts with increase BD-exposure. Considering that the detection limit for HB-Val in this 
study was between 1-8 pmol/g hemoglobin, the authors concluded that the method was not 
sensitive enough for the detection of HB-Val adducts at BD-exposures of < 1 ppm. For the 
Richardson 1996 study, they incorporated the use of in-vitro multispecies erythrocytes as well as 
in-vivo exposures for rodents (B6C3F1 mice and Sprague-Dawley rats). In-vitro rat, mice and 
human washed erythrocytes were treated with EB (0.7 mg/mL for 2h). Rodents were exposed to 
EB at different ranges via intraperitoneal injection (0, 10, 20, 40 and 60mg/kg of body weight for 
6h). They encountered numerous difficulties during their experiments that included: lack of an 
appropriate/corresponding internal standard, an LOD of 10-20 pmol/g hemoglobin in vitro, and 
low adduct levels with a high background signals for in-vivo samples. Authors didn’t discuss the 
data any further due to these innumerable limitations (Richardson, 1996).  
In 1997, we started seeing more progress with studies being performed to measure 2 out 
of the 3 BD-Hb adducts (Perez, 1997). Here, they measured both HB-Val and THB-Val across 
species via derivatization of the N-terminal valine using Edman degradation and later analysis 
via GC-MS/MS. Male Sprague Dawley rats were directly exposed to all BD-epoxides [EB (78.3 
mg/kg), DEB (16.7 and 33.4 mg/kg) and EB-diol (30 and 60 mg/kg)] via intraperitoneal 
injection. Male Wistar rats were exposed to BD via inhalation (0, 50, 200, or 500 ppm, 6 h/day 
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for 5 days). A few BD occupationally exposed workers (~ 1 ppm) from a Portuguese 
petrochemical plant and controls were also examined (n = 4; two exposed and two controls). HB-
Val and THB-Val adducts were also quantified to determine the Hb binding index (HBI) and this 
numerical value indicated that in rats, EB-diol has an HBI of 10, whereas in DEB is 8. Authors 
explained that the closeness in the value of the HBI demonstrates that both EB-diol and DEB are 
similarly capable in alkylating nucleophilic sites in vivo. For BD-Hb adducts, THB-Val was not 
linearly related to exposed rats. The highest formed adduct was THB-Val followed by HB-Val in 
both rats and humans. Authors concluded that now in addition to HB-Val, THB-Val was also a 
useful biomarker of BD, specifically for BD-exposure for humans due to its abundance at low 
levels of exposure.  
In 1998, Osterman-Golkar and others measured HB-Val adducts in rodents, estimated 
adduct stability in vivo and the corresponding EB concentration in blood using the area under the 
concentration curve (AUC) (Osterman-Golkar, 1998). Here, male rodents (B6C3F1 mice and 
Sprague Dawley rats) were exposed to low BD concentrations (0, 2, 10, or 100 ppm of 1,3-
butadiene, 6 h/day, 5 days/week for 1, 2, 3, or 4 weeks). HB-Val adducts were found to be 
chemically stable in vivo and were detected as early as one week of exposure for all BD 
concentrations (following the turnover of red blood cells). Also, HB-Val adducts increased 
linearly with BD exposure in mice within these ranges. In rats, the same pattern followed up to 
10 ppm, but from 10 to 100 ppm the increase of HB-Val was a lesser rate, indicated by a 
shallower slope. Comparing both species at 100 ppm BD, HB-Val adducts were 4-fold greater in 
mice than rats, but this difference was less evident at lower levels of exposure. Estimated blood 
concentrations of EB from HB-Val were similar to those previously published in rodents 
exposed to BD at 62.5 ppm. Authors successfully showed that HB-Val adducts were useful in the 
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prediction of blood concentration of EB in exposed rodents, despite their low levels at the ranges 
of BD-exposure that were considered.  
Begemann presented the analysis of THB-Val adducts in 2001 for humans occupationally 
exposed to low levels of BD from two sites: subjects of a BDM plant in Italy, and diesel-exposed 
subjects from a Potassium Mine (PoM) in Germany (Begemann, 2001a). THB-Val adducts were 
analyzed by derivatization of the N-terminal valine via modified Edman degradation with post 
procedure acetylation, and final quantitation of derivatives by GC-MS. BD air exposures were 
measured by personal sampling after one 8h shift [average of 0.014 ppm BD (31ug/m3)] for 
BDM workers. Diesel-particulate measurements were available for the PoM workers. THB-Val 
in BDM subgroups from highest to lowest in polymerization (44.8 pmol/g globin) > co-
polymerization (33.0 pmol/g globin) > and controls (35.3 pmol/g globin). Since THB-Val is 
known to be endogenously formed, as well as through low levels of BD-exposure, the authors 
couldn’t show a dose-response correlation or distinction between sub-groups. For the PoM 
workers in Germany, average THB-Val levels (43.5 pmol/g globin) were similar to those found 
in BDM polymerization. Here, THB-Val increase was associated with increasing diesel 
particulate exposure. Different from BDM-workers, PoM-workers had both smokers and no-
smokers. Smoking status showed a positive contribution to these THB-Val adducts (42.3 pmol/g 
globin), when compared to non-smokers (35.1 pmol/g globin). The authors concluded that 
smoking was an important confounding variable in the formation of THB-Val adducts. 
The same year, Begemann et al. presented a second publication for another BD-exposed 
worker population in a BDM plant in the Czech Republic following a similar procedure with 
similar results (Begemann, 2001b). This time, they analyzed HB-Val instead of THB-Val. BD-
workers were exposed to 0.200 ppm BD, whereas controls had background concentrations of BD 
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at 0.0027 ppm. Significant sample clean-up was developed in the method, until they finally 
achieved an LOD of 0.2 pmol/g globin prior to its analysis via GC/MS. Average HB-Val adducts 
were 0.7 pmol/g globin for BD-exposed, whereas controls had 0.2 pmol/g globin. Smoking status 
was found to have significantly higher levels of HB-Val in control group, indicating the 
contribution of this lifestyle factor to BD exposure.  
1.4.1.3.2 Recent Studies   
In the last 15 years, several methods have been developed and employed for the detection 
and quantitation of BD-NTV Hb adducts (Fred 2004, Boysen 2004, Georgieva 2007, Georgieva 
2010, Stednigk 2010). Initially, detection of pyr-Val, HB-Val and THB-Val from both Hb-chains 
(H-α and H-β) were attempted by employing the N-alkyl Edman method with subsequent 
analysis via gas chromatography-mass spectrometry (GC-MS and GC-MS/MS). Although this 
approach worked for specific BD-adducts HB-Val and THB-Val, it presents limitations. First, 
this method cannot distinguish if those adducts are from the α-Hb or β-Hb chains, second it is 
unsuitable for pyr-Val, and third it had limited sensitivity on samples at low levels of BD 
exposure (Törnqvist 1986, Booth 2004, Powley 2005). The N-terminal pyr-Val adduct cannot be 
detected by the Edman degradation because it blocks coupling of phenylisothiocyanate and the 
subsequent cleavage required to generate the phenylthiohydantoin derivates used in the 
quantitation step (Törnqvist 1986). Also, earlier work performed in our laboratory using the N-
alkyl Edman method, resulted in poor recovery of THB-Val analyte and internal standard 
(Powley 2005).  
These particular challenges led to method improvement. Alternatively, tryptic digestion 
of Hb and an LC-MS/MS method incorporating the use of N-terminal modified pyr-Val-[2H8] 
heptapeptide standards (Fred, 2004a) were used for quantitation of pyr-Val adducts, while the 
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use of the N-alkyl Edman method was employed for both HB-Val and THB-Val adducts (Fred, 
2004b). Using two methods for the detection of all three adducts is labor intensive and costly 
because each sample has to be processed twice (once for pyr-Val adducts and separately for HB-
Val and THB-Val adducts). Also, most of these in-vivo samples from rodents, as well as the 
human samples are limited (valuable and irreplaceable). It became apparent that further method 
development was needed in order to improve the following: (1) reduce the amount of globin used 
per sample; (2) reduce the cost of materials for sample processing plus cost of analysis; (3) 
reduce the sample processing time; (4) increase the sensitivity for more accurate quantitation in 
both animal and human samples at low levels of exposures; and (5) uniformly process samples 
for all adducts and all species simultaneously using a single method. 
1.5 Single Immunoaffinity Enrichment Method 
Georgieva and Boysen with collaborators from our group generated a novel alternative technique 
that incorporated the use of N-terminal Valine (NTV) modified (1-11) pyr-Val [2H3] and (1-11) 
HB-Val-[13C5 15N] peptide standards for rat, mouse and human α Hb chain sequences. The 
method opened the possibility of not only analyzing the pyr-Val adduct but also HB-Val at low 
levels of exposure. In brief, rabbit polyclonal antibodies recognizing these modified peptides 
were generated and the globin tryptic digest was enriched via immunoaffinity (IA) and coupled 
to analysis by nano-UPLC-ESI+ MS/MS (Nanoflow Ultra Performance Liquid Chromatography 
Positive Electrospray Ionization Tandem Mass Spectrometry). This method proved to be 
successful for pyr-Val and HB-Val quantitation and estimation of multispecies DEB and EB 
internal epoxide formation (Boysen, 2004, Georgieva, 2007, Georgieva, 2010, Boysen, 2012). IA 
enrichment is more attractive alternative to just tryptic digest analysis because it reduces the 
complexity of the mixture down to the fraction of interest. The initial amount of globin required 
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for the analysis is species and exposure dependent ranging from 10-50mg and has an LOD/LOQ 
of 1 & 4 fmol injected on column (nanoLC). These single antibody IA columns have proven to 
be a suitable method for the measurement of both pyr-Val and HB-Val using N-terminal 
modified (1-11) peptide standards.  
Recently the method has been adjusted in our laboratory to perform simultaneous adduct 
enrichment and analysis. These improvements significantly reduce the use of laboratory supplies, 
labor time, amount of globin required as well as the number of samples to be analyzed and 
overall sample processing expenses over previously existing methods. Another advantage of 
using IA enrichment was that it enabled quantitation of pyr-Val which has been unsuitable for N-
alkyl Edman method. Results for single IA columns have been published for both pyr-Val and 
HB-Val but not for THB-Val using this method (Boysen, 2004, Georgieva, 2007, Georgieva, 
2010). In order to complete the evolution from single IA enrichment (just pyr-Val or just HB-
Val) to simultaneous IA enrichment, it required the generation of unique alpha N-terminal 
modified (1-11) peptide standards for THB-Val. These standards were readily available for pyr-
Val and HB-Val peptides, but not for THB-Val.  
1.6 Simultaneous Immunoaffinity Enrichment Method 
Initial production of N-terminal Val (1-11) THB-Val peptides of alpha hemoglobin was 
developed and optimized by our group using the human sequence1. This synthetic peptide was 
used to first, optimize the synthesis direct alkylation conditions, and second to generate 
antibodies for later use in the construction of IA enrichment columns. In addition, the human 
sequence required substitution of a Cysteine at the C terminus, instead of the normal Lysine at 
                                                 
1 Human 1-11 sequence (VLSPADKTNVC) 
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the 11th position, to enhance antibody conjugation. THB-Val peptide standards were not only 
necessary for polyclonal antibody generation and construction of IA columns, but also needed 
for calculation of IA columns recovery, instrument tuning and optimization, method validation, 
and evaluation of calibration curves and LOD’s. The overall goal was to integrate the THB-Val 
peptide standards into the IA method to facilitate the future analysis of all three BD adducts (pyr-
Val and HB-Val, and THB-Val) simultaneously, across our comprehensive sample sets of mice, 
rat and human species. The N-terminal modified (1-11) THB-Val peptide standards were critical 
for the simultaneous quantitation of pyr-Val, HB-Val and THB-Val adducts across species under 
a simultaneous IA enrichment method.  
1.6.1 THB-Val Peptide Standards  
The generation of THB-Val peptide standards entailed direct alkylation of species 
specific NTV (1-11) peptide sequences for: rat2, mouse3 and human4 and their corresponding 
[15N 13C5-Val] stable isotope labeled peptide sequences by reaction with EB-diol. THB-Val 
peptide standards were purified by separation of the mono-alkylated fraction of the reaction 
mixture by HPLC. Characterization of NTV alkylation was confirmed through the analysis of b 
and y peptide fragment ions generated by collision induced dissociation (MS/MS) (Roepstorff 
and Fohlman, 1984). Each peptide standard was quantified by performing acid hydrolysis 
followed by UPLC-MS/MS analysis for amino acid quantitation (as previously described by 
Bordeerat, 2009). After the combined IA columns were built, they underwent a process of 
validation, in which the THB-Val was incorporated with both pyr-Val and HB-Val, by using 
known concentrations of both analyte and internal peptide standards. Simultaneous IA 
                                                 
2 Rat 1-11 sequence (VLSADDKTNIK) 
3 Mouse 1-11 sequence (VLSGEDKSNIK) 
4 Human 1-11 sequence (VLSPADKTNVK) 
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enrichment was successfully validated, and adducts from mouse samples were quantitated, 
including samples at low levels of BD-exposure. In contrast, human samples proved difficult to 
measure.  
1.6.2 Quantitative Analysis of N-terminal Valine Adducts in Mice   
 Exposed to 1,3-Butadiene, Internal Blood Dose Formation, and   
 EB-equivalency 
Overall, THB-Val is the major adduct formed in Hb across species after BD exposure. 
The development and validation of this method provided additional tools on the role of the EB-
diol epoxide formation and its contribution to mutagenesis and carcinogenesis across species. 
There was an existing gap in our comprehensive BD inhalation dataset for this particular adduct, 
under the same method for the subset of mice samples. Species dependent differences in the 
metabolic activation of BD into EB-diol can be better understood through the use of the specific 
hemoglobin adduct, THB-Val, as a surrogate marker of exposure.  
Specific Aims 1 and 2 (Chapter 2 and 3) included the preparation of THB-Val peptide 
standards followed by a validation of the triple IA columns and completion of simultaneous 
quantitation of our samples by nano-UPLC MS/MS. It was important to develop a method 
sensitive enough that could simultaneously analyze all BD-Hb adducts, including now THB-Val 
from our comprehensive rodent data set exposed to BD at low levels of exposure. The specific 
focus of this work was to first generate multispecies NTV analyte and internal (1-11) THB-Val-
[13C5 15N] peptide standards in order to perform method validations and THB-Val adduct 
measurements in rodents; including now the mice dataset.  Ultimately, multispecies comparisons, 
now incorporating these THB-Val adducts, allowed rats and mice species comparisons. These 
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values were transformed into the internal blood dose of EB-diol to determine the epoxide 
influence in the overall contribution to the EB-Equivalency. 
1.7 Butadiene DNA Adducts 
1.7.1 DNA Adducts Introduction  
As reviewed in section 1.2; BD is metabolized mainly by Cytochrome P450 enzyme 
CYP2E1 into three epoxides; EB5, DEB6 and EB-diol7. DEB has shown to be the minor 
metabolite formed with the highest mutagenicity, whereas EB-diol is the mayor metabolite with 
the lowest mutagenicity. There is a 200-fold difference among BD-epoxides mutagenicity, with 
DEB being 50 times more mutagenic than EB, and 200 times more mutagenic than EB-diol.  
All three butadiene epoxides (EB, DEB, EB-diol) have the ability to react DNA and form 
covalent adducts. These BD-DNA adducts can be subdivided into three categories: (1) DNA-
monoadducts, (2) DPCs8 or (3) DNA-DNA crosslinks. In vitro, all BD-epoxides have 
demonstrated the capacity to alkylate all DNA bases. However, only two DNA bases have been 
found to be alkylated in vivo: with the most predominant being with Guanine (Gua), and to a 
lesser extent Adenine (Ade). Therefore, it is important to recognize BD-Gua adducts as relevant 
to study due to their higher abundance. In the literature, it has been reviewed that there are three 
key aspects of BD-DNA adducts: (i) the distinction of the N7 position of Gua as main site of 
alkylation from all DNA bases, (ii) EB-diol adducts are the multispecies predominant BD-DNA 
adducts in all tissues, (iii) mice are the species with the highest number of BD-DNA adducts 
formed, and (iv) liver is the target tissue for overall highest BD-DNA adduct formation.  
                                                 
5 1,2-epoxybutene 
6 1,2:3,4-diepoxybutane 
7 3,4-epoxy-1,2-butanediol 
8 DNA-protein crosslinks 
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1.7.2 Butadiene Epoxide Specific Guanine Adducts 
1.7.2.1 Mono-adducts 
The most metabolically abundant epoxide formed from BD is EB-diol, and consists of 
four stereoisomers (2R,3R; 2R,3S: 2S,3R; and 2S,3S) that react with Gua and form THB-Gua9. 
Followed in abundance is EB, which consists of two enantiomers (2S; 2R) that react with Gua 
generating HB-Gua10. Alternatively, some of these HB-Gua adducts can be transformed back 
into THB-Gua, if the remaining unbound portion becomes hydrolyzed. The third and least 
abundant epoxide, DEB, consists of three stereoisomers (2R,3R,; 2S,3S and meso-S,R/R,S) that 
react with Gua and form monoadduct DEB-Gua.  
1.7.2.2 DNA Crosslinks  
There are two main BD-Gua monoadducts that are considered to be the precursors of 
those DNA-DNA crosslinks or DNA-Protein crosslinks: HB-Gua and DEB-Gua. The only 
difference between HB-Gua and DEB-Gua is the opposite side of the chemical that remains 
unbound. Once HB-Gua is formed, the unbound portion can become hydrolized and turn into 
more THB-Gua, or get oxidized and turn into DEB-Gua. Now, the DEB-Gua unbound epoxy-
ring remains available to react and produce differenct crosslinks depending on the target: (i) if it 
reacts with another Gua at the 7th position or an (ii) Ade at the 1st position they become DNA-
DNA crosslinks. If it reacts with (iii) a protein it becomes a DPC. The first DNA-DNA crosslink 
is N7Gua-N7Gua-BD11 adduct, whereas the second is the N7Gua-N1Ade-BD12 adduct. The 
latter is rearranged into N7Gua- N6Ade-BD (Goggin, 2009). In addition, it has been reported 
that the DEB-Gua unbound epoxy-ring target certain proteins, leading to DPC’s formation with: 
                                                 
9 N-7-(2,3,4-trihydroxybut-1-yl)guanine 
10 HB-Gua I & II: N-7-(2-hydroxy-3-buten-1-yl)guanine & N-7-(1-hydroxy-3- buten-2-yl)guanine 
11 1,4-bis-(guan-7-yl)-2,3-butanediol 
12 1-(guan-7-yl)- 4-(aden-1-yl)-2,3-butanediol 
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AGT13, GADPH14, Histone 3, and PARP-115 (Loeber, 2006, Loecken, 2007 & 2009, Tretyakova, 
2010).  
1.7.3 Integration of Hemoglobin and DNA Adducts 
Similar to BD-Hb adducts, BD-DNA adducts are considered biomarkers of exposure, are 
indicators of internal dose, and tissue distribution to ultimately provide insights on metabolic 
activation differences across species. When integrating molecular dosimetry results, BD-Hb 
adducts have shown sex-independent but multispecies dependent differences in metabolic 
epoxide formation: mice (~200 fold) > rat (~40 fold) > human (1 fold), and BD-epoxide 
abundance of EB-diol > EB > DEB. These metabolic species differences are parallel to the 
formation of BD-DNA adducts in rodents: EB-diol specific THB-Gua (10-20 fold) > EB specific 
HB-Gua ≈ followed by DEB specific crosslinks N7Gua-N7Gua-BD (~100 fold) > N7Gua-
N6Ade-BD. However, striking evidence has shown gender differences are only highlighted in 
DNA crosslinks, mutations, and tumor formation. DNA cross-links, from DEB specific N7Gua-
N7Gua BD crosslink, were higher in females (2-3 fold) than males in liver tissue of exposed 
mice at 625ppm. Furthermore, rodents exposed to BD, presented additional sex-specific 
differences where females had: higher mutagenicity (2.5-3 fold) at the HPRT gene, greater 
number of MFs (2.3 fold) in mice exposed to 1250 ppm, mice tumor formation (10 fold) in lung 
and livers at 6.25 and 20 ppm, and rats IBD from EB-diol (6 fold) 6 hour inhalation. The weight 
of evidence presented here suggest that the sex specific differences seen in DNA crosslinks, 
along with tumor formation and mutagenicity, is more attributable to sex-dependent DNA repair 
efficiency rather than metabolism itself as shown by our results from Hb adducts.  
                                                 
13 O6-alkylguanine DNA alkyltransferase 
14 glyceraldehyde 3-phosphate dehydrogenase 
15 Poly [ADP-ribose] polymerase 1 
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1.8 Biomarkers of Effect  
1.8.1 DNA Adducts and DNA Repair  
DNA adducts are considered biomarkers of exposure, and DNA repair is considered a 
biomarker of effect, and both have been recognized as non-mutational manifestations for BD-
carcinogenic MOA (Albertini, 2010). In the absence of DNA repair, or if DNA replication occurs 
before DNA adducts are repaired, point mutations, single and double stand breaks and deletions 
might occur, leading to mutations, and consequently tumor formations. Previously, the literature 
has presented how other biomarkers of effect such as mutagenesis, and gene expression, have 
provided information on translational animal and human carcinogenic potential for BD.  
1.8.2 Damage Induced by DNA Adducts  
In contrast to globin adducts, DNA adducts undergo DNA repair and loss from chemical 
depurination, so there are less consistent half-lives to model exposure. In addition, all BD DNA 
mono-adducts adducts have been classified as non-promutagenic due to their chemical instability 
and the fact that the N7 position has no participation in the Watson Crick base pairing (Boysen, 
2009). These adducts are lost from DNA primarily by chemical depurination, with a half-life of 
∼4 days. This results in the formation of AP-sites16, which if not repaired, can result in 
mutations. However, the 2R,3S isomer is 30-fold more cytotoxic and mutagenic than the other 
three forms of EB-diol (Meng, 2007). In the case of DNA-DNA crosslinks, it is important to 
recognize that there are differences in their half-lives. For example, the half-life of intrastrand 
crosslink N7Gua-BD is 35h while interstrand bis- N7Gua-BD is 147h. Interstrand cross-links are 
more toxic because they affect both DNA strands, preventing DNA transcription, replication, and 
repair. Still, these BD adducts can alter DNA bases by forming AP-sites due to their chemical 
                                                 
16 apurinic/apyrimidinic site or abasic site 
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instability and can either further be repaired, cause point mutations, or cause DNA strand breaks 
(Goggin, 2009). Recent investigations presented in this dissertation have integrated how DNA 
repair is modulated by BD-epoxides into the description of BD MOA.  
1.8.3 DNA Damage Response Pathways and Butadiene DNA Adducts 
All cells are equipped with DNA-repair components that are capable of reducing the number 
of mutations that might arise. These components can work in two ways. (1) Some will execute its 
function before replication, and identify unusual modifications to these DNA nucleotides by 
adducts, resulting in bypass, or repair before replication occurs. (2) Other components will 
operate after replication to survey newly synthesized DNA for mistakes, to make corrections of 
such errors. When a mutation arises, it indicates that repair has been deficient in the removal of 
the direct modification or the indirect damage caused by it. Therefore, DNA-repair is an 
orchestrated network of sensors, transducers, and effectors organized in interactive repair 
pathways that execute a response upon DNA damage. Several DNA repair pathways have 
evolved to guard cells against the DNA damage induced from endogenous sources and by 
alkylating agents such as BD-epoxides. These pathways include: direct repair, mismatch repair 
(MMR), base excision repair (BER), nucleotide excision repair (NER), homologous 
recombination (HR), non-homologous end-joining (NHEJ) and translesion synthesis (TLS). 
Moreover, the specific response of one or more of these will vary depending on the types of 
DNA adduct formed. 
1.8.3.1 Base Excision Repair 
In base excision repair (BER), the enzyme involved in removing adducted nucleobases from 
the sugar-phosphate back-bone is a glycosylase, leading to an AP-site (Robertson, 2009). The 
site is incised by an AP-endonuclease, and the single nucleotide gap is ultimately filled with a 
36 
 
new unmodified nucleotide by BER-specific DNA Pol β17, successively the nick is sealed with 
ligase complex XRCC118/Ligase III. Alternatively, BER also repairs any single strand breaks. 
Here, PARP119 senses the damage and gets activated via auto-poly-ADP-ribosylation20, 
recruiting the ligase complex to close the gap.  
1.8.3.2 Nucleotide Excision Repair 
Nucleotide Excision Repair (NER), has two different ways to detect DNA damage: TC-
NER21, and GG-NER22. In TC-NER, transcription is allowed to resume after it stalls due to a 
lesion. First, damage is sensed anywhere in the actively transcribed genome by stalled 
polymerase RNAP223, followed by its stabilization via interaction with intermediates CSB with 
subsequent recruitment of CSA24 to modify and reposition the stalled RNAP2. However, in GG-
NER, the damage is recognized and discriminated via two intermediate complexes: (1) 
XPC25/hHR23B26 and (2) UV-DDB27 (DDB128 and DDB229/XPE30). Both TC-NER and GG-
NER pathways have their previously respective intermediates converge in the recruitment of 
NER helicase TFIIH31 along with endonuclease XPG32. This bi-directional helicase (TFIIH) 
opens the damaged DNA segment of ~30 nucleotides, and the helix is stabilized by the assembly 
                                                 
17 Polymerase β 
18 X-Ray Repair Cross Complementing Protein 1 
19 Poly [ADP-ribose] polymerase 1 
20 Auto-poly-Adenosine diphosphate ribose ribosylation 
21 Transcription Coupled Nucleotide Excision Repair 
22 Global Genome Nucleotide Excision Repair 
23 Ribonucleic Acid Polymerase II 
24 Cockayne syndrome factors A and B 
25 Xeroderma pigmentosum Complementation Group C 
26 Human Homolog Rad23 B 
27 Ultra-Violet Damage Deoxyribonucleic Acid Binding Protein B 
28 DNA Damage Binding Protein Component 1 
29 DNA Damage Binding Protein Component 2 
30 Xeroderma pigmentosum Group E 
31 Transcription Factor II Human  
32 Xeroderma pigmentosum Group G 
37 
 
of XPA33 and RPA34, both of which also further orientate any of the two endonucleases that cuts 
the damaged strand (~30-50 nucleotides) with respect to the lesion. These endonucleases cut 5ʹ 
from the lesion by XPG and 3ʹ from the lesion by the ERCC135-XPF36 complex. The single 
strand gap is filled by DNA replication proteins (RFC37, PCNA38, RPA, and DNA polymerases 
δ, ε, or к). The nicks are then sealed by DNA ligases I or III (Giglia-Mari, 2011). 
1.8.3.3 Homologous Recombination  
 Homologous recombination (HR) requires a homologous sister chromatid to perform 
repair, and thus takes place when cells are in the S and G2 phases of the cell cycle.  HR initiates 
repair of double strand breaks (DSB) via sensor PARP-1, which competitively binds against 
Ku7039 to damaged DNA, leading to the recruitment of the MRN40 complex (3 proteins: Nbs141 
brings MRE1142 and RAD50 into the nucleus). In turn, the MRN complex binds to broken strand 
ends and holds them, while leading to a secondary successive recruitment with nuclease CtIP43. 
This generates complex MRN-CtIP that together with complex BRCA1/BARD1 initiate 
resection of un-even DSB ends. Resections are processed in tandem by now endo/exo-nuclease 
active* MRN-CtIP complex (*MRE11 in active contact with DNA). Two exonucleases: EXO144, 
and DNA245, along with helicase BLM46 extend the resection to several 1,000 base pairs. Double 
strands with 3ʹ ends are degraded towards the 5ʹ end, producing 3ʹ single strand tails (or 
                                                 
33 Xeroderma pigmentosum Group A 
34 Replication Protein A 
35 Excision Repair Cross Complementation Group 1 
36 Xeroderma pigmentosum Group F 
37 Replication Factor C 
38 Proliferating Cell Nuclear Antigen 
39 Protein Ku70 Recognizes free ends from DNA double breaks 
40 Mre11/Rad50/Nbs1 
41 Nijmegen Breakage Syndrome-1 Protein 
42 Meiotic Recombination 11 Protein 
43 C terminal interacting protein 
44 Exonuclease 1 
45 DNA2 nuclease  
46 Bloom Syndrome RecQ Like Helicase 
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overhangs). MRN complexes detach, and RPA proteins instantly coat these exposed 3ʹ single 
strand tail regions. BRCA1/BRCA2/PALB2 assist RAD51 in replacing RPA proteins from the 3ʹ 
single strand regions by forming RAD51 single stranded nucleofilaments. This step allows 
homologous search and invasion of the single stranded RAD51 coated portions with its 
homologous sequence from a sister chromatid. Strand exchange occurs, and complementary 
DNA is synthesized by polymerase using the sister chromatid as a template. Once the process is 
completed, the ends are sealed by a DNA ligase (Chen, 2017, De Lorenzo, 2013, Giglia-Mari, 
2011).  
1.8.3.4 Non-Homologous End-Joining  
The Non-Homologous End-Joining (NHEJ) pathway trims and ligates un-even DNA 
DSB to keep helix integrity. Different from HR, NHEJ: (1) does not require a sister chromatid as 
a template, (2) is more prone to generate downstream replication errors, and (3) it operates at 
different phases of the cell cycle. NHEJ initiates DSB repair after the break is recognized by the 
Ku70/Ku80 complex, which binds to DSB ends, recruiting intermediate DNA-PKcs47. In turn, 
DNA bound DNA-PKcs undergoes both auto-phosphorylation and dissociates from the DSB 
ends. The ends are now free for binding, and complex XRCC4/Ligase IV (known as XL) ligates 
the ends. However, if the ends have been damaged by 3ʹ phosphate or 5ʹ hydroxyl groups, 
XRCC4 proceeds to recruit PNKP48 to repair the ends.  DNA-PKcs further phosphorylates other 
downstream factors (nuclease Artemis, PNKP and DNA polymerases). The Artemis nuclease 
then recognizes and cleaves any overhanging DNA tails. The ends are then aligned by 
XRCC4/XLF into a protein-DNA filament that allows ligation. The final step is carried by other 
DNA polymerases (Pol μ and Pol λ) to process the ends (Chu, 2014, Goodarzi et. al., 2006). 
                                                 
47 DNA-dependent protein kinase catalytic subunit 
48 Polynucleotide kinase/phosphatase 
39 
 
1.8.3.5 Mismatch Repair 
Mismatch repair (MMR) is a post-replicative pathway that corrects mismatched base-
base nucleotides, or insertion/deletion loops (IDLs). Replication errors by synthesis or proof-
reading executed via low-fidelity polymerases can lead to DNA mismatches. The most abundant 
mismatch binding factor is heterodimer MSH249/MSH650 (or MutSα), and it repairs base-base 
mismatches and 1-3 IDLs. Larger sequences of IDLs (2-10) are repaired by heterodimer 
MSH2/MSH351 (or MutSβ). In absence of MSH2, MMR becomes completely impaired. 
Therefore, the initial proteins implicated in MMR will vary depending on the type of damage. In 
addition, in MMR, protein-protein and DNA protein interactions are modulated by 
ATP52/ADP53. First, damage is recognized: (1) for mismatched bases, helix distortion is 
recognized via MutSα complex. (2) Alternatively, recognition of IDLs are via MutSβ complex. 
MutS (α or β) complex binds where DNA has been damaged and recruit their corresponding 
MutL (α or β) as well as MutH (MLH154/PMS255). This generates a ternary complex 
(MutS/MutL/MutH). In base-base-MMR, the ternary complex is (1) [MutSα/MutLα/yPMSI], and 
for IDL-MMR the ternary complex is (2) [MutSβ/MutLβ/hPMSI]. The PMS2 protein present on 
the ternary complex has endonuclease activity that’s stimulated by ATP/ADP, leading to the 
introduction on nicks in the discontinuous strand of DNA. A secondary recruitment takes place 
where nuclease EXO1 allows the mismatch containing strand to be cleaved in a 5′ to 3′ direction. 
The PCNA clamp is then loaded with polymerase Pol δ at the 3′ terminus. Both PCNA and Pol δ 
fill the gap finalized by sealing the nick via DNA ligase I (Hsieh, 2008, Jiricny, 2006). 
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50 MutS Homolog 6 
51 MutS Homolog 3 
52 Adenosine triphosphate 
53 Adenosine diphosphate 
54 MutL Homolog 1 
55 Mismatch Repair Endonuclease PMS2 
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1.8.3.6 Translesion Synthesis (bypass) 
Translesion synthesis is not a repair pathway but a damage tolerance pathway. TLS can 
take place during replication or post replication. For example, during replication, a high-fidelity 
polymerase may encounter DNA damage and stalls at the replication fork. The now exposed 
single stranded DNA gets coated by protein RPA. This stimulates ubiquitin ligase-RAD18 (along 
with enzyme RAD6) to form complex RAD18/RAD6, and this complex monoubiquitylates the 
PCNA polymerase clamp. PCNA monoubiquitylation enhances its interaction with other 
translesion polymerases. This step allows the replicative polymerase to be replaced by another 
translesion polymerase. Depending on the specific damage, any of these TLS polymerases are 
then recruited to resume replication. This allows the damage to be tolerated via lesion bypass. 
TLS polymerases belong to the y-family polymerases and they could insert complementary 
correct or incorrect bases. The TLS replication extends for a short tract and then replaced by the 
original replicative polymerase.  
1.8.4 DNA Damage Response and Butadiene Epoxides  
One of the main gaps of BD-carcinogenesis MOA that remains unanswered is what 
specific DNA repair pathways are involved in the repair of each BD-epoxide. Upon BD-induced 
DNA damage, we hypothesize that several lesions can arise. Let’s consider first that the most 
prevalent lesions from N7Gua monoadducts (HB-GuaI, HB-GuaII, and THB-Gua) will be 
chemically unstable and thus spontaneously depurinate, leaving an abasic site.  
Taking all this information into account the identity of each one of these DNA lesions 
will ultimately influence a corresponding biological response. We have a clear understanding of 
what specific DNA-epoxide lesions are formed, but as for what DNA damage response is 
summoned upon the damage caused by each individual epoxide remains unclear. To gain 
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knowledge on BD-induced DNA repair, we proposed as the third Aim of this project (Chapter 4) 
to identify those relevant DNA repair pathways involved in the response of DNA damage 
induced by BD-epoxides. Ultimately, the assessment and elucidation of DDR (DNA damage 
response) by BD-epoxides will provide valuable information on DNA repair as a non-mutational 
event to the BD-carcinogenic MOA. The determination of BD epoxides DDR pathway can be 
assessed by using the DT40/XTT DNA damage response system. This high throughput multi-
well plate approach employs the use of normal and DNA repair and cell cycle pathway-deficient 
mutant DT40 chicken lymphocytes. These cells are treated with chemicals such as BD-epoxides 
and later stained with XTT dye to quantitatively determine the LD50 by absorbance with an 
automatic absorbance well plate reader. Survival data is statistically analyzed to compare wild 
type and mutant DT40 cells, identifying those pathways involved in BD-epoxide specific DNA 
repair. To better understand the effects on the genotoxicity of BD-epoxides, we screened several 
DNA-repair-deficient DT40 mutants [Table 1.3] and compared results with the parental DT40 
cell line. The genotoxicity profiles were calculated as the relative LD50. This calculation 
requires the LD50 of the parental DT40 vs the mutant DT40 LD50. Ultimately, results from this 
assay will provide information of what potential mechanisms of repair might be involved by BD-
epoxides.   
1.8.4.1 EB and EB-diol Epoxides Potentially Repaired by   
 Base Excision Repair  
BER could be the DNA Damage Response (DDR) pathway to repair EB and EB-diol 
(and its isomers) epoxide damage using their BD-monoadducts (both HB-Gua and THB-Gua) as 
reference. Since these N7 adducts have half-lives of ~4 days, both N7 adducts and resulting AP-
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sites from spontaneous depurination will arise. The BER specific protein MPG56, flips the 
damaged base out of the double helix and excises the N7 monoadducts leaving an AP-site. AP-
sites generated upon N7 monoadducts removal or their spontaneous depurination would be 
repaired by filling the gap via Pol β with a new unmodified Gua, and repair is finished by closing 
the gap with the ligase complex. Therefore, we hypothesize that the DDR induced from EB, and 
EB-diol (and its isomers) that repairs their corresponding HB-Gua, THB-Gua adducts, or its AP-
sites lesions would require the involvement of the BER pathway. 
1.8.4.2 DEB Epoxide Potentially Repaired by    
 Homologous Recombination or Non-Homologous   
 End-Joining 
HR or NHEJ could be the DNA Damage Response (DDR) pathway to repair DEB 
epoxide damage using their crosslinks as reference. Therefore, we hypothesize that the DDR 
induced from DEB that repairs their corresponding crosslinks, AP-sites or double strand breaks 
would require the involvement of the HR and or NHEJ pathway.  
1.8.5 DNA Damage Response and DT40/XTT System 
Dr. Jun Nakamura and colleagues at UNC-Chapel Hill, developed a novel assay 
employing a reverse genetic approach with chicken DT40 B-lymphocyte cell lines that are DNA-
repair-deficient for numerous DDR pathways. The assay facilities the process of narrowing 
specific DDR pathways involved when exposing them to an agonist (i.e.: BD). In addition to 
being specific for elucidating the mechanism of DDR that’s involved against the agonist, it 
provides sensitive quantitation per each of DDR pathways (Ridpath, 2007, Ridpath, 2011). 
Therefore, this method is an excellent tool to attain our goal; to elucidate those DDR pathways 
                                                 
56 Methyl purine glycosylase 
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involved in each specific BD-epoxides. The DT40/XTT assay will identify those critical DDR 
pathways summoned by each individual BD-epoxide 
1.9 Research goal and specific aims 
The overall goal of this project was to address dataset gaps in BD-epoxide metabolic 
activation and DNA repair and improve our understanding of BD’s MOA, and its relationship to 
BD-carcinogenesis. Our hypothesis was that through the development and combination of new 
and improved analytical methods, incorporation of comprehensive data sets, and in vitro 
techniques, we would identify multispecies similarities and differences in BD-metabolic 
activation. Also, the integration of DNA-damage response would serve as an endpoint to 
strengthen BD carcinogenic MOA and identify relevant epoxide-specific differences in repair. 
Results contributed in the improvement of scientific risk assessment, public health, and further 
employed as an application to other known multispecies carcinogens.  
This dissertation, integrated and applied previously developed methods from our laboratory. 
Aim 1 was the generation, puriifcation, and quantitation of EB-diol epoxide-specific THB-Val 
peptide standards. In Chapter 2, methods are described for the direct alkylation, purification by 
LC/MS, characterization by MS/MS, and quantitation by UPLC/MS/MS-based amino acid 
analysis of BD specific α (1-11) NTV peptide standards containing the EB-diol-specific adduct 
THB-Val. Three analyte, and three internal THB-Val peptide standards were successfully 
prepared and used in several downstream analytical applications. THB-Val peptide standards 
were later integrated in the validation of a simultaneous IA-enrichment method used in the 
analysis and completion of a unique multispecies data-set exposed to BD. The second Aim was 
to further develop an improved method for simultaneous analysis of all three adducts (HB-Val, 
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pyr-Val, THB-Val) formed by butadiene epoxides at the NTV of Hb α chain in mice exposed to 
butadiene via inhalation. 
This completed the quantitation of BD Hb adducts in our comprehensive rodent dataset. Chapter 
3 integrates the use of species specific mice (1-11) peptide standards with a recently improved 
IA coupled UPLC-positive mode electrospray ionization-tandem mass spectrometry (UPLC-ESI+ 
-MS/MS) method for the simultaneous quantitative analysis of all three BD-Hb adducts from 
globin of mice exposed to BD. Tryptic digests of isolated globin cleaved the protein into peptides 
containing the BD-Hb adducts.  The digests were processed via triple antibody IA enrichment. 
Samples were quantitated with nano-UPLC-MS/MS analysis using 13C15N5-labeled internal 
standard peptides. BD-Hb adducts results were integrated in the calculation of the IBD of BD-
epoxides, and transformed into the EB-equivalency for further comparisons. The third Aim was 
to evaluate DNA damage response pathways induced by selected BD-epoxides. Chapter 4 
incorporates the use of a high-throughput in vitro vertebrate cell assay.  DT40 wild type cells, 
and an extensive collection of DNA repair mutant clones, were used to assess BD-epoxides DNA 
Damage Response pathways. Effects were expressed as the Relative LD50, using DT40 parental 
cells and DT40-/- mutants. These mutants were deficient in seven DNA repair pathways and 
include mutants in cell cycle checkpoint, BER, NER, HR, NHEJ, MMR, TLS, DNA damage 
sensors and Helipses. 
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Table [1.1]: Albertini et al 2001 (Albertini I): Analysis for urine metabolites by group in occupationally exposed  workers to 
BD. (a) n = 34 
 
 
 
 
 
 
 
 
 
Net Work Group 
(After-Before) 
n BD 
ppm 
M1 
(ug/l) 
SD M2 (ug/l) SD Fold Difference 
(M1/M2) 
After-Work Ratio 
Activity of 
Conjugation 
M2/(M1 + M2) 
Control 25 0.290 −219 274 −0.50 1.22 4.4 0.0049 
Monomer 24 0.812 213 565 5.28 8.54 40.3 0.0115 
Polymer 33 0.010 2683 5868 84.26 225.95 31.8 0.0182a 
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After Work 
Group  
n BD 
 
M1  SD M2  SD Fold 
Difference 
After-Work Ratio Activity of 
Conjugation 
After-Work Ratio Activity of 
Hydrolysis 
  ppm (ug/l)  (ug/l) + (M1/M2) M2/(M1 + M2) M1/(M1 + M2) 
Females 51         
Control 26 0.004  331.6 284.9 8.3  10.1 40.0 0.024 0.976 
Exposed 23 0.180 508.1 597.4 19.2  27.5 26.5 0.037 (1.54 fold) a 0.964 (0.98 fold) a 
Males 55         
Control 25 0.003  512.8 272.1 14.9 10.3 34.4 0.029 0.972 
Exposed 30 0.367 854.1 567.0 47.9 44.3 17.8 0.052 (1.79 fold) a 0.947 (0.97 fold) a 
All Controls 51 0.0035 422.2  11.6  37.2 0.027 0.973 
All Exposed 53  681.1  33.5  22.2 0.045 (1.68 fold) a 0.953 (0.98 fold) a 
 
 
Table [1.2]: Albertini et al 2007 (Albertini II): Urine metabolites by group in occupationally exposed workers to BD. (a) Fold 
differences calculated from [Ratio of Activity Exposed/Ratio of Activity Control] 
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Pathway DT40 Cell Line 
 Wild-Type DT40 
Checkpoint ATM-/- 
Sensor RAD17-/- 
HR 
RAD54-/- 
RAD51c-/- 
RAD51d-/- 
XRCC2-/- 
XRCC3-/- 
BRCA1-/- 
BRCA2-/- 
FANCD2-/- 
HEL BLOOM
-/- 
WERNER-/- 
NHEJ 
KU70-/- 
DNAPKcs-/- 
LIGIV-/- 
TLS 
RAD18-/- 
REV1-/- 
POLH-/- 
POLK-/- 
POLQ-/- 
BER 
POLB-/- 
FEN1-/- 
PARP1-/- 
NER XPA
-/- 
XPG-/- 
MMR MSH3-/- 
 
Table [1.3]: DT40 wt and DT40 mutant cells  
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1.11FIGURES: 
 
 
 
 
 
Figure [1.1]: Butadiene Metabolism and Fate 
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Figure [1.2]: Survival Adjusted Tumor Rates of Neoplasms in Female and Male B6C3F1 
Mice Exposed to 1,3 Butadiene via Inhalation (adapted from Melnick, 1993) 
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Figure [1.3]: Butadiene Hemoglobin Adducts; Metabolism and NTV Adducts 
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CHAPTER II: DIRECT ALKYLATION, CHARACTERIZATION, AND 
QUANTITATION OF BUTADIENE SPECIFIC α (1-11) N-TERMINAL THB-VAL 
HEMOGLOBIN PEPTIDE STANDARDS1 
 
2.1 OVERVIEW 
1,3-Butadiene (BD) generates three reactive epoxides that can form covalent bonds 
forming protein adducts at the N terminal Valine (NTV) of Hemoglobin (Hb). Of all three 
epoxides formed from BD, the most abundant across species is 1,2-epoxy-3,4-butenediol (EB-
diol), and when bound to Hb it forms BD-Hb adduct N-(2,3,4-trihydroxybutyl)-valine (THB-
Val). These adducts can be measured and used as biomarkers of exposure to estimate the internal 
dose of the epoxides that arose from BD exposure. Recent methods for the detection of all three 
Hb-adducts of BD were adjusted for simultaneous Immunoaffinity (IA) enrichment. Part of this 
development required the use of THB-Val analyte and internal peptide standards that were not 
previously available. Here we describe the methods for the direct alkylation, purification by 
LC/MS, characterization by MS/MS, and quantitation by UPLC/MS/MS-based amino acid 
analysis of BD specific α (1-11) NTV peptide standards containing the EB-diol-specific adduct 
THB-Val. Three analyte, and three internal THB-Val peptide standards were successfully 
prepared and used in several analytical applications. THB-Val peptide standards were later 
                                                 
1 A portion of this Chapter previously appeared as part of a major article in Elsevier: Journal of Chemico-Biological 
Interactions. The original citation is as follows: J.A, Swenberg et al “1-3, Butadiene: Biomarkers and Application to 
Risk Assesment”, Chemico-Biological Interactions 192 (2011): 150-54. 
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integrated in the validation of a simultaneous IA-enrichment method used in the analysis and 
completion of a unique multispecies data-set exposed to BD.  
2.2 INTRODUCTION 
Exposure to Butadiene (BD) has been associated with multi-site carcinogenesis in rodents 
(Swenberg 2000, Booth 2004) and with an increased incidence of leukemia and lymphoma in 
humans in occupationally exposed workers (Ospina 2005). BD is relatively non-reactive, until 
absorbed, distributed and metabolically activated, leading to the generation of reactive epoxides 
that ultimately generate covalent binding with proteins, such as Hemoglobin (Hb) and DNA.  
The first step of BD activation [Figure 2.1] is the oxidation of BD into the first 
monoepoxide, 1, 2-epoxy-3-butene (EB) by enzymes CYP2E1 and CYP2A6. The second step is 
further oxidation of EB, into the diepoxide: 1,2;3,4 diepoxybutene (DEB) by enzymes CYP2E1 
or CYP3A4. Both EB and DEB can undergo hydrolysis and form Butene-diol (BD-diol) from 
EB or the formation of the second mono epoxide, 1,2-epoxy-3,4-butanediol (EB-diol) from DEB, 
by the enzyme epoxy hydrolase (EH). Ultimately BD-diol can be oxidized again into more EB-
diol. Of all three epoxides, EB-diol is the most abundantly produced across species. 
There is an inversely proportional relationship across BD-epoxides; whereas the most 
mutagenic epoxides are the least abundantly generated (DEB > EB > EB-diol) and the least 
mutagenic epoxides are most abundantly generated (EB-diol > EB > DEB) (Swenberg 2011, 
Meng 2010). The individual mutagenic potency of these BD-epoxides can vary up to 200 fold 
(Walker 2009, Meng 2007); going from most to least mutagenic in the following order DEB > 
EB > EB-diol (Walker 2009). When looking closer at gender and species; the mutagenic 
response to BD has shown to be higher in female mice > male mice > female rats > male rats 
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(Meng 2007b). In part, this has presented as to why BD is a potent carcinogen for mice but weak 
in rats.  
The epoxy terminus of EB, DEB and EB-diol, reacts with the N-terminal Valine (NTV) 
of Hb upon BD exposure (Moll 1999) forming three epoxide specific adducts. The most 
abundant epoxide formed across species upon BD activation is EB-diol and produces epoxide 
specific Hb-adduct (N-(2,3,4-trihydroxybutyl)-valine (THB-Val). Epoxide EB and DEB also 
bind to the NTV of Hb forming adducts N-(2-hydroxy-3-butenyl)valine (HB-Val) and N,N-(2,3-
dihydroxy-1,4-butadiyl)valine (pyr-Val) respectively.  
All three Hb-adducts can be measured as biomarkers of exposure, and are used to 
calculate the internal dose resulting from exposure to BD. Earlier reports have identified species 
differences in the formation of both endpoints; ultimately indicating BD has a species dependent 
metabolic activation. In the last 15 years, several methods were developed and employed for the 
measurement and quantitation of BD-NTV Hb adducts (Fred 2004a, Fred 2004b, Boysen 2004, 
Georgieva 2007, Georgieva 2010, Stednigk 2010). Initially, detection of pyr-Val, HB-Val and 
THB-Val from both Hb-chains (α-Hb and β-Hb) were attempted by employing the N-alkyl 
Edman method (Edman 1950) with subsequent analysis via gas chromatography-mass 
spectrometry (GC-MS and GC-MS/MS). Although this approach worked for specific BD-
adducts HB-Val and THB-Val, it presents limitations. First, this method cannot distinguish if 
those adducts are from the α-Hb or β-Hb chains, second it is unsuitable for pyr-Val 
measurement, and third it had limited sensitivity on samples at low levels of BD exposure 
(Törnqvist 1986, Booth 2004, Powley 2005). Particularly, pyr-Val adduct detection was not 
possible because its cyclic structure blocks coupling and cleavage required for the N-alkyl 
Edman reaction reagents to generate the derivatives which are the products used in the 
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quantitation step (Törnqvist 1986). Also, earlier work performed in our laboratory using the N-
alkyl Edman method, resulted in poor recovery of analyte and internal THB-Val standard 
(Powley 2005).  
Earlier work from our laboratory presented a method that opened the possibility of 
analyzing both the pyr-Val and HB-Val adducts at low levels of exposure. The alternative 
technique incorporated the use of NTV modified (1-11) pyr-Val [2H3] and (1-11) HB-Val-[13C5 
15N] peptide standards for rat, mice and human α Hb chain sequences. First, globin (10-50mg) 
undergoes tryptic digest and it’s later enriched via immunoaffinity (IA). Elutes obtained from IA 
undergo analysis of the fraction of interest using a nano-UPLC-ESI+ MS/MS. The method was 
sensitive enough to quantitate both pyr-Val and HB-Val adducts with a LOD/LOQ of 1 & 4 fmol 
on column. (Boysen 2004, Georgieva 2007, Georgieva 2010, Boysen, 2012). Results from these 
single antibody IA columns proved to be a suitable method for measuring both pyr-Val and HB-
Val using N-terminal modified (1-11) peptide standards.  
Recently, the method has been adjusted to perform simultaneous adduct enrichment and 
analysis by our laboratory. These improvements significantly reduce the use of laboratory 
supplies, labor time, amount of globin required as well as the number of samples to be analyzed 
and overall sample processing expenses over previously existing methods. Another advantage of 
using IA enrichment was that it was suitable for pyr-Val quantitation, overcoming the limitation 
of N-alkyl Edman method. Results for single IA columns have been published for both pyr-Val 
and HB-Val but not for THB-Val (Boysen, 2004, Georgieva, 2007, Georgieva, 2010). To 
complete the evolution from single IA enrichment (just pyr-Val or just HB-Val) to simultaneous 
IA enrichment, first required the generation of unique N-terminal modified α (1-11) THB-Val 
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peptide standards for mouse, rats and human. These were readily available for pyr-Val and HB-
Val, but not for THB-Val.  
2.3 METHODS 
2.3.1 Materials: 
All reagents and solvents were ACS grade or higher. NTV (1-11) peptides [Rat 
(VLSADDKTNIK & [15N 13C5 V]-LSADDKTNIK; MW 1203/1209), Mouse (VLSGEDKSNIK 
& [15N13C5V]-LSGEDKSNIK; MW 1189/1195) and Human (VLSPADKTNVK & [15N13C5V]-
LSPADKTNVK; MW 1172/1178)] were purchased from Anaspec (Fremont, CA). Microspin 
ﬁlter tubes (regenerated cellulose, 0.2 um) were from Alltech Associates Inc. (Deerﬁeld, IL). 
Jupiter Proteo 4, 90A, 250 x 4.60 mm Chromatographic Column was purchased from 
Phenomenex (Torrance, CA). The UPLC™ BEH SHIELD RP18 2.1 mm × 150 mm, 1.7 μm 
column was purchased from Waters Corp. (Milford, MA). EB-diol (MW 104) was synthesized 
and purified by the UNC Chapel Hill Chemistry Core in the Department of Environmental 
Sciences and Engineering.  
2.3.2 Methods:  
2.3.2.1 Hemoglobin α (1-11)-THB-Val peptide standards 
2.3.2.1.1 Direct alkylation of peptide standards  
Generation of THB-Val analyte and internal [13C5 15N] peptide standards were achieved 
by direct alkylation of the NTV with EB-diol as previously described (Fred 2004a and Fred 
2004b) with modifications. All peptides were weighed and diluted in 18 Mega Ohm deionized 
water to a final concentration of 10mM. Small test reaction mixture solutions were mixed with 
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10mM analyte peptide at both 1:10 and 1:20 ratios peptide: EB-diol in 0.1M Ammonium 
Bicarbonate at pH 4, pH 6.8, and pH 8. Reaction mixtures were incubated at 37.5oC with shaking 
and monitored every 24 hours for three days (data not shown). The final optimized conditions for 
direct alkylation reaction were performed at 1:20 molar ratio of peptide: EB-diol in 0.1M 
Ammonium Bicarbonate buffer (pH 6.8) with shaking at 37.5oC for 72 hours [Figure 2.2]. 
Aliquots of diluted reaction mixtures were analyzed by direct (loop) injection in a Thermo 
Finnigan LCQ DECA Ion Trap Mass Analyzer (Thermo Fisher Scientific, Waltham, MA),  to 
characterize reaction products by setting the MS to do a Full Scan (range 200-2000 m/z) in 
positive ion mode [Table 2.1].  Once monoalkylation was achieved, formic acid was added to 
reduce the pH of the reaction mixtures down to pH2. This destroyed any excess of EB-diol, 
preventing any further unwanted alkylation at other positions other than at the NTV. Reaction 
mixtures were kept at -20 oC until purified.  
2.3.2.1.2 Purification by LC-ESI+ MS/MS 
Analyte and internal THB-Val peptide standards were purified from reaction mixtures by 
monitoring and separating the monoalkylated products via LC-ESI+ MS/MS. Five channels were 
monitored to observe ion Chromatograms for (1) the Full Scan Spectra, and the MS/MS of the 
(2) unalkylated, (3) monoalkylated, (4) dialkylated and (5) trialkylated reaction mixture products 
[Table 2.1]. Different mobile phases and gradients were tested until appropriate conditions were 
met. Reverse phase chromatographic separation of each reaction products was achieved by 
monitoring the monoalkylated fraction [(1-11 THB-Val)] by MS/MS m/z in each reaction 
mixtures, using a Jupiter 4u Proteo 90A 250 x 4.60 mm column in a DECA Ion Trap Turbo 
analyzer. Mobile phases were tested to monitor retention times for the (1-11) THB-Val peptide 
standards [Table 2.2]. Purification of peptide standards was completed once there was separation 
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of the chromatographic peaks of the reaction products. By manually diverting the valve to waste, 
the corresponding (1-11) THB-Val peptide standards were collected into Eppendorf tubes. These 
purified fractions were concentrated by vacuum centrifugation in a Savant speed-vac (Thermo 
Scientific, Waltham, MA) and reconstituted with 500uL of 18 Mega Ohm deionized water. 
Micro-spin filters were pre-rinsed with water and purified fractions were filtered, followed by an 
additional rinse. The purified (1-11) THB-Val fractions were stored at -20 oC until characterized. 
2.3.2.1.3 Characterization by MS/MS (b and y   
    fragments) 
The THB-Val adducted peptides were characterized using MS/MS comparing the 
expected and obtained THB-Val specific b and y ion fragments.  
Analyte and stable isotope labeled internal (1-11) THB-Val peptide standards were re-
analyzed on column using the same chromatographic conditions as described above for isolation 
[Figure 2.3]. In addition, aliquots of 10-20uL were also assessed by loop injection to confirming 
collection of the monoalkylated fraction by Full Scan 1001500 m/z [Table 2.1]. Both on 
column injections, and loop injections were used to perform an MS/MS fragmentation analysis 
(collision energy of 35) that provided the spectrum of THB-specific b fragments, confirming the 
specific alkylation at the NTV [Figure 2.5a]. Theoretical b and y fragments of each peptide 
standard were calculated using the free online proteomic tool MS-Product Peptide Sequence, 
from the Protein Prospector Database v 5.10.1 (University of California, San Francisco, CA), 
available online [Tables 2.3, 2.4 and 2.5]. Experimental b and y fragmentation patters obtained 
from the MS/MS fragmentation analysis were compared to those theoretical fragments, and 
THB-specific fragments and NTV alkylation was confirmed [Figure 2.5b]. Un-quantitated 
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purified and characterized THB-Val peptide standards were prepared in aliquots and stored at -
80oC until further analysis.   
2.3.2.1.4 Quantitation of 1-11-THB-Val peptide   
    standards by UPLC MS/MS 
Peptide standards were acid hydrolyzed and analyzed by UPLC MS/MS to perform 
amino acid quantitation based on a procedure previously described (Bordeerat 2009). In brief, 
duplicate 50uL aliquots of each peptide standard was acid hydrolyzed with HCl for 4 hours at 
150oC. Peptide standard samples were quantitated based on the concentration of at least 3 amino 
acids from the peptide standard sample sequence and using Norleucine as internal standard in 
both samples and calibration peptide standard amino acid mix [Figure 2.6a and 2.6b]. Samples 
were analyzed in SRM mode using a 2.1 mm × 150 mm UPLC™ BEH SHIELD RP18 1.7 μm 
column in a linear gradient from 20% methanol-0.1% formic acid to 80% methanol-0.1% formic 
acid for 7 minutes at a flow rate of 200 μL/min. Amino acids from the (1-11) peptide sequence 
were monitored using their individual MS/MS transitions [Table 2.6 and 2.7]. Peptide standard 
amino acids with the best reference factors were obtained and used for the quantization and the 
peptide final concentrations [Table 2.8]. Quantitated (1-11) THB-Val peptide standards were 
prepared in aliquots and stored at -80oC until used for validation, instrument tuning and sample 
analysis. 
2.4 RESULTS 
Here we present the methods for the direct alkylation, purification, characterization an 
quantitation of BD specific (1-11) NTV peptide standards containing the EB-diol-specific adduct 
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N-(2,3,4-trihydroxybutyl)-valine (THB-Val). Direct alkylation of α (1-11) peptide sequences by 
EB-diol, and the resulting mono-alkylated adducts (1-11 THB-Val) were purified by HPLC, 
characterized by LC-ESI+ MS and LC/MS/MS peptide fragmentation, and finally quantitated by 
UPLC/MS/MS-based amino acid quantitation after acid-hydrolysis. 
2.4.1 Direct alkylation of Hb α (1-11) peptide sequences for (1-11)   
 THB-Val peptide standards  
Generation of THB-Val analyte and internal [13C5 15N] peptide standards were achieved 
by direct alkylation of the NTV with EB-diol. The direct alkylation approach allowed us to 
identify three main direct alkylation reaction products in the reaction mixtures; unalkylated, 
monoalkylated [1-11-THB-Val], dialkylated and in some trialkylated. Details of reaction mixture 
products by species are illustrated in [Table 2.1]. At 72 hours we achieved a high proportion of 
monoalkylation in all peptides reaction mixtures. The most critical variable that affected reaction 
mixture products was pH. When reaction mixtures were above 6.8 pH, the indiscriminate 
alkylation of Lysines was favored. Since the goal was to alkylate the NTV, we had to monitor 
pH through the course of the incubation to ensure we avoided unwanted Lysine alkylations at the 
7th and 11th position of the (1-11) peptide sequence. Optimal direct alkylation conditions were 
obtained at 1:20 molar ratio of peptide-EB-diol in 0.1M Ammonium Bicarbonate buffer (pH 6.8) 
incubated-shaking at 37.5oC for 72 hours.  
2.4.2 Purification of (1-11) THB-Val by LC-ESI+ MS/MS 
Analyte and internal (1-11)-THB-Val peptide standards were purified from reaction 
mixtures by monitoring and separating the monoalkylated products via LC-ESI+ MS/MS, and 
using a single reverse phase chromatographic column Jupiter 4u Proteo 90A 250 x 4.60 mm.  
Both rat and human (1-11) THB-Val peptide standards were successfully separated with similar 
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solvent conditions, and by adjusting the pH we were able to separate the human reaction mixture 
[Table 2.2]. We were not able to separate the mouse reaction mixture with the same solvents 
used as we did for the rat and human reaction mixtures. We overcame this obstacle by switching 
both solvents and only using TFA as a mobile phase modifier [Table 2.2].  
2.4.3 Characterization of NTV Alkylation by MS/MS (b and y    
 fragments) 
The (1-11) THB-Val peptide standards were positively collected by Full Scan MS and 
confirmed that EB-diol alkylated the NTV by THB-specific b fragments using MS/MS. The most 
common THB-Val specific fragments were b10, and b9.  Also, fragments y5 and y6 served as 
confirmation that the Lysines were not alkylated. Since all three species have Lysines in 
positions 7th and 11th, this was a critical step to ensure we directly alkylated and purified the 
correct (1-11)-THB-Val peptides standards. In addition, all (1-11) peptide sequences had Serine 
in the 3rd position, and their corresponding fragments b3-b10 and y10-y9 were also clear from 
EB-diol alkylation [Figure 2.5a and 2.5b]. Previous reports have indicated the alkylation of 
Lysine, Histidine, Serine, and Methionine residues in both α-Hb and β-Hb chains by EB and 
DEB (Moll 2000, Basile 2001, Miraglia 2002, Badghisi 2002). 
2.4.4 Quantitation of 1-11-THB-Val peptide standards by UPLC   
 MS/MS 
Amino acid quantitation for all (1-11)-THB-Val peptide standards was obtained by using 
3 or more amino acids as reference. All (1-11) THB-Val peptide standards shared 3 common 
reference amino acids were Threonine, Leucine and Aspartic Acid. The specific amino acids 
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used as reference in the peptide standard quantitation were as follows: (1) Proline, Threonine, 
Leucine and Aspartic Acid for Human-THB-Val; (2) Alanine, Threonine, Isoleucine, Leucine 
and Aspartic Acid for Rat-THB-Val; (3) and Alanine, Threonine, Isoleucine, Leucine and 
Aspartic Acid for Mice-THB-Val [Table 2.6].  
2.5 CONCLUSIONS 
2.5.1 THB-Val peptide standards 
The combined methods here presented the direct alkylation of Hb α (1-11) NTV peptides, 
chromatographic purification and characterization by LC-ESI+ MS/MS prior to amino acid 
quantization by UPLC MS/MS. These combine methods successfully generated both analyte and 
internal peptide standards for Hb α (1-11) Human THB-Val, Rat THB-Val, and Mouse THB-Val 
are here described.  
Optimal direct alkylation conditions were obtained at 1:20 molar ratio of peptide-EB-diol 
in 0.1M Ammonium Bicarbonate buffer (pH 6.8) incubated-shaking at 37.5oC for 72 hours. 
Direct alkylation presents a more straightforward peptide standards synthesis than the alkylation 
of single valine- followed by its derivatization as previously reported (Stedingk 2010). As an 
advantage, we separated monoalkylated products from their reaction mixtures by using a single 
reverse phase chromatographic column (Jupiter 4u Proteo 90A 250 x 4.60 mm). The only 
difference was the type of mobile phase solvents used. The (1-11) peptide sequences are very 
similar, between the Human and the Rat THB-Val peptide standards, sharing a 73% sequence 
homology. However, we speculate that differences in the purification conditions were different 
in the Mouse THB-Val peptide standard because it has a 64% sequence homology when 
compared to that of Human and Rat. All (1-11) THB-Val peptide standards shared 3 common 
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reference amino acids for their quantitation (Threonine, Leucine and Aspartic Acid). Final THB-
Val peptide standards concentrations obtained through this method were sufficient to generate 
enough material for future method development and validation, instrument tuning and sample 
processing.  
2.5.2 Incorporation and Application of peptide standards 
Several downstream analytical applications incorporated the use of THB-Val peptide 
standards. These included: tryptic digest optimization and nano-UPLC-ESI+ MS/MS instrument 
tuning. Of most importance, our goal was to incorporate the use of these standards to test 
recovery in our combined antibody IA columns. We were able to validate these columns with (1-
11) pyr-Val, (1-11) HB-Val and now including (1-11) THB-Val. Once validation of the columns 
was completed, we measured all three BD Hb- adducts and compared them across species from 
our comprehensive data set.  
2.5.3 Achievements  
Generating sensitive and accurate methods for the quantitation BD-Hb adducts provides 
the opportunity to determine the role on the formation of the EB, DEB and EB-diol reactive 
epoxides and their contribution to mutagenesis and carcinogenesis after exposure to BD. The 
goal of this report was to generate α (1-11) THB-Val peptide standards and employ them in the 
detection, quantitation, and comparison of THB-Val adducts across species. This initial step was 
required to complete our ultimate goal the detection and quantization of BD-specific Hb-adducts, 
including pyr-Val, HB-Val and THB-Val, using simultaneous IA enrichment coupled to nano-
UPLC-ESI+ MS/MS (Chapter 3).  
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THB-Val continues to be the major adduct formed in Hb across species, and also serves 
as a surrogate marker of EB-diol formation in blood. Being the greatest contributor in the 
internal blood dose, compared to EB and DEB, EB-diol poses the greatest risk to humans 
(Swenberg, 2011). The group’s overall final goal was to improve our understanding in the role of 
BD reactive epoxides and their toxicity across species to ultimately determine which of the two 
rodent species was the most appropriate for human risk assessment. 
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2.7 TABLES: 
 
 
(a) 
Species 
α (1-11) THB-Val analyte peptide standard reaction mixture products 
M/Z 
Unalkylated Monoalkykated Dialkylated Trialkylated 
 
Human 1170 1275 1379 1483 
 
Rat 1202 1307 1411 1515 
 
Mouse 1188 1293 1397 1501 
 
(b)     
     
Species 
α (1-11) THB-Val-[13C5 15N] internal peptide standard reaction 
mixture products 
M/Z 
Unalkylated Monoalkykated Dialkylated Trialkylated 
 
Human 1176 1281 1385 1489 
 
Rat 1208 1313 1417 1521 
 
Mouse 1194 1299 1403 1507 
 
Table [2.1]: Observed EB-diol + (1-11) Peptide reaction mixture products for all three 
species and their m/z: (a) α (1-11) THB-Val analyte and (b) α (1-11) THB-Val-[13C5 15N] 
internal peptide standards with other reaction products in and their corresponding MW.  
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Species 
 
1-11-THB-Val Peptide Standards 
 
Solvent A Solvent B M/Z Retention Time (minutes) 
Human 
 
 
15mM Ammonium 
Formate pH9 Methanol 1282/1288 20.6-21.0 
Rat 
 
15mM  
Ammonium Formate 
pH5 
Methanol 1308/1314 7.0-9.0 
Mouse 
 0.1% TFA Water 
0.1% TFA in 45% 
Acetonitrile 1293/1299 14.7-15.0 
 
Table [2.2]: (1-11) THB-Val Peptide Standards Chromatographic Purification Conditions 
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Mouse α (1-11) VLSGEDKSNIK Mouse α (1-11) THB-Val-LSGEDKSNIK 
Fragments Position Amino-Acid Position Fragments Fragments Position Amino-Acid Position Fragments 
b y b y 
                    
--- 1 V 11 --- --- 1 V 11 --- 
213.1598 2 L 10 1090.5739 317.26 2 L 10 1090.574 
300.1918 3 S 9 977.4898 404.30 3 S 9 977.4898 
357.2132 4 G 8 890.4578 461.32 4 G 8 890.4578 
486.2558 5 E 7 833.4363 590.36 5 E 7 833.4363 
601.2828 6 D 6 704.3937 705.39 6 D 6 704.3937 
729.3777 7 K 5 589.3668 833.48 7 K 5 589.3668 
816.4098 8 S 4 461.2718 920.51 8 S 4 461.2718 
930.4527 9 N 3 374.2398 1034.56 9 N 3 374.2398 
1043.5368 10 I 2 260.1969 1147.64 10 I 2 260.1969 
--- 11 K 1 147.1128 --- 11 K 1 147.1128 
 
Table [2.3]: Protein Prospector b and y fragments for Mouse α (1-11) peptide and Mouse α (1-11) THB-Val peptide standard. 
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Rat α (1-11) VLSADDKTNIK Rat α (1-11) THB-Val-LSADDKTNIK 
Fragments Position Amino-Acid Position Fragments Fragments Position Amino-Acid Position Fragments b y b y 
                    
--- 1 V 11 --- --- 1 V 11 --- 
213.1598 2 L 10 1104.5895 317.2648 2 L 10 1104.59 
300.1918 3 S 9 991.5055 404.2968 3 S 9 991.5055 
371.2289 4 A 8 904.4734 475.3339 4 A 8 904.4734 
486.2558 5 D 7 833.4363 590.3608 5 D 7 833.4363 
601.2828 6 D 6 718.4094 705.3878 6 D 6 718.4094 
729.3777 7 K 5 603.3824 833.4827 7 K 5 603.3824 
830.4254 8 T 4 475.2875 934.5304 8 T 4 475.2875 
944.4684 9 N 3 374.2398 1048.5734 9 N 3 374.2398 
1057.5524 10 I 2 260.1969 1161.6574 10 I 2 260.1969 
--- 11 K 1 147.1128 --- 11 K 1 147.1128 
 
Table [2.4]: Protein Prospector b and y fragments for Rat α (1-11) peptide and Rat α (1-11) THB-Val peptide standard. 
 
 
 
 
 76 
 
Human α (1-11) VLSPADKTNVK Human α (1-11) THB-Val-LSPADKTNVK 
Fragments Position AminoAcid Position Fragments Fragments Position AminoAcid Position Fragments 
b y b y 
                    
--- 1 V 11 --- --- 1 V 11 --- 
213.16 2 L 10 1072.60 317.26 2 L 10 1072.60 
300.19 3 S 9 959.52 404.30 3 S 9 959.52 
397.24 4 P 8 872.48 501.35 4 P 8 872.48 
468.28 5 A 7 775.43 572.39 5 A 7 775.43 
583.31 6 D 6 704.39 687.41 6 D 6 704.39 
711.40 7 K 5 589.37 815.51 7 K 5 589.37 
812.45 8 T 4 461.27 916.56 8 T 4 461.27 
926.49 9 N 3 360.22 1030.60 9 N 3 360.22 
1025.56 10 V 2 246.18 1129.67 10 V 2 246.18 
--- 11 K 1 147.11 --- 11 K 1 147.11 
 
Table [2.5]: Protein Prospector b and y fragments for Human α (1-11) peptide and Human α (1-11) THB-Val peptide 
standard. 
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Amino Acid Molecular Weight M/Z 
Amino Acids (RF) for THB-Val peptide standard 
quantitation 
   Human Rat Mice 
Glycine (G) 76.1 30.1   x 
Alanine (A) 90.1 44.1 x x  
Serine (S) 106.1 60.1 x x xx* 
Proline (P) 116.1 70.1 x   
Valine (V) 118.1 72.1 (Adducted) 
Threonine (T) 120.1 74.1 x x  
Isoleucine (I), Leucine (L) and 
Norleucine 132.1 86.1 
 (I) x (I) x 
(L) x (L) x (L) x 
Asparagine (N) 133.1 87.1 x x x 
Aspartic Acid (D) 134.1 88.1 x xx* x 
Lysine (K) 147.1 84.1 (Could be adducted) Glutamine (Q) xx* xx* xx* 
Glutamic Acid 148.1 89.1   x 
 
Table [2.6]: Amino acids Used for Peptide Standard Quantitation (as described in Bordeerat et al. 2009). The (x) marks selected 
amino acids for quantitation of the standard peptide. * Indicates that there are two of the same amino acids in the specific (1-11) 
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Amino Acid Position from Valine 
CID1 energy  MS/MS 
transitions [eV] 
Human  
  
Leucine (L) 2 10 132 → 86 
Proline (P) 4 10 116 → 70 
Aspartic Acid (D) 6 10 134 → 88 
Threonine (T) 8 10 120 → 74 
Norleucine Int. Standard 10 132 → 86 
Rat   
  
Alanine (A) 4 10 90 → 44 
Threonine (T) 8 10 120 → 74 
Isoleucine (I) 10 10 132 → 86 
Leucine (L) 2 10 132 → 86 
Aspartic Acid (D) 5 and 6 10 134 → 88 
Norleucine Int. Standard 10 132 → 86 
Mice  
  
Serine (S) 3 and 8 10 106 → 60 
Isoleucine (I) 10 10 132 → 86 
Leucine (L) 2 10 132 → 86 
Aspartic Acid (D) 4 10 134 → 88 
Glutamic Acid (E) 6 10 148 → 102 
Norleucine Int. Standard 10 132 → 86 
 
Table [2.7]: UPLC-MS/MS Reference Table for CID energy [eV] and MS/MS transitions of 
selected amino acids used for peptide standard quantitation of Human, Mice, and Rat Hb α 
(1-11) THB-Val peptide standards using Norleucine as Internal Standard.  
 
 
 
 
                                                 
1 Collision Induced Dissociation 
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Species Hb α (1-11)-N-Terminal Val 
Peptides 
THB-Val Quantitation concentrations pmol/uL 
RF Amino 
acids 
Analyte 
St (+/-) 
Internal 
St (+/-) 
Human P T L D 42.9 1 5.6 0.06 
VLSPADKTNVK 
Mouse S I L D E 1.62 0.09 49.8 2.2 VLSGEDKSNIK 
Rat 
A T I L D 61.4 0.08 23.5 1.1 
VLSADDKTNIK 
 
Table [2.8]: (1-11) THB-Val peptide standards Amino acids Reference Factors (RF) used 
for Quantitation and Final Measured Concentrations 
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2.8 FIGURES: 
 
 
 
 
 
 
 
 
 
 
Figure [2.1]: BD metabolism and formation of N-terminal valine adducts  
 
 
 
 
 
 
 
 
 
 
 
= 
= 
= 
N-(2-hydroxy-3-buten-1-yl)-valine  
N,N-(2,3-dihydroxy-1,4-butadiyl)-valine 
1,2,3-trihydroxybutyl-valine 
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Figure [2.2]: Schematic representation of 1-11 THB-Val standard peptides. (1-11) NTV 
Peptides sequences were mixed with EB-diol in a 1:20 ratio. Optimal conditions for direct mono-
alkylation of (1-11) NTV peptides by EB-diol were achieved in 0.1M Ammonium Bicarbonate 
buffer, pH 6.8, incubated at 37.5oC for 72 hours. Final products of mono-alkylation were 
identified as 1-11 THB-Val standard peptides: [Human (THB-Val-VLSPADKTNVK; MW 
1282/1288*), Mouse (THB-Val-VLSGEDKSNIK 1293/1299*), and Rat (THB-Val-
VLSADDKTNIK 1308/1314*).  
* = Labeled Valine in internal standard peptides. (Increases the MW +6). 
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Figure [2.3]: MS/MS of Purified (1-11) NTV Mouse labeled peptide from Reaction Mixture. 
Mouse (1-11) THB-Val-[13C5 15N] labeled peptide standard (MW 1299.86) was purified by from 
unwanted reaction mixture products and collected. The Mouse internal peptide standard fraction 
was verified by LC-ESI+ MS/MS in a in a DECA Ion Trap Turbo analyzer. 
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Mice IS THB-Val 
MS/MS at 1299.83 
Unalkylated (1-11) Mice peptide 
MS/MS at 1195.79 
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Figure [2.4]: Full Scan Spectrum of (1-11) NTV Mouse labeled peptide by EB-diol in a 1:20 
ratio. Two other reaction mixture products were identified with the Mouse (1-11) THB-Val-[13C5 
15N] labeled peptide standard (MW 1299.86). Purification of the standard peptide was performed 
by chromatographic separation and collection of the peptide standard fraction by LC-ESI+ 
MS/MS in a in a DECA Ion Trap Turbo analyzer. 
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Figure [2.5]: Schemes of b and y fragments and Fragmentation Spectrum of Rat THB-Val 
Internal Standard: (a) General schematic representation of theoretical B and Y fragments of 
THB-Val peptide standards. (b) Full Scan MS/MS in positive ion mode of purified Rat (1-11) 
THB-Val-[13C515N] labeled peptide standard (MW 1314). The most commonly abundant ions 
were y5, y6, b9, and b10. The Full Scan MS/MS of the purified peptide standard was performed in 
a DECA Ion Trap Turbo analyzer. 
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Figure [2.6]: Schematic Representations of Amino-acid Quantitation. (a) General schematic 
representation of the amino acid quantitation method used for THB-Val peptide standards. (b) 
Schematic representation of specific amino acids used to calculate the RF for each THB-Val 
peptide standard.  
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AMINOACID QUANTITATION 
METHOD 
Aliquots Un-quantitated/Purified THB-Val peptide standards 
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CHAPTER III: SIMULTANEOUS QUANTITATIVE ANALYSIS OF ALL BUTADIENE 
N-TERMINAL VALINE ADDUCTS IN MICE EXPOSED TO 1,3-BUTADIENE (10 
DAYS) WITH A RECENTLY IMPROVED METHOD2,3 
 
3.1 OVERVIEW 
 1,3-Butadiene (BD) is a well-characterized carcinogen that is both an 
occupational and environmental hazard. It is an important industrial chemical widely used in the 
production of rubber and plastic and is also present in automobile exhaust and cigarette smoke. 
BD is metabolized mainly by P450 2E1 to three epoxides, 1,2-epoxybutene (EB), 1,2:3,4-
diepoxybutane (DEB) and 3,4-epoxy-1,2-butanediol (EB-diol). They have the ability to react 
with hemoglobin (Hb) in blood. The globin adducts formed by EB, DEB, and EB-diol are N-(2-
hydroxy-3-buten-1-yl)-valine (HB-Val), N,N-(2,3-dihydroxy-1,4-butadiyl)-valine (pyr-Val) and 
1,2,3-trihydroxybutyl-valine (THB-Val), respectively. The goal of this research was to integrate 
the use of species specific mice (1-11) N-terminal Valine (NTV) peptide standards with a 
recently improved immunoaffinity (IA) coupled UPLC-positive mode electrospray ionization-
tandem mass spectrometry (UPLC-ESI+ -MS/MS) method for the simultaneous quantitative 
analysis of all three BD-Hemoglobin (BD-Hb) adducts from globin of mice exposed to BD. 
Using the tryptic digest approach, BD-Hb adducts are cleaved from globin proteins. Digests are 
                                                 
2 This Chapter previously appeared as part of a major article in Elsevier: Journal of Chemico-Biological Interactions. 
The original citation is as follows: J.A, Swenberg et al “1-3, Butadiene: Biomarkers and Application to Risk 
Assesment”, Chemico-Biological Interactions 192 (2011): 150-54. 
3 Chapter III of this Thesis is limited to the discussion of Butadiene Hemoglobin Adducts in Mice.  
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processed by triple antibody IA enrichment followed by sample quantitation by nano-UPLC-
MS/MS analysis using 13C15N5-labeled internal peptides standard. The detection limit of the 
method is 5-10 fmol in globin (10 mg). We previously used this method for the analysis of BD-
Hb adducts in rats and is now used for the quantitation in mice samples exposed to BD, as low as 
0.5 ppm via inhalation. This method successfully allowed the simultaneous quantitation of mice 
BD-Hb adducts, including those at low levels of exposure. The formation of BD-epoxide adducts 
increased with exposure, and the highest formation ratio of all three adducts per ppm BD was 
observed at low exposures (0.5-1.5 ppm). The amounts of pyr-Val, HB-Val and THB-Val 
formation showed no signs of saturation at exposures up to 625 ppm for 10 days. Previous results 
obtained by this method in BD-exposed rats were integrated for comparisons, and we found that 
formation ratios for all BD-Hb adducts were higher in mice than in rats but continued to be more 
efficiently formed at lower levels of exposure; making this relevant due to similar levels of 
exposure in occupational settings. BD-Hb adducts results were integrated in the calculation of 
the Internal Blood Dose (IBD) of Epoxides and transformed into the EB-equivalency for further 
comparisons.  
3.2 INTRODUCTION 
1,3-Butadiene (BD) is an important  industrial chemical used primarily in the production 
of synthetic rubbers and plastics. The general population is exposed to BD from cigarette smoke, 
burning of wood and automotive exhaust (Brunnemann, 1990; Gustafson, 2007, Pelz, 1990). 
Epidemiologic studies have linked occupational BD exposure to increased mortality from 
lymphatic and hematopoietic cancers (Santos-Burgoa, 1992). In long-term (6 h/day, 5 
days/week, 2 years) carcinogenicity studies, inhaled BD was weakly tumorigenic in rats exposed 
to 1,000 or 8,000 ppm (Owen, 1990) but was highly effective in mice exposed to BD 
91 
 
concentrations ranging from 6.25 to 625 ppm (Melnick, 1990). Furthermore, rodents exposed to 
BD, presented additional sex-specific differences in rodents where females had: (1) higher 
mutagenicity (2.5-3 fold) at the HPRT gene (Walker, 2009), greater number of mutation 
frequencies (MFs) (2.3 fold) in mice exposed to 1250 ppm (Meng, 2007), and tumor formation 
(10 fold) in mice lung and livers exposed at 6.25 and 20 ppm (Melnick, 1993). Therefore, the 
International Agency for Research on Cancer (IARC) has classified BD as group 1, a human 
carcinogen via inhalation (IARC, 2008) using epidemiologic studies and laboratory animal data. 
BD is a potent carcinogen in mice and considerably weaker in rats. In addition, species and 
gender differences related to BD metabolism and DNA repair can be examined by measuring 
suitable biomarkers in order to elucidate the formation of individual epoxides and assign their 
importance in mutagenesis and carcinogenesis.  
Differences are generally related to species-specific metabolic activation to reactive 
epoxy metabolites, mainly 1,2-epoxy-3-butene (EB), 1,2:3,4-diepoxybutane (DEB) and 1,2-
epoxy-3,4-butanediol (EB-diol). The primary pathways in BD metabolism are shown in Figure 
3.1. Oxidation of BD by cytochrome P450 results in the formation of EB, which can be further 
oxidized by P450 to DEB. EB and DEB can be conjugated with glutathione (GSH) in presence 
of GSH transferase (GST) and can also be hydrolyzed by epoxide hydrolase (EH) to the 
detoxication pathways forming 3,4-dihydroxy-1-butene (BD-diol) from EB and EB-diol from 
DEB. BD-diol can be oxidized by CYP450 to EB-diol and by alcohol dehydrogenase to 1-
hydroxy-2-butanone, 1-hydroxy-3-butene-2-one and 2-hydroxy-3-butenal. 
Globin adducts have been widely used as surrogate biomarkers for the formation of each 
epoxide after exposure to chemicals. The globin adducts formed by EB, DEB, and EB-diol are 
N-(2-hydroxy-3-buten-1-yl)-valine (HB-Val), N,N-(2,3-dihydroxy-1,4-butadiyl)-valine (pyr-Val) 
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and 1,2,3-trihydroxybutyl-valine (THB-Val), respectively [Figure 3.1]. Our laboratory has 
previously developed quantitative immunoaffinity (IA) LC-ESI+-MS/MS method for two 
adducts: the EB-specific adduct, HB-Val, and the DEB-specific adduct, pyr-Val, (Boysen, 2004, 
Georgieva, 2007). Both types of adducts were observed in globin extracted from laboratory 
animals that were exposed to BD by inhalation (Georgieva, 2007, Georgieva, 2010). We have 
recently used an IA ultra-pressure liquid chromatography-tandem mass spectrometry (UPLC-
ESI+-MS/MS) method for analysis of pyr-Val (Georgieva, 2010). This method allowed the 
measurement of pyr-Val in a wide range of BD exposed samples from mice and rats, ranging 
from concentrations as low as 0.1 ppm BD to 1250 ppm BD. However, this current method was 
not available for analysis of THB-Val specific adduct of EB-diol. Furthermore, the application of 
the method is labor intensive requiring extensive sample processing time since the analysis of all 
three adducts cannot be measured in a single run due to the single IA enrichment. We recently 
developed a method with triple IA enrichment that allows simultaneous quantitative analysis of 
all three BD derived NTV adducts in the globin. Previously, data was generated for the rodent 
database for female and male rats, but not mice. The goal of this research was to integrate the use 
of species specific mice (1-11) N-terminal Valine (NTV) peptide standards with an improved 
immunoaffinity (IA) coupled UPLC-positive mode electrospray ionization-tandem mass 
spectrometry (UPLC-ESI+ -MS/MS) method for the simultaneous quantitative analysis of all 
three BD-Hemoglobin (BD-Hb) adducts from globin of mice exposed to BD. This will complete 
our data set of rodents exposed to BD, that include low levels of exposures (0.5ppm-1.5ppm), 
which are relevant due to its similarity to at which human occupational exposures occur.  
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3.3 MATERIALS AND METHODS 
3.3.1 Materials:  
Chemicals for standard peptides synthesis, Immunoaffinity (IA) enrichment, and UPLC-
MS/MS analysis.  
 3,4-epoxy-1-butene (98%) and 1,2,3,4 diepoxybutane (97%) were purchased from 
Sigma-Aldrich (St. Louis, MO). 3,4-epoxy-1,2-butanediol was generously provided by Dr. 
Karupiah Jayraj, Dr. Avram Gold and Dr. Louise M. Ball from the Department of Environmental 
Science and Engineering, University of North Carolina at Chapel Hill. The N-terminal alpha 
chain peptides sequences were as follows: Rat VLSADDKTNIK; analyte and internal standards 
[2H3]pyr-Val, HB-Val-[13C515N] and THB-Val-[13C515N]. (2) Mice VLSGEDKSNIK; analyte and 
internal standards [2H3]pyr-Val, HB-Val-[13C515N] and THB-Val-[13C515N]. (3) Human 
VLSPADKTNVK; analyte and internal standards [2H3]pyr-V-11, HB-Val-[13C515N] and THB-
Val-[13C515N] [Table 3.1]. These peptides were either synthesized by the peptide synthesis 
facility core at the University of North Carolina at Chapel Hill or purchased from Anaspec. 
Trypsin (biotin-agarose from bovine pancreas) was purchased from Sigma-Aldrich. All reagents 
and solvents were ACS grade or higher. Amicon ultra-4 filters were obtained from Amicon Inc. 
(Deerfield, IL). Polyclonal antibodies against all three adducts (HB-Val, pyr-Val, and THB-Val) 
were produced by Anaspec (San Jose, CA). The N-terminal alpha chain analyte and internal 
standard peptides for all three adducts were synthesized based on the procedure described below 
and used for antibody production. 
 
 
94 
 
3.3.2 Methods 
3.3.2.1 Synthesis of standard peptides 
Analyte standard peptides, internal standard peptides, and calibration standards for tuning 
the analytical equipment were synthesized as described below. 
3.3.2.1.1 pyr-Val (analyte) and [2H3] (internal   
   standard) 
 The N-terminal alpha chain standard peptide for pyr-Val in rat, mice and human stable 
isotope (Leu-d3) labeled rat, mice and human standard peptide were synthesized as described 
previously (Jayaraj, 2003). 
3.3.2.1.2 HB-Val (analyte) and [13C15N5] (internal   
   standard) 
 The analyte and stable isotope-labeled rat, mice and human, internal standard peptides 
were synthesized for accurate quantitation by direct alkylation method. The in vitro alkylation 
was done by addition of EB to an aqueous solution of (1-11) peptide at molar ratio of 1:100, in 
0.1 M ammonium bicarbonate (NH4HCO3) buffer pH 6.5. The concentration of the peptides and 
the pH of the reaction solution were optimized in order to increase the reactivity of valine, to 
minimize the alkylation of lysine, and to minimize the cross-linking of peptides. The reaction 
was incubated at 37ºC for 72 h. After incubation, the reaction was stopped with 20% formic acid 
and adjusted to pH 2. The yield of reaction products was characterized and profiled by LC-ESI+-
MS/MS. 
95 
 
3.3.2.1.3 THB-Val (analyte) and [13C15N5] (internal   
   standard) 
 The analyte and stable isotope-labeled rat, mice and human internal standard peptides 
were synthesized by the direct alkylation method, similar to HB-Val standard peptides. The in 
vitro alkylation was done by addition of EB-diol to an aqueous solution of (1-11)-NTV-peptide 
at a molar ratio of 1:20, in 0.1 M ammonium bicarbonate buffer pH 6.8. The concentration of the 
peptides and the pH of the reaction solution have been re-optimized. The reaction was incubated 
at 37ºC for 72 h. After incubation, the reaction was stopped with 20% formic acid and pH was 
adjusted to strong acid condition (pH 2). The yield of reaction products were characterized and 
profiled by LC-ESI+-MS/MS. 
3.3.3 Animal and Exposures 
 Male and female F344 rats and B6C3F1 mice were exposed by inhalation to 0.1, 0.5, 1, 
1.5, 6.25, 62.5, 200, and 625 ppm BD for 10 days (2 weeks, 5 days/week, and 6 hours/day). All 
exposures were performed at the Lovelace Respiratory Research Institute (LRRI, Albuquerque, 
NM) as described previously in (Georgieva, 2010). Animal procedures were approved by the 
LRRI Institute Animal Care and Use committee. Within 2 hours of the last exposure, animals 
were killed by exsanguination under CO2 anesthesia. Blood samples were collected by cardiac 
puncture. Red blood cells were isolated, washed twice with 0.9% saline, diluted in distilled 
water, and stored at -80ºC before globin extraction (Georgieva, 2010).  
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3.3.4 Globin extraction and trypsin hydrolysis  
 Globin was isolated according the protocol of (Mowrer, 1986). Globin was precipitated 
by adding 6 volumes of 50 mM of hydrochloric acid in isopropanol, followed by centrifugation 
for 45 min at 3,000 g at 4 oC. The supernatant was washed three times with cold ethyl acetate to 
precipitate globin. The precipitate was washed with pentane and dried overnight under a gentle 
stream of nitrogen gas in vacuum oven. The globin was stored at -70oC until use. In sample 
processing, globin samples were digested with trypsin as described previously (Georgieva, 
2007).All globin samples (5-50 mg) were dissolved in 1-2 ml of 0.1 M NH4HCO3, pH 8 
containing 2 pmol of [2H3] pyr-Val (1-11) peptide, 2 pmol of [13C15N5] HB-Val, and 10pmol of 
[13C15N5] THB-Val as internal standard peptides. Ten μl of 10% SDS were added and the globin 
was digested with 50-100 μl of trypsin-biotin agarose enzyme suspension at 37oC overnight. 
Samples were filtered through Centricon-3 filters and dried by centrifugal lyophilization.  
3.3.5 Immunoaffinity (IA) enrichment 
 After trypsin hydrolysis, the samples were dried and redissolved in 600 µL PBS buffer 
and loaded on immunoaffinity columns that had been pre-conditioned twice with PBS. The IA 
columns were built specifically to retain all three N-terminal peptides (HB-Val, pyr-Val, and 
THB-Val). The columns were capped and left for 4 h, washed 5 times with 7 ml of water (5×7 
ml), eluted in 5% formic acid (3ml), followed by drying under reduced pressure, filtration on 
microspin filters, and final drying. Samples were stored at -20ºC until analysis and dissolved in 
20 µl of water prior to nano-UPLC-MS/MS analysis. 
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3.3.6 Liquid chromatography mass spectrometry 
 A Thermo-Finnigan TSQ Quantum Ultra-triple quadrupole mass analyzer 
(ThermoFinnigan, San Jose, CA) interfaced to Waters Acuity nano-UPLC system (Waters 
Corporation, Milford, MA) was used in all analyses. The system utilized a 2.0 × 20 mm 
Symmetry C18, 5 μm column (Waters) as a “trap column” for samples loading at 15 μl/min 15 
mM ammonium formate-0.7% formic acid for 1 min. After sample loading, the flow rate was 
reduced to 1.2 μl/min and the column exit flow was directed to a 100 μm × 100–mm BEH C18 
UPLC column (Waters) for analysis. The LC solvents were 15 mM ammonium formate in 0.7% 
aqueous formic acid (A) and acetonitrile in 0.1% aqueous formic acid (B). A linear gradient was 
run from 5% B to 70% B for 15 min, at a flow rate of 1.2 µl/min. After elution, the column was 
washed at 90% B for 10 minutes and equilibrated at 5% B for 5 min. Under these conditions, all 
three adducts and internal standard eluted within the range 5.9 - 6.1 min4.  The MS was operated 
in the positive ion mode with nitrogen used as a sheath gas. Electrospray ionization was 
performed at a spay voltage of 1800 V and capillary temperature of 240 ºC. Collision induced 
dissociation (CID) energy was achieved at 28 V. The MS parameters were optimized during the 
infusion of standard peptides solution and sample analysis was performed in the selected reaction 
monitoring (SRM) mode by monitoring either the singly or doubly charged molecular ions for 
rodents analyte and internal (1-7) peptide standards, depending on the adduct [Table 3.1]. 
 
 
 
                                                 
4 Adducts and internal standard eluted 9-16 minutes. 
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3.3.7 Method validation 
3.3.7.1 Neat Standards 
A total of 32 combined BD-Hb adduct columns were built and tested for neat standard 
recovery using pyr-Val, HB-Val and THB-Val mice standard peptide. Both pyr-Val and HB-Val, 
were tested with 0.5, 1, 2.5 and 5 pmol of analyte to 5 pmol of internal standard peptide. THB-
Val was tested for 0.5, 2.5, 5 and 10 pmol of analyte to 10 pmol of internal standard peptide (n = 
3 per concentration). Internal standard peptide and blanks were included in the recovery test (n = 
2 per group). Relative recoveries for all 32 combined BD-Hb adduct columns were calculated as 
the response for all three adducts divided by the actual spiked concentration.  
3.3.7.2 Matrix Spike 
After neat standard recovery test was completed, we selected 16 BD-Hb adduct columns 
with the highest peptide standards recovery. We proceeded to then use these prescreened 
columns to test control globin for validation and to assess matrix effects. The original matrix test 
was done in our laboratory using control globin from unexposed mice. A three-point validation 
was run on three days (n=3 for each validation point for one day, n=9 for each validation point 
for three days). Validation samples were prepared by spiking control globin with standard 
peptides. Relative recoveries in matrix effects were calculated as the response for all three 
adducts in a biological matrix spike, divided by the actual spiked concentration. Results were 
reported in % recovery for each standard peptide. The limits of detection (LOD) were 
determined by signal to noise ration 3:1 based on 5 µl injection volume of calibration standard. 
The lower limit of quantitation (LOQ) was defined as the lowest concentration to be detectable 
from diluted spiked control globin. The interday and intraday precisions were expressed as % 
99 
 
relative standard deviation (%RSD) and accuracies were expressed as % relative error (%RE)  
3.3.7.3 Statistical analysis 
All statistical analyses were performed using Microsoft Excel spreadsheet analysis tools. 
Classified precision and accuracy were estimated by simple statistics of mean and standard 
deviation of the estimated concentration of the determined peptide standards. 
3.3.8 Mice Internal Blood Dose Formation and EB-Equivalency 
3.3.8.1 Mice Internal Blood Dose 
The internal dose in blood (IBD) of the BD-epoxides (EB, DEB, and EB-diol) was 
calculated from those results obtained from BD-Hb adducts of mice exposed to BD for 10 days. 
The formation of BD-Hb adducts work as an indirect internal dosimeter in blood per BD-
epoxide. The IBD is obtained with two values: (1) quantitated BD-Hb adduct values (A, and 
expressed in mol/grams of globin), (2) divided by the reaction rate of the BD-epoxide to react 
with the NTV (or Kval ,and expressed in L/grams of globin/hours of exposure). We used Fred’s 
previously reported Kval rate constants values (Fred, 2008) for our calculations. Mouse BD-
epoxides Kval  values were: 
 
Mouse-EB Kval = 2.9×10-5 L·g-1·h-1 
Mouse-DEB Kval = 4.7×10-5 L·g-1·h-1  
Mouse-EB-diol Kval = 2.1×10-5 L·g-1·h-1 
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This Dose (or D expressed in mM per hour/ppm per hour) and was individually calculated for 
each individual epoxide with the equation considering that mice total exposures were 60 hours:  
D = A / Kval 
D = Mice-EB-Internal Blood Dose = HB-Val Adducts (mol/g) / 2.9×10-5 L·g-1·h-1 
D = Mice-DEB-Internal Blood Dose = pyr-Val Adducts (mol/g) / 4.7×10-5 L·g-1·h-1 
D = Mice-EB-diol-Internal Blood Dose = THB-Val Adducts (mol/g) / 2.1×10-5 L·g-1·h-1 
3.3.8.2 Mice EB-Equivalency 
 The EB-equivalency reflects the total genotoxic dose by considering the sum of each 
individual BD-epoxide genotoxic dose that’s adjusted by their genotoxic potency. The Mice EB 
Dose Equivalency was calculated by first multiplying each epoxides’ IBD (D), with its 
corresponding epoxide mutagenic potency. The mutagenic potency is a numerical value that was 
assigned by the efficiency of each epoxide to induce mutations in the hprt loci in human TK6 
cells as previously reported by Meng in 2010. These individually adjusted IBDs genotoxic doses 
are summed to generate the total genotoxic dose in terms of EB in mice. 
EB-IBD  x 1 
DEB-IBD  x 100 
EB-diol-IBD  x 0.2 
Mice EB-Dose Equivalency 
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3.4 RESULTS AND DISCUSSION 
3.4.1 A simultaneous IA-UPLC-MS/MS method 
 It is well known that N-terminal globin adducts are well suited to study BD carcinogen 
metabolism across species (Törnqvist, 2002). Specific globin adducts formed by each BD 
metabolite need to be identified and quantified in order to reveal important insight into species, 
gender, and exposure concentration differences in BD metabolism. We have recently 
demonstrated DEB specific adduct, pyr-Val, in mice and rats exposed to BD at different 
concentrations (Georgieva, 2010). Since our previous analyses of pyr-Val adducts was labor 
intensive and time consuming, the objective of this study was to improve the IA UPLC-MS/MS 
method and simultaneously detect all three globin adducts specific for BD metabolites in a single 
run. We employed the same concept as the method for pyr-Val and were able to adapt the 
method for the analysis of HB-Val and THB-Val in the concurrent sample. 
 IA columns were produced by combining antibodies raised against all three alkylated 
standard peptides and used for sample purification. Control globin was spiked with different 
amounts of analyte and internal standard peptides to determine the reproducibility of IA column. 
The results showed that the percentage of recovery was lower compared to IA columns prepared 
with individual antibodies. To overcome this problem, we adjusted the incubation time on IA 
columns from 1 h to 4 h at room temperature. Using this approach, better recoveries (>70%) 
were obtained for all three adducts (data not shown).  
The MS was performed in the selected reaction monitoring (SRM) mode by monitoring 
of the singly charged molecular ion (m/z 817→141) for HB-Val, (m/z 851→175) for THB-Val, 
and the corresponding transition of the [13C15N5]-label internal standard peptide (m/z 823→147) 
for HB-Val, (m/z 857→181) for THB-Val. At the same time, we monitored the doubly charged 
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molecular ion (m/z 417→158) for pyr-Val and the corresponding transition of the [2H3]-labeled 
internal standard peptide (m/z 418→158), since this transition, presented better sensitivity 
compared to the singly charged molecular ion.  
Quantitative measurement was based on the ratio of area under the peak in the selected 
ion chromatogram corresponding to the analyte and internal standard peptides. Calibration 
curves were constructed by analyzing the solutions containing all three adducts (0.050 – 0.5 
pmol) and internal standard peptides (0.5 pmol), followed by regression analysis [Figure 3.3]. 
All curves showed a linear response over the range of concentrations with a high coefficient of 
determination (R2= 0.992, R2= 0.998, and R2= 0.999 for HB-Val, pyr-Val and THB-Val, 
respectively). 
3.4.2 Method validation 
3.4.2.1 Limit of detection (LOD) and limit of quantitation (LOQ) 
 LOD was 1 fmol for all three adducts based on 5 µL of injection volume and a signal to 
noise ratio of 3:1, while the LOQ was 5 fmol on column for HB-Val and pyr-Val and 10 fmol on 
column for THB-Val. The lower LOQ for THB-Val adducts compared to the other two adducts 
was attributed to the lower signal on ESI+-MS/MS. This LODs and LOQs allowed detection of 
all three adducts in mice exposed to BD at 0.5 ppm for 10 days. 
3.4.2.2 Simultaneous Immunoaffinity Recovery Tests 
3.4.2.2.1 Neat Standards 
The pre-screened neat standard test helped us select a set of 16 out of 32 combined BD-
Hb adduct columns with the highest relative recovery values. Results for the top 16 columns with 
the highest recoveries were evaluated as % recovery for each standard peptide. Average recovery 
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was above 80% for all neat peptide standards, and the internal standard contribution was less 
than 2% [Table 3.2].  
3.4.2.2.2 Matrix Spike 
 Relative recovery values for all three adducts in matrix were as follows; 92-96% for HB-
Val, 90-95% for pyr-Val, and 63-73% for THB-Val (data not shown). The relatively low yield of 
THB-Val was likely due to the low titer of the THB-Val antibody, which may have cause less 
retention during the immunoaffinity purification step. However, despite the low yield, our 
method produced a highly linear calibration curve with acceptable precision and accuracy. 
3.4.2.3 Accuracy and Precision 
 The method accuracy and precision were determined for three replicates of three 
concentrations of all three adducts. The validated samples were analyzed on three separate days, 
the interday and intraday precision and accuracy. The RSD of both interday and intraday for all 
three adducts on the nano-UPLC-ESI+-MS/MS were below 7% (1.1%-6.6%). The accuracies 
calculated as relative error (RE) were within the range of 2%-6%. The improved quantitation 
method in this study is highly sensitive, accurate, and selective for all three BD adducts, allowing 
the detection of low amounts of adducts in 10-15 mg globin in mice from exposures as low as 
0.5 ppm BD. However, the detection of adducts at 0.1 ppm BD exposure for 10 days was under 
the LOQ due to the presence of very small amounts of adducts. 
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3.4.3 Simultaneous Butadiene Hemoglobin Adducts in Samples  
3.4.3.1 B6C3F1 Mice  
Here, we completed our comprehensive exposure-response for BD reactive epoxides in 
both female and male rodents by incorporating samples from B6C3F1 mice exposed to BD by 
inhalation to various concentrations of BD, ranging from 0.1 to 625 ppm for 10 days. Previous 
reports have shown occupational exposures of BD at concentrations ranges form to 0.3 to 3 ppm 
(Albertini, 2003; Hayes, 2002; Sram, 1998; Tates, 1996; Ward, 2001). Therefore, this previously 
improved quantitative assay allowed analysis of NTV-adducts after BD exposures for mice at 
low levels, similar to those found in BD-exposed workers. This is the first time that all three BD-
epoxide Hb adducts in B6C3F1 mice have been simultaneously quantitated under one method. 
Our results are will ultimately help understand important aspects of BD metabolism, 
carcinogenesis and mutagenicity. Using this validated quantitative immunoaffinity nano-UPLC-
MS/MS method will enhance the accurate measurement of BD-Hb adduct formation in mice, at 
low levels of BD-exposure, and complete the rodent dataset.  
To test the method, background levels of HB-Val, pyr-Val, and THB-Val adducts were 
determined in each of the control globin samples (n = 5/group/per exposure). The control 
animals did not contain detectable amounts of HB-Val or pyr-Val, suggesting that these adducts 
are not formed endogenously. However, THB-Val was detected in both control female mice (35 
± 8 pmol/g globin) and male mice (38 ± 5 pmol/g globin) without any exposure to BD. 
Moreover, endogenous formation of THB-Val has been previously reported as result of NTV 
alkylation by erythrose and threose (Rohlfing, 2002). Even though pyr-Val is the least abundant 
of the three BD adducts quantified, it was higher than the method’s LOQ, ensuring accurate 
quantification and presenting excellent signal to noise ratio for those samples exposed at lower 
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levels (0.5 ppm). Finally, we were able to quantitate the formation of the three BD adducts in 
mice exposed at ranges of exposure from 0.5-625 ppm BD for 10 days, and acquired data on 
exposure-response relationships [Table 3.3].  
Overall results showed that at low levels of BD exposures (< 6.25 ppm), HB-Val was 10-
15 fold lower than THB-Val. However, both pyr-Val and HB-Val continue to increase at 200 
ppm or less, that until it reaches the 625 ppm BD-exposure, where we see HB-Val being 2 fold 
that of pyr-Val in both female and male mice. This indicates that mice are capable of efficiently 
metabolize all three BD-epoxides without saturation when exposed to BD up to 625ppm. The 
exposure response curves are shown in [Figures 3.5 and 3.7] and individual results are discussed 
below. 
3.4.3.1.1 Mice Exposure Response to HB-Val 
The exposure response curve for the HB-Val adduct is illustrated in Figure 3.8 and 
Table 3.3. We observed a linear exposure-response curve for the HB-Val adducts. The levels of 
HB-Val in mice increased with exposure and did not show any signs of metabolic saturation at 
the levels studied (0-625 ppm). When comparing adduct formation ratio as (pmol/g/ppm BD), 
mice HB-Val adducts showed a higher formation ratio at lower levels of BD exposure (0.5 ppm, 
1.5 ppm) than at higher levels (200 ppm-625 ppm) [Figure 3.11 and Table 3.4]. In comparison 
to previous results, the overall HB-Val fold difference in formation ratio for mice was higher 
than rats at lower levels of BD-exposure. The formation ratio of HB-Val adducts indicate that EB 
is most efficiently formed at low BD-exposures (0.5 ppm, 1.5 ppm) but does not saturate at high 
exposures (200 ppm, 625ppm) in mice. This parallels previous findings in rats, where HB-Val 
formation continues to increase at all levels of exposure (up to 625ppm), indicating that EB 
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metabolic activation via CYP2E1/CYP2A6 does not saturate in rodents. Similar results have 
reported this linear dose-response increase in HB-Gua adducts for rodents exposed to BD at low 
levels (20ppm), and high levels where it has shown tumor formation (Koc, 1999, Swenberg, 
2001).  
3.4.3.1.2 Mice Exposure response of pyr-Val  
 The exposure response curve for the pyr-Val adduct is illustrated in Figure 3.8 and 
Table 3.3. The formation of pyr-Val increased with BD-exposures in a linear manner. Different 
from rats, mice pyr-Val formation does not plateau at any of the exposure levels (up to 625 
ppm). When comparing adduct formation ratio (pmol/g/ppm BD), pyr-Val adducts also showed a 
higher formation rate at lower levels of BD exposure (0.5 ppm, 1.5 ppm) than at higher levels 
(200 ppm-625 ppm) [Figures 3.11 and Table 3.4]. Comparing our previous results in rats, the 
overall pyr-Val fold difference in adduct formation ratio for mice was higher in both females and 
males [Tables 3.4, 3.5, 3.6 and 3.8]. This indicates that DEB is metabolized more efficiently by 
CYP2E1/CYP3A4 at lower levels of exposures (0.5 ppm, 1.5 ppm) but does not saturate at high 
exposures (200 ppm, 625ppm) in mice. This contrasts previous findings in rats, where pyr-Val 
formation plateaus, as a sign of saturation of DEB metabolic activation via CYP2E1/CYP3A4.  
3.4.3.1.3 Mice Exposure response of THB-Val   
The exposure response curve for the THB-Val adducts are illustrated in Figures 3.5, 3.7 
and 3.8. Formation of THB-Val (pmol/g) showed a linear dose-response at all levels of 
exposure.  Not only it presented to be the most predominant adduct for mice exposed to BD, but 
also had no evident saturation in its formation, even at 625 ppm. When comparing THB-Val with 
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other BD-Hb adducts, we noticed that at low BD exposures (< 6.25 ppm), THB-Val was 10 to 
15-fold higher than HB-Val, and at higher levels (> 62.5 ppm), THB-Val is 11-fold higher than 
HB-Val in male, but only 3-fold higher in females [Tables 3.3 and 3.7]. In contrast, previous 
results have shown rats THB-Val formation being supralinear; increasing at low levels, followed 
by a decrease in its formation (1.5ppm-6.25ppm), until saturation is reached (200ppm-625ppm) 
[Figures 3.6, 3.7, and 3.9]. Values of THB-Val adducts formation ratio (pmol/g/ppm BD), were 
higher at lower levels of BD exposure (0.5 ppm, 1.5 ppm) than at higher levels (200 ppm, 625 
ppm) [Figures 3.10 and 3.11, and Table 3.4]. In comparison with previous results for THB-Val 
in rats, the overall formation ratio was higher in mice at all BD-exposures [Table 3.8]. These 
species difference indicates that metabolic activation of EB-diol by EH is more efficient at low 
levels without saturation at high levels BD-exposures, whereas in rats, EB-diol metabolic 
activation reaches saturation by EH.  
Integrating our results with BD-DNA adducts, we compared THB-Val to THB-Gua 
formation for those animals from the same exposure study. THB-Gua formation rate remains 
consistent to THB-Val in both female and male mice, with a reduction in its formation as 
exposure concentration increases. However, at higher concentrations (200ppm-625ppm), there 
are signs of saturation only for female mice (Troutman, 2011). This confirms that both 
biomarkers are not evidencing saturation from BD to EB-diol at any low levels of exposure (< 
200 ppm) in blood or tissue.  
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3.4.3.1.4 Mice Internal Blood Dose Formation and   
   EB-Equivalency 
The IBD of BD-epoxides, and their corresponding EB-equivalencies for mice, were 
calculated and presented in [Table 3.9]. Quantitated BD-Hb adducts were first converted into 
IBDs and represent circulating BD-epoxides in blood5. The EB-equivalency was the sum of all 
three BD-epoxides, which were first adjusted by their individual genotoxic potency to convert 
both EB-diol and DEB into EB equivalents.  
There is an undeniable species differences in the formation of both the BD-epoxides as 
evidenced by both the IBD and the EB-equivalency. Here we present that mice are more 
effective in metabolizing BD-epoxides at lower levels of exposure. First, as exposure increases, 
the IBD decreased for all epoxides. The highest values of IBDs were found at the lowest levels 
of exposures (0.5 ppm). Mice had a similar contribution from both DEB and EB from their IBD 
values. Furthermore, the IBD of DEB is lower in both rats and humans. The greatest fold 
difference is the IBD equivalency was Mice vs. Humans (~200-fold), whereas the lowest was 
Rats vs. Humans (~5-fold).  
It’s important to understand that the attributable carcinogenic potential of BD in mice is 
directly influenced a greater contribution of DEB in their IBDs. DEB has been identified as the 
epoxide with the greatest genotoxic potential, and has shown to be the most influential epoxide 
in tumor formation in mice. However, the contribution in rats seems to be driven by EB and EB-
diol, but not by DEB which reaches saturation around 200ppm. These differences across rodents 
explain why there is greater susceptibility in mice due to a greater contribution of DEB in blood 
and lack of saturation in the metabolic activation of BD.  
                                                 
5 Additional calculations were performed to adjust for the half-life of adducts. 
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3.5 CONCLUSION 
We successfully employed the use of (1-11) THB-Val peptide standards into the 
development, validation, and analysis of samples exposed to BD. The recently improved and 
adjusted immunoaffinity enrichment nano-UPLC-ESI+-MS/MS method allowed the 
simultaneous quantitation of all three BD-derived epoxide NTV globin adducts in mice. These 
results were critical for the completion of our comprehensive rodent dataset exposed to BD by 
inhalation (10days), by including data for both female and male mice, and using as little as 10mg 
of globin. Employing this method proved to reduce processing time, materials and experimental 
analysis costs by two thirds when compared to the original single immunoaffinity enrichment.   
BD-Hb adducts formation in mice was dominated by the THB-Val adduct, followed by 
HB-Val, and lastly pyr-Val as the minor adduct. We observed no indications of metabolic 
saturation in the formation BD-Hb adducts, even at exposures of 625ppm. The formation of all 
BD-Hb adducts are species dependent with mice generating more overall adducts than those 
previously reported for rats (Bordeerat, 2011). Integrating our results with rats, we found that 
mice shows no saturation in the metabolic activation of BD into any of the BD-epoxides, 
including DEB and past exposures above 200ppm. However in rats, both pyr-Val and HB-Val 
presented saturation. No sex specific differences were identified in mice at any of the exposure 
concentrations. Similar than previous results in rats, this confirms that BD-Hb adducts formation 
was species depended but sex independent.  
Mice had the highest formation ratio for all adducts (pmol/g/ppm), at all exposures (0-
625ppm), and with the greatest difference being at low levels (0.5ppm and 1.5ppm). Also, BD-
Hb adduct formation ratio was greater in mice than that of rats across all adducts and 
concentrations. It is of key importance to consider that where rodents have shown to have highest 
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BD-Hb formation ratio is at the same levels where occupationally exposed subjects are involved 
in the industrial production of BD.  
The IBD of BD-epoxides, and their corresponding EB-equivalencies, were calculated for 
mice using Fred’s 2008 Kval constants for BD-epoxides and mutagenic potency from Meng’s 
2010 publication. The IBD is highest at lower levels of exposure (0.5 ppm) and decreases with 
increasing concentration. A previous collaborator of this project presented her results for the 
same dataset but in rats (Bordeerat, 2011). There is an undeniable species differences in the 
formation of both the BD-epoxides and the EB-equivalency. Mice are more efficient in BD-
epoxides metabolism at lower levels of exposure than at higher levels. No sex specific 
differences were noted. The attributable carcinogenic potential of BD in Mice is directly 
influenced by the greater contribution of DEB, rather than EB and EB-diol as shown by the EB-
equivalency. DEB has been identified as the epoxide with the greatest genotoxic potential, it’s 
the most influential epoxide in tumor formation in mice.  
These findings provide important information relevant to why mice are the most 
susceptible species from the rodent models, and accounts for the specific species differences in 
BD metabolic activation as estimated by BD-Hb adducts. The current investigation has provided 
insights of our knowledge on BD risk assessment. Finally, mice’s greater DEB contribution in 
blood, and their corresponding biomarker of exposure pyr-Val does point out the reason for this 
species susceptibility to BD and tumor formation. However, mice don’t represent to be the most 
appropriate animal model for BD risk assessment in human, rat does. 
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3.6 ADDITIONAL NOTES 
Part of our initial goal was the development and integration of this method to quantitate 
BD-Hb adduct formation in our occupationally exposed human dataset. This data set has been 
previously processed by a combination of two different methods, and results for pyr-Val, HB-
Val and THB-Val have been acquired. In attempts to process the same human samples under this 
method, we encountered at early stages that it proved to be difficult for its application, 
specifically for the quantitation of THB-Val. Specifically, human samples presented successful 
in the recovery of pyr-Val, and HB-Val but not for THB-Val. Although attempts to achieve this 
goal were made through the development of two other alternative methods6, a number of 
limitations hindered the re-evaluation of human samples under this simultaneous method. 
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6 Derivatization using PITC, PFPITC, tryptic digest followed by fraction collection and the FIRE Method (data not 
shown). 
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3.8 TABLES: 
 
 
Species NTV alpha 
Hemoglobin 
Sequence 
m/z 
(1-11) BD-NTV peptide standards m/z 
pyr-Val HB-Val THB-Val 
Analyte 
Standard 
Internal 
Standard 
Analyte 
Standard 
Internal 
Standard 
Analyte 
Standard 
Internal 
Standard 
Rat (1-11)   1203 1209 1308 1314 
VLSADDKTNIK (1-7) 417 418 817 823 851 857 
  a1 142 147 141 147 175 181 
Mice (1-11)   1189 1195 1293 1299 
VLSGEDKSNIK (1-7) 417 418 817 823 851 857 
  a1 142 147 141 147 175 181 
Human (1-11)   1172 1178 1282 1288 
VLSPADKTNVK (1-7) 813 815 833 839 833 839 
  a1 155 158 141 147 175 181 
 
Table [3.1]: Molecular weights and m/z (1-11) BD-NTV peptide standards: pyr-Val, HB-
Val and THB-Val. 
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N Ratio AS/IS 
pyr-Val HB-Val THB-Val 
Recovery SD Recovery SD Recovery SD 
3 0.10  97.7% 7.8% 116.6% 5.5% 111.9% 1.6% 
3 0.20 96.6% 7.2% 102.6% 2.7% 98.7% 10.8% 
3 0.50 92.4% 7.4% 91.7% 9.6% 88.4% 12.9% 
3 1.00 92.4% 8.7% 83.5% 6.5% 89.3% 3.3% 
 
       
2 IS Blank 0.5% 0.3% 1.6% 0.03% 1.0% 0.2% 
 
       
  Recovery 94.8% 2.8% 98.6% 14.3% 97.1% 10.9% 
 
Table [3.2]: Mice NTV Neat Peptide Standard Recovery on BD Triple IA Columns.  
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B6C3F1 Mice 
(N = 5) 
BD Adducts (pmol/g) 
ppm Hb-Val (+/-) pyr-Val (+/-) THB-Val (+/-) 
Female 
0 ND   ND   35 8 
0.1 2.3 0.8 2.1 1.4 15 8 
0.5 11 1 11 3 152 43 
1 16 1.2 20 2 352 34 
1.5 30 5 38 2 525 160 
6.25 59 9 76 10 1008 235 
62.5 364 55 419 63 1448 445 
200 751 23 859 62 2587 238 
625 3644 534 1532 170 4490 467 
Male 
0 ND  ND  38 5 
0.1 2.3 0.5 3 1 19 5 
0.5 11 1 15 2 142 17 
1.5 32 3 50 9 260 15 
200 1165 112 859 126 2324 212 
625 3644 520 1980 195 4383 373 
 
Table [3.3]: Hemoglobin Adducts (pmol/g) of B6C3F1 Mice Exposed to Butadiene for 10 
days. ND: not detected, Endogenous THB-Val was subtracted in all groups using data from 
control mice.  
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B6C3F1 Mice 
N = 5 
BD Adducts per ppm of BD 
ppm Hb-Val pyr-Val THB-Val 
Female 
0       
0.1 23 21 150 
0.5 22 22 304 
1 26 20 352 
1.5 20 25 350 
6.25 9 12 161 
62.5 6 7 23 
200 4 4 13 
625 6 2 7 
Male 
0       
0.1 23 30 190 
0.5 22 30 284 
1.5 21 33 173 
200 6 4 12 
625 6 3 7 
 
Table [3.4]: Hemoglobin Adduct Formation Ratio (Adducts/ppmBD) in B6C3F1 Mice 
Exposed to Butadiene for 10 days. 
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F344 Rats BD Adducts (pmol/g) 
ppm Hb-Val (+/-) pyr-Val (+/-) THB-Val (+/-) 
Female 
0 ND   ND   36.8 3.9 
0.1 NQ  NQ  NQ  
0.5 0.9 0.1 0.8 0.1 2.4 0.3 
1 1.6 0.5 1.4 0.2 29.0 3.0 
1.5 2.5 0.4 2.0 0.5 59.0 6.0 
6.25 8.1 0.7 6.7 0.7 220.0 19.0 
62.5 60.0 3.0 46.5 8.3 481.0 53.0 
200 148.0 19.0 123.0 8.0 606.0 75.0 
625 410 15 124.0 11.0 737 74.0 
Male 
0 ND   ND   34 4 
0.5 0.8 0.1 0.7 0.2 1.1 0.2 
1.5 2.3 0.4 2.00 0.40 70 3 
200 171 0.4 120 11 585 7 
625 394 8 117 12 796 84 
 
Table [3.5]: Hemoglobin Adducts (pmol/g) of F344 Rats Exposed to Butadiene for 10 days.* 
 
*Data from this table was presented in N.K. Bordeerat’s dissertation. Results for were included 
for comparisons with her permission.  
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F344 Rats 
BD Adducts per ppm of BD 
ppm Hb-Val pyr-Val THB-Val 
  0       
Female 
0.5 1.8 1.8 4.8 
1 1.6 1.4 29 
1.5 1.7 1.30 39 
6.25 1.3 1.1 35 
62.5 1 0.8 7.7 
200 0.7 0.6 3 
625 0.7 0.2 1.2 
Male 
0       
0.5 0.8 1.4 2.2 
1.5 1.5 1.30 46 
200 0.9 0.6 3 
625 0.6 0.2 1.3 
 
Table [3.6]: Hemoglobin Adduct Formation Ratio (Adducts/ppmBD) in F344 Rats Exposed 
to Butadiene for 10 days.*  
 
*Our results were calculated using data presented in N.K. Bordeerat’s dissertation. Results were 
included for comparisons with her permission.  
 
 
 
 
 
 
 
 
 
 118 
 
B6C3F1 Mice  
N = 5 
BD Adducts (pmol/g) Fold Differences [Adducts (pmol/g)] 
ppm Hb-Val (+/-) pyr-Val (+/-) THB-Val (+/-) THB to HB Mean Fold THB to pyr Mean Fold HB to pyr Mean Fold 
Female 
0 ND   ND   35 8             
0.1 2.3 0.8 2.1 1.4 15 8 7 
15 
7 
13 
1.1 
1 
0.5 11 1 11 3 152 43 14 14 1.0 
1 16 1.2 20 2 352 34 22 18 0.8 
1.5 30 5 38 2 525 160 18 14 0.8 
6.25 59 9 76 10 1008 235 17 13 0.8 
62.5 364 55 419 63 1448 445 4 
3 
3 
3 
0.9 
1 200 751 23 859 62 2587 238 3 3 0.9 
625 3644 534 1532 170 4490 467 1 3 2.4 
Male 
0 ND   ND   38 5             
0.1 2.3 0.5 3 1 19 5 8 
10 
6 
7 
0.8 
1 0.5 11 1 15 2 142 17 13 9 0.7 
1.5 32 3 50 9 260 15 8 5 0.6 
200 1165 112 859 126 2324 212 2 2 
3 
2 
1.4 
2 
625 3644 520 1980 195 4383 373 1 2 1.8 
 
Table [3.7]: Hemoglobin Adducts (pmol/g) and Fold Differences in BD-adducts in B6C3F1 Mice Exposed to Butadiene for 10 
days. Females and males have been divided as low (0-6.25ppm) and high (62.5-625ppm) BD exposures. Mean fold differences in both 
groups for both sexes have been calculated as fold differences in Hb-adducts for: (THB/HB), (THB/pyr) and (HB/pyr).   The THB/HB 
and THB/pyr fold difference in Hb-adducts decrease with increasing concentration of exposures in both female and male mice. 
However, in HB/pyr the fold difference remains similar.  
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B6C3F1 Mice 
F344 Rats 
BD Adducts per ppm of BD and Fold Differences in Rodents 
ppm M-Hb-Val R-Hb-Val Fold Hb-M/R M-pyr-Val R-pyr-Val Fold pyr-M/R M-THB-Val R-THB-Val Fold THB-M/R 
Female 
0                   
0.1 23     21     150     
0.5 22 1.8 12 22 1.8 12 304 4.8 63 
1 26 1.6 16 20 1.4 14 352 29 12 
1.5 20 1.7 12 25 1.30 19 350 39 9 
6.25 9 1.3 7 12 1.1 11 161 35 5 
62.5 6 1 6 7 0.8 9 23 7.7 3 
200 4 0.7 6 4 0.6 7 13 3 4 
625 6 0.7 9 2 0.2 10 7 1.2 6 
Male 
0                   
0.1 23     30     190     
0.5 22 0.8 28 30 1.4 21 284 2.2 129 
1.5 21 1.5 14 33 1.30 25 173 46 4 
200 6 0.9 7 4 0.6 7 12 3 4 
625 6 0.6 10 3 0.2 15 7 1.3 5 
 
Table [3.8]: Hemoglobin Adducts Formation Ratio (Adducts/ppmBD) and Fold Difference in B6C3F1 Mice vs F344 Rats 
Exposed to Butadiene for 10 days. Females and males have been divided as low (0-6.25ppm) and high (62.5-625ppm) BD 
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Species/Sex 
N = 5 
BD Exposure Doses in Blood nMh/ppmh 
ppm ppmh EB DEB EB-diol EB-equivalency 
Female Mice B6C3F1  
0           
0.1           
0.5 30 12 10 242 1060 
1 60 9 7 280 765 
1.5 90 11 9 278 967 
6.25 375 5 4 128 431 
62.5          3,750  3 2 18 207 
200        12,000  2 2 10 204 
625        37,500  3 1 7 105 
Male Mice B6C3F1  
0           
0.1           
0.5 30 13 11 225 1158 
1.5 90 12 12 137 1240 
200        12,000  3 2 9 205 
625        37,500  3 1 6 104 
 
Table [3.9]: Individual estimated Butadiene-epoxides doses in blood [nMh/ppmh] and the 
EB-equivalency for Female and Male B6C3F1 Mice exposed to Butadiene (10 days). 
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3.9 FIGURES: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure [3.1]: BD metabolic activation and formation of BD reactive epoxides. 
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Figure [3.2]: BD metabolism and formation of N-terminal valine adducts 
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Figure [3.3]: Calibration Curve for N-terminal valine adduct THB-Val. Concentrations 
ranged between 50-500 fmol of analyte and 500 fmol of internal peptide standard. Limit of 
detection was 1fmol and limit of quantitation was 10fmol on column with a 5uL injection.  
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Figure [3.4]: Ion chromatogram of THB-Val adduct in B6C3F1 Mice exposed to BD and its 
corresponding internal standard. Analyzed in selected reaction monitoring mode (SRM) and 
obtained the best sensitivity with the singly charged molecular ion. Mice samples were anaylzed 
(m/z 851→175) for THB-Val analyte and (m/z 857→181) for the THB-Val [13C15N5]-internal 
peptide standard 
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Figure [3.5]: Exposure response curves of THB-Val adducts formation (pmol/g) in B6C3F1 
mice exposed to BD for 10 days. 
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Figure [3.6]: Exposure response curves of THB-Val adducts formation (pmol/g) in F344 
rats exposed to BD for 10 days. 
*Data to make this figure was presented in N.K. Bordeerat’s dissertation. Results for were 
included for comparisons with her permission.  
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Figure [3.7]: Exposure response curves of THB-Val adducts formation (pmol/g) in Rodents 
exposed to BD for 10 days. 
*Partial data from this figure was presented in N.K. Bordeerat’s dissertation. Results for were 
included for comparisons with her permission.  
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Figure [3.8]: Exposure response curves of HB-Val, pyr-Val, and THB-Val adducts 
formation (pmol/g) in B6C3F1 mice exposed to BD for 10 days. 
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Figure [3.9]: Exposure response curves of HB-Val, pyr-Val, and THB-Val adducts 
formation (pmol/g) in F344 rats exposed to BD for 10 days.  
*Data to make this figure was presented in N.K. Bordeerat’s dissertation. Results for were 
included for comparisons with her permission.  
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Figure [3.10]: THB-Val Adduct Formation Ratio ([pmol/g]/[ppmBD]) in Rodents Exposed 
to BD for 10 days. 
*Partial data use to make this figure was presented in N.K. Bordeerat’s dissertation. Results for 
were included for comparisons with her permission.  
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Figure [3.11]: Hemoglobin Adducts Formation Ratio ([pmol/g]/[ppmBD]) in Rodents 
Exposed to BD (10 days) 
*Partial data to make this figure was presented in N.K. Bordeerat’s dissertation. Results for were 
included for comparisons with her permission.  
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Figure [3.12]: IBD: Internal Blood Doses Formation [nMh/ppmh] in Female and Male 
Mice Exposed to Butadiene by Inhalation (10 days). 
*Partial data to make this figure was presented in N.K. Bordeerat’s dissertation. Results for were 
included for comparisons with her permission.  
 
 
 
 
 
 
 
EB DEB EB-diol EB DEB EB-diol
Female Mice Male Mice
0.5 ppm 12 10 242 13 11 225
1.5 ppm 11 9 278 12 12 137
200 ppm 2 2 10 3 2 9
625 ppm 3 1 7 3 1 6
0
50
100
150
200
250
300
E
po
xi
de
D
os
es
 in
 B
lo
od
 n
M
h/
pp
m
h
Mice B6C3F1
133 
 
 
 
 
Figure [3.13]: EB-equivalency of Male and Female Mice Exposed to Butadiene (10 Days)  
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CHAPTER IV: IN VITRO ASSESSMENT OF DNA DAMAGE RESPONSE 
TO BUTADIENE EPOXIDES1  
 
4.1 OVERVIEW 
All three Butadiene (BD) epoxides (EB, DEB, EB-diol) have the ability to react DNA and 
form covalent adducts. Limited information is available regarding those DNA damage response 
(DDR) pathways involved in counteracting each specific BD-epoxide insult. Therefore, we have 
identified that BD-DDR is a gap in knowledge in BDs current biomarkers of exposure-effect 
database. DT40 cells provide the most extensive collection of DNA repair mutant clones in 
vertebrate cells to assess DDR using a high-throughput in vitro assay. BD-epoxides DDR were 
assessed with the DT40/XTT assay, and results were expressed as the Relative LD50, using both 
wild type and several DT40 mutants cells. Results showed that EB’s DDR was primarily TLS, 
EB-diol’s DDR was FA-TLS-HR, and DEB’s DDR was FA-TLS. Our results unraveled that EB-
diol induced a DDR that correspond to the repair of a crosslink (DNA-DNA or DNA-protein 
crosslink). In humans, metabolism favor the hydrolytic pathway towards the formation of EB-
diol. Our results offer a new perspective on how BD-epoxides DDR plays a role in improving 
our understanding in the importance of EB-diol in human risk assessment.  
 
                                                 
1 Manuscript 3: This manuscript will be incorporated elsewhere for publication. 
 
138 
 
4.2 INTRODUCTION 
4.2.1 Butadiene Epoxides 
Epoxides that arise from Butadiene (BD) metabolism, their corresponding mutagenicity, 
and DNA adducts, have been extensively studied in vitro and in vivo: in rodents and humans. 
Overall, BD-epoxides have shown an inversely proportional relationship; whereas the most 
mutagenic epoxides are the least abundantly generated (DEB > EB > EB-diol) and the least 
mutagenic epoxides are the most abundantly generated (EB-diol > EB > DEB) (Meng, 2010, 
Swenberg 2011). To this day, DEB remains to be BDs minor metabolite formed across species, 
and has shown to be the most mutagenic and genotoxic of all three BD-epoxides. The overall 
individual epoxide mutagenicity varies greatly, with up to a ~200 fold difference in the following 
order: DEB > EB > EB-diol (Swenberg, 2011, Meng, 2007a, Meng, 2007b, Meng, 2010). An 
interesting observation was noted in EB-diol epoxide mutagenicity. EB-diol is composed of 4 
different isomers, and it was observed that in vitro, the EB-diol 2R3S isomer was the most 
mutagenic when compared to the other three (2R,3R, 2S,3S, and 2S,3R) (Meng, 2010). When 
integrating these mutagenicity results with other BD-epoxides, the EB-diol isomer 2R,3S was 5-
10 fold less potent than DEB, and 10-20 fold more potent than EB in both HPRT and TK locus 
(Meng, 2010, Swenberg, 2011).  
4.2.2 BD-Epoxide DNA-Adducts 
All three butadiene epoxides (EB, DEB, EB-diol) have the ability to react with DNA and 
form covalent adducts. These BD-DNA adducts can be subdivided into three categories: (1) 
DNA-monoadducts, (2) DNA-Protein crosslinks (DPC) or (3) DNA-DNA crosslinks (Swenberg, 
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2011). In vitro, all BD-epoxides have demonstrated the capacity to alkylate all DNA bases. 
However, only two DNA bases have been found to be alkylated in vivo: with the most 
predominant being with Guanine (Gua), and to a lesser extent Adenine (Ade) (Tretyakova, 
1998). Therefore, it is important to recognize BD-Gua adducts are relevant due to their higher 
abundance when compared to the BD-Ade adducts. In the literature, it has been reviewed that 
there are three key aspects of BD-DNA adducts: (i) the distinction of the N7 position of Gua as 
main site of alkylation from all DNA bases, (ii) EB-diol derived adducts are the multispecies 
predominant BD-DNA adducts in all tissues, (iii) mice are the species with the highest number of 
BD-DNA adducts formed, and (iv) liver is the target tissue for overall highest BD-DNA adduct 
formation.  
The most metabolically abundant epoxide formed from BD is EB-diol, and consists of 
four stereoisomers (2R,3R; 2R,3S: 2S,3R; and 2S,3S) that react with Gua and form THB-Gua2. 
Followed in abundance is EB, which consists of two enantiomers (2S; 2R) that react with Gua 
generating HB-Gua3. Alternatively, some of these HB-Gua adducts can be transformed back into 
THB-Gua, if the remaining unbound portion becomes hydrolyzed by EH. The third and least 
abundant epoxide, DEB, consists of three stereoisomers (2R,3R,; 2S,3S and meso-S,R/R,S) that 
react with Gua and form monoadduct DEB-Gua.  
From all BD-Gua monoadducts adducts, two are considered to be the precursors of DNA-
DNA crosslinks, or DNA-Protein crosslinks (DPC); HB-Gua and DEB-Gua. The only difference 
between HB-Gua and DEB-Gua is the opposite side of the chemical that remains unbound. Once 
HB-Gua is formed, the unbound portion can become hydrolized by EH and turn into more THB-
Gua, or get oxidized by CYP450 and turn into DEB-Gua. Now, the DEB-Gua unbound epoxy-
                                                 
2 N-7-(2,3,4-trihydroxybut-1-yl)guanine 
3 HB-Gua I & II: N-7-(2-hydroxy-3-buten-1-yl)guanine & N-7-(1-hydroxy-3- buten-2-yl)guanine 
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ring remains available to react and produce differenct crosslinks depending on what the epoxide 
targets: (i) if it reacts with another Gua at the 7th position or an (ii) Ade at the 1st position they 
become DNA-DNA crosslinks. If it reacts with (iii) a protein it becomes a DPC. The most 
abundant BD DNA-DNA crosslinks are N7-Gua-N7-Gua4, followed by N7-Gua-N1-Ade5. The 
latter is rearranged into N7-Gua-N6-Ade (Goggin et al, 2009). In addition, it has been reported 
that the DEB-Gua unbound epoxy-ring target certain proteins, leading to DPC’s formation with: 
AGT6, GADPH7, Histone 3, and PARP18 (Loeber, 2006, Loecken, 2007, Loecken, 2009 and 
Michaelson, 2010, and Gherezghiher, 2013) 
4.2.3 BD-Epoxides Genotoxicity 
Information on BD’s animal and human carcinogenic potential has been well documented 
in previous studies where they have examined, toxicity, DNA adduct formation, mutagenesis, 
and gene expression. BD requires metabolic activation to induce genotoxic damage through its 
reactive metabolites. These are capable of producing epoxide-specific genotoxic insults by 
directly alkylating DNA, and ultimately, generating several adducts that include: DNA-
monoadducts, DNA-DNA adducts (DNA-DNA), and DNA-Protein cross links (DPC) (Swenberg 
et al 2001).  
Extensive studies on BD-biomarkers of effect done in mice and rats, exposed to various 
concentrations of BD by inhalation have been previously reported. Results showed the induction 
of point mutations, large deletions, and chromosomal aberrations. For instance, in transgenic 
                                                 
4 1,4-bis-(guan-7-yl)-2,3-butanediol 
5 1-(guan-7-yl)- 4-(aden-1-yl)-2,3-butanediol 
6 O6-alkylguanine DNA alkyltransferase 
7 glyceraldehyde 3-phosphate dehydrogenase 
8 Poly [ADP-ribose] polymerase 1 
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mice (B6C3F1 laci) exposed to BD there was a statistically significant increase in A:T  G:C 
and AT:  T:A (traversions) mutations (Recio, 2001). Particularly, EB induces point mutations: 
where A:T  T:A (traversions) with  small deletions, whereas DEB results in large deletions. 
However, no significant differences in sister-chromatid exchange frequencies, chromosomal 
aberrations or hprt mutations were found in studies of human occupationally exposed to BD 
(Albertini, 2001 and Albertini, 2007).  
4.2.4 Gaps in Knowledge in DNA Repair  
In Chapter1 and 3, we discussed how BD-epoxides molecular dose and tissue distribution 
have shown that metabolic activation of BD has species-dependent differences by using BD-Hb 
adducts. However, a clear distinction has to be made in the use of DNA vs Hb adducts. The lack 
of repair mechanisms in Hb-adducts are ideal to make inferences in metabolic activation 
contribution by each epoxide. However, DNA adducts can be more informative about potential 
differences in how DNA repair is modulated by each epoxide. Moreover, the formation of BD-
DNA adducts provides indication(s) of one or more genotoxic event(s) that leads to non-
mutational manifestations, contributing in the initiation of mutagenesis, and thus considered a 
relevant event to BD-carcinogenic mode of action (MOA). The formation of these BD-DNA-
adducts across species have been previously studied, as well as their importance with regard to 
the genotoxicity of BD. Limited information is available regarding those DNA damage response 
(DDR) pathways involved in counteracting each specific BD-epoxide insult. Therefore, we have 
identified that BD-DDR is a gap in knowledge in BDs current biomarkers of exposure-effect 
database. Of particular interest, all EB-diol isomers will be pre-evaluated for cytotoxicity, to test 
reproducibility from that obtained by Meng’s in 2010, and if positive results are obtained, then 
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be included as part of the elucidation of what DDR pathways are involved in their repair.  
4.2.5 DNA Damage Response XTT-DT40 System 
Several in vitro cell-based assays have been developed to assess toxicity of chemicals, 
but none have presented to be as versatile, quick, reproducible and as cost effective as the 
DT40/XTT system. This application has been developed, validated as an integrated system for 
the assessment of DNA damage response with other chemicals (Ridpath 2007 & 2011). In 
addition, DT40 cells present many positive advantages that make them an ideal choice for this 
aim. DT40 cells were originally generated in 1985 from a chicken B lymphocyte cell line derived 
from an avian leucosis virus induced bursal lymphoma (Baba, 1985). These cells have provided a 
stable karyotype/phenotype, quick doubling time (8-10 hours) (Yamazoe, 2004) and lack 
functional p53 genes, to ensure the event of cell death to be a cause of defective repair upon 
DNA damage (Ulrich, 1992). In addition, these cells are not adherent and do not require 
trypsinization, reducing hands-on time and cell stress.  
Adjustments have been made to perform experiments in both 24 and 96 well plates to 
include the use of multiple concentrations (6 concentrations in 24 well plates, and 9 
concentrations in 96 well plates), with their corresponding controls and blanks. Following this 
plate format, exposures were performed in replicates, with controls and blanks; easing the 
process or reproducibility between experiments. DT40 cells and their multiple DNA-repair 
deficient mutants come from the same single parent cell (isogenic) and allowing direct multiple 
mutant comparisons. This system covers DNA repair pathway and cell cycle checkpoint mutants 
in base excision repair (BER), nucleotide excision repair (NER), homologous recombination 
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(HR), non-homologous end-joining (NHEJ), mismatch repair (MMR), translesion synthesis 
(TLS), DNA damage sensors and Helipses.  
4.3 MATERIALS AND METHODS 
4.3.1 Materials:  
4.3.1.1 Chemicals for exposures and XTT 
High purity EB and DEB were purchased from Sigma. Stereoisomers of EB-diol and 
racemic EB-diol were synthesized by Dr. Zhenfa Zhang (UNC-Chapel Hill Chemistry Core). All 
BD-epoxides were kept in aliquots and stored at -80oC. 
4.3.1.2 Chemicals for cell culture 
Fetal Bovine Serum and Chicken Serum, RPMI-1640 cell culture medium, penicillin, 
streptomycin, trypan blue dye, and PBS were purchased from Invitrogen (Grand Island, NY). 
 
4.3.1.3 Cell Lines 
4.3.1.3.1 DT40 and Mutants 
DT40 normal and 28 different DT40 mutants [see Table 1] were cultured and maintained 
in RPMI-1640 cell culture medium, supplemented with 10% fetal bovine serum (heat 
inactivated), 1% chicken serum, 100 μg/ml penicillin, and 100 μg/ml streptomycin and kept in 
humidified 5% CO2 at 39.5˚C.  
4.3.1.3.2 TK6 cells 
  TK6 cells were a gift from Dr. Rebecca Fry, and were cultured in RPMI-1640 cell culture 
medium, supplemented with 10% fetal bovine serum (heat activated), 100 μg/ml penicillin, and 
100 μg/ml streptomycin, and kept in humidified 5% CO2 at 37.0˚C. 
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4.3.2 Methods 
4.3.2.1 Exposures  
Before exposures, cells were counted using an hemocytometer and Trypan blue dye, to 
estimate required cell aliquot volumes required for 104,000 cells; in order to seed ~4,000 cells x 
250 μL/well. A total of 7 mL of supplemented media was pre-warmed at the incubator and mixed 
with the cells aliquot, capped and gently tilted 10-times to ensure equal distribution of cells 
across the well plates. Plates were seeded and returned to incubation for ~2h to allow recovery 
from cell passage and to for cells to acclimate to incubation conditions.  
Frozen stocks of 100mM of the BD-epoxides were left to thaw and serial dilutions were 
freshly prepared, Wells were distributed to accommodate from 9 to 20 concentrations of 
exposure in replicates, media blanks and vehicle controls [Figure 4.1]. 
a) EB-diol: (1,000, 500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91 and 0 μM). 
b) EB: (500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91, 1.95 and 0 μM). 
c) DEB: (500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91, 1.95, 0.98, 0.49, 0.24 μM);& 
(122.07, 61.04, 30.52, 15.26, 7.63, 3.81, 1.91, 0.95 and 0 nM) 
Dilutions were done in PBS. Cells were exposed to for a period of ~48 hours, and 
monitored by microscope to verify that control wells reached desired confluence by visual 
inspection. 
4.3.2.2 DT40/XTT Absorbance 
At the end of the exposures, cells were dyed with an XTT cocktail returned to incubation 
at a lower temperature (33˚C) to allow metabolic reduction of the dye by living cells without 
overgrowing them for ~8-12 hours (Ridpath, 2007 & 2011). The XTT dye developed from a 
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colorless yellow dye into a bright orange formazan product. The amount of formazan dye formed 
directly correlates to the number of metabolically active cells in the culture. The absorbance of 
the dye was quantitated with spectrophotometer Tecan Safire multi-well plate well reader (Tecan 
Systems San Jose, CA) and analyzed with Magellen6 software (Tecan version 6.4). Software was 
set to quantitate formazan dye at 450 nm with a 650 nm reference.  Absorbance data was 
background corrected from each plate blanks and percentage of living cells was calculated using 
individual controls per plate. 
4.3.2.2.1 Relative LD50 Calculation 
Concentrations of exposures were converted into log values, and standard deviations 
were calculated using Excel. This data was further analyzed using GraphPad Prism 5 software 
for LD50 estimation using a log-linear regression and basic statistical analysis. 
4.3.2.2.2 DNA Damage Response Categories  
Our research group assessed the DNA Damage Response of BD-epoxides. Here we 
report quantitative data for EB-diol and qualitative data for EB and DEB, as EB-diol was the 
original objective of this project without excluding results of the other two epoxides and identify 
pathways similarities and differences. The dose required to induce the LD50 was first calculated 
for DT40wt and each DT40 mutant. These values were transformed into the Relative LD50 to 
generate an equivalent endpoint comparison across BD-epoxides. The relative LD50 was 
calculated by using the following formula: 
 
Relative LD50  = DT40 mutant LD50 
DT40wt LD50 
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Results for all DT40wt LD50s were expressed as 1, and categories of response were 
created with cut-off lines to distinguish DT40 mutants degree of sensitivities and determine their 
significance.  A Relative LD50 = or > than 1 was as sensitive as DT40wt, and therefore not a 
significant pathway involved whereas Relative LD50s < 0.50 were considered as required. Also, 
four subcategories of Relative LD50 sensitivities were created to describe; low sensitivity (0.76-
0.99), moderate sensitivity (0.50-0.75), sensitivity (0.26-0.50) and high sensitivity (< 0.25) 
[Table 4.1]. A total of 28 cell lines were tested, including DT40wt and 26 DT40 mutants.  
4.4 RESULTS AND DISCUSSION: 
4.4.1 EB-diol Isomers [Limitations] 
Initially, Dr. Zhenfa Zhang (UNC Chemistry Core), synthesized for us racemic EB-diol 
and each one of its stereoisomers (2R,3R, 2R,3S, 2S,3S, 2S,3R). Originally, we planned to test 
DNA Damage response pathways on every EB-diol isomer; of particular interest, EB-diol 2R,3S. 
The goal was to better understand if DNA repair was modulated differently, and be able to 
further explain how this was a driving factor in differential cytotoxicity and mutagenicity 
observed in isomer EB-diol 2R,3S (Meng, 2010). Cytotoxicity was extensively tested for all 
isomers, to verify reproducibility, to that previously reported. Cell lines Tk6 and DT40wt were 
simultaneously tested at concentration ranges (1,000, 500, 250, 125, 62.5, 31.25, and 0 μM) that 
included those previously tested.  
Results in TK6 cells showed no significant difference in cytotoxicity amongst EB-diol or 
any of the individual isomers at all concentrations tested. Also, results with DT40wt confirmed 
similar results [Figure 4.2]. Combinations of paired isomers were also tested but in Tk6 cells 
only.No differences in cytotoxicity were observed (data not shown). The last effort was made to 
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acquire aliquots of those EB-diol isomers synthesized from the original experiments, to test them 
directly the DT40/XTT system, and analyze the purity of the material. No additional material 
from Meng’s experiments was available to perform additional tests or analysis. With this at hand, 
we had to redirect our efforts into testing all three BD-epoxides.  
4.4.2 Butadiene Epoxides DNA Damage Response 
The most sensitive DT40-/- mutant cell line for all three BD-epoxides was REV1-/- cells 
[Figure 4.11]. Interestingly, our findings not only connected REV1 with the TLS pathway, but 
also describes how the FA pathway is involved in the repair of EB-diol. This plays an new and 
important role in BD human risk assessment. 
4.4.2.1 DEB DNA Damage Response 
DEB DDR does not involve BER or MMR pathways due to the lack of sensitivity on any 
of the MMR or BER mutants treated with DEB [Table 4.3a and 4.4a]. The only DT40 mutant 
that exhibited any sensitivity in NER, and it was moderate in XPA-/- cells [Table 4.3b]. XPA has 
been implicated in the repair of crosslinks (Wood, 2010), maintaining helix stabilization when 
helicase TFIIH opens the strands in damaged areas (Fadda, 2016), and regulating cell cycle 
checkpoint kinase ATR (Chk1) (Martejin, 2014). The XPA protein seems to have a role in DEB 
DDR, but NER does not seem to be a primary pathway for repairing DEB damage.  
TLS mutants with high sensitivity to DEB were REV1-/- cells, followed by RAD18-/- cells, 
sensitivity in Pol η-/- cells, and low to no sensitivity for Pol к-/- > Pol θ-/- cells respectively [Table 
4.4b]. Sensor RAD18 functions as a ubiquitin ligase in complex RAD18/RAD6, which mono-
ubiquitylates polymerase clamp PCNA. This enhances the clamp interaction with adaptor REV1 
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and facilitates the switch from a replication polymerases, to a TSL polymerase to perform lesion 
bypass. REV1’s function in TLS is to incorporates dCTP 9 opposite to AP-sites and adducted 
Gua (Nair, 2005). REV1 also participates in the FA pathway. When a replication fork encounters 
an ICL, the FA core complex recruits a secondary complex formed by both REV1 and 
Polymerase ζ (Pol zeta) (Budzowska, 2015), to promote the extension step during ICL repair 
(Räschle et al, 2008). It our understanding then that DEB DDR primarily involves the bypass of 
mono adducts and crosslinks via TLS, in particular via polymerase Pol η. TLS polymerase Pol η 
has been found to specialize in the bypass intrastrand T-T dimers (Rey, 2009). In parallel, DEB 
can not only intrastrand crosslinks, but also intrastrand crosslinks, making Pol η an important 
player in the bypass of these lesions. We are not excluding the participation of other specialized 
polymerases in the repair of DEB induced damage, with the exception of Pol θ due to its lack of 
sensitivity in this assay.  
In both FA and HR pathways, DEB induced the highest sensitivity in mutant cells 
FANCD2-/- > followed by BRCA2-/- > and moderate sensitivity in XRCC2-/- and XRCC3-/-- [Table 
4.5a and 4.5b]. However, the lack of sensitivity in specific HR mutant cells BRCA1-/-, RAD54-/-, 
RAD51c-/-, RAD51d-/-, BLM-/-, and WER-/- clearly indicates that FA repair does require the direct 
involvement of the HR pathway. Here, DEB DDR primarily requires FA proteins FANCD2 and 
BRCA2, and HR proteins XRCC2 and XRCC3 but only moderately. The FA pathway repairs 
ICL (Ceccaldi, 2016, Giglia, 2011) such as DEB-crosslinks. Both FANCD2 and BRCA2 proteins 
participate in the initial steps of unhooking the ICL from the DNA double strand (Ceccaldi, 
2016). Alternatively, proteins XRCC2, and XRCC3 are part of the group that carries out the 
invasion-extension in HR (Sung, 2006). Since DEB induced moderate sensitivity in XRCC2-/- 
                                                 
9 dCTP: Deoxycytidine triphosphate (Cytosine nucleotide) 
149 
 
and XRCC3-/- we understand that both XRCC2 and XRCC3 proteins participate in DEB DDR, 
but independently from HR related repair.  
Mutant cells from the NHEJ pathway showed that DEB induces moderate sensitivity in 
Ku70-/-> LIGIV-/- cells, whereas the sensitivity in DNAPKcs-/- cells was low [Table 4.6a]. 
Protein Ku70 forms part of the Ku70/Ku80 recognition complex that binds to DSB-DNA, and 
recruits other NHEJ intermediates to trim (Burma, 2006) and ligate then un-even DNA ends via 
Ligase IV [complex XRCC4/Ligase IV] (Lieber, 2008). DEB DDR in NHEJ presents that 
proteins Ku70 and LIGIV have a modest participation in the recognition and sealing of the 
broken ends of DSB without the specific involvement of intermediate DNA-PKcs. This suggests 
that NHEJ plays an alternative role in DEB DDR. 
The DNA Damage Sensor mutant RAD17-/- was moderately sensitive to DEB. Cell cycle 
checkpoint mutant ATM-/- sensitivity was low. [Table 4.6b]. DEB crosslinks can lead to stalled 
replication forks. The exposed single-stranded DNA gets coated by Replication protein A (RPA), 
leading to the recruitment and binding of DNA Damage Sensor RAD17 and ATR kinase 
complex [ATR-ATRIP] stimulating the activation of Chk1, to hold cells at the G2 phase 
(Marechal, 2013, Zhang, 2014). Sensor RAD17 also recruits the clamp-shaped 9-1-1 complex 
[RAD9/HUS1/RAD1] around damaged DNA (Parrilla, 2004) to function as a checkpoint 
coordination, activation of DNA repair (Delacroix, 2007) and to facilitates ATR-phosphorylation 
of Chk1, regulating cell cycle and slowing down replication. At this point, the replication fork 
stabilizes to preventing stalling that could lead to DNA strand breaks. DEB DDR partially 
requires sensor RAD17 signaling for the recruitment of other downstream proteins involving 
repair, fork stalling prevention. However, the lack of sensitivity in ATM-/- cells suggests that 
DEB DDR responds independently of cell-cycle checkpoint ATM. 
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4.4.2.2 DEB DNA Damage Response Pathway 
4.4.2.2.1 DEB Monoadducts  
We hypothesize that the primary DEB DDR will be to bypass monoadducts via TLS. 
DEB predominantly generates monoadducts THB-Gua and THB-Ade. Whereas THB-Ade 
adducts may persist, THB-Gua adducts will undergo spontaneous depurination, creating AP-
sites. A high-fidelity replicative polymerase will recognizes both DEB monoadducts and AP-
sites as DNA damage at the replication fork. Exposed single-stranded DNA gets coated by 
protein RPA. This triggers the recruitment and DNA binding of sensor RAD17 and ATR kinase 
complex [ATR-ATRIP]. This is followed by the activation of Chk1, arresting cells at the G2/S 
phase. RAD17 recruits the clamp-shaped 9-1-1 complex [RAD9/HUS1/RAD1] near damaged 
DNA to activate its repair. Simultaneously, RPA coated DNA stimulates ubiquitin ligase-RAD18 
to form complex RAD18/RAD6. The complex mono-ubiquitylates the PCNA polymerase clamp, 
enhancing its interaction with REV1, and recruiting TLS polymerase Pol η. Replication is 
resumed by Pol η to bypass the DEB monoadduct or AP-sites and extend replication for a short 
track. The final step is the replacement of the TLS polymerase by the original replicative 
polymerase. The strands are then ligated to close the gap when it reaches an Okazaki Fragment. 
4.4.2.2.2 DEB Crosslinks 
We hypothesize that a mixture of all variations of DEB-crosslink will have a DDR that 
involves FA-TLS coupled repair. A replicative polymerase encounters the DEB-crosslink at the 
replisome/replication fork. Exposed single-stranded DNA gets coated by protein RPA, 
stimulating the recruitment of DNA damage sensors RAD17 and RAD18. Sensor RAD17 and 
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ATR kinase complex [ATR-ATRIP], to activate Chk1, and arrest cells at the G2/S phase. The 9-
1-1 DNA clamp assembles near damaged DNA site to activate its repair.  
First, the FA pathway will stabilize the replication fork. The DEB-crosslink is recognized 
by FANCM with FAAP24 by associating with the DNA-bound MHF complex (MHF1 and 
MFH2). The FANCM-FAAP-24 serves as a platform to recuit and assemble the rest of the FA 
core complex, ultimately acting as a ubiquiting ligase. Sensor RAD18 recruits PCNA via mono-
ubiquitilation, initiating the convergence of TLS pathway and the FA pathway. Ubiquitilated 
PCNA also promotes the recuitment of both FANCL and FANCD2 subunits. Subunits FANCL 
and FANCT of the DNA-bound FA-core complex proceeds to mono-ubiquitinates FANC-ID 
[FANCD2-FANCI], loading onto DNA, and initiating the ICL-unhooking process. The 
FANCD2 protein allows FANC-ID to control the incision of the DEB-crosslink from one of the 
sides of the DNA strand near the replication fork by two effector proteins: nucleases FANCP and 
FANCQ. The DEB-crosslink is cut out from one side of the parental strand, resulting in (1) a 
strand with an anti-space (or DSB), and (2) the opposite strand with the one-sided left-over DEB-
crosslink.  
The second step is processing the strand that has the leftover DEB-crosslink via TLS 
bypass. First, protein FAAP20 binds to the FA core complex forming FAAP20-FA core 
complex. The RAD18 ubiquitinated PCNA clamp, in conjunction with the FAAP20-FA core 
complex, assesmbles TLS related complex PCNA-REV1 via ubiquitin-binding with REV1 
(Mirchandani, 2008, Kim, 2012, Kim & D’Andrea, 2012). This interaction switches the 
replicative polymerase for REV1 and Pol η. Replication is resumed by Pol η, bypassing the 
leftover DEB-crosslink, and extending replication for a short track. Once the extension is 
completed beyond the lesion (Räschle, 2008), Pol η is switched back to the replicative 
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polymerase. The final product is ligated to close the gap when it reaches an Okazaki Fragment 
(Buzowska, 2015).  
DEB generates six predominant DNA-crosslinks, favoring the formation of inter-strand 
over intra-strand DNA crosslinks (Millard 1993, Sawyer, 2004, Parker, 2005). Inter-stand DEB-
crosslinks include: (1) N7-Gua-DEB-N7-Gua, (2) N7-Gua-DEB-N6-Ade, (3) N7-Gua-DEB-N3-
Ade, and (4) N6-Ade-DEB-N6-Ade. Intra-strand DEB-crosslinks are: (5) N2-Gua-DEB-N2-Gua 
and (6) N7-Gua-DEB-N7-Gua. REV1 in TLS to bypass these DEB-crosslinks by directly 
incorporating a dCTP opposite to the crosslink. This could potentially create post-repair 
mismatches on DEB-crosslinks that have adducted Ade by incorporating a Cyt via REV1.  
4.4.2.3 EB DNA Damage Response 
All mutant cells in BER (PARP1-/-, Pol β-/-, and FEN1-/- cells), NER (XPA-/-, and XPG-/- 
cells), had no sensitivity to EB [Table 4.3a and 4.3b]. MMR mutant (MSH3-/- cells) had low 
sensitivity to EB [Tables 4.4a]. EB DDR does not depend on BER or NER repair of due to the 
lack of sensitivity in the panel of mutant cell lines for those pathways. MSH3-/- low sensitivity 
denotes that if the MSH3 protein participates in EB monoadducts repair, it could be MMR 
independent.  
In the TLS pathway, EB induced sensitivity in mutant cell line REV1-/-, moderate 
sensitivity in RAD18-/- cells, and similar sensitivity to that of wt in Pol к-/- and Pol θ-/- cells 
[Table 4.4b]. EB DDR is via TLS bypass of EB monoadducts but without requiring the 
involvement of polymerases Pol к, Pol θ. However, what it will require is the stimulation of 
ubiquitin ligase-RAD18 to activate REV1 and perform repair.  
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All FA mutant cells (FANCD2-/-, BRCA2-/-, BRCA1-/-, and RAD51c-/-), showed that EB 
sensitivity was close to that of wt [Table 4.5a]. HR mutant cells EB sensitivities were in the 
following order: moderate sensitivity in RAD51d-/-, > RAD54-/-, = XRCC2-/- and low sensitivity in 
XRCC3-/- [Table 4.5b]. The remaining HR mutant cell lines (BRCA2-/-, BRCA1-/-, RAD51c-/- and 
BLM-/-), were close to that of wt. Proteins RAD51d, RAD54, XRCC2 and XRCC3 are implicated 
in the invasion-extension step of HR (Sung, 2006). EB DDR is primarily carried via other 
pathways, however, the moderate/low EB sensitivity suggests that proteins RAD51d, RAD54, 
XRCC2 and XRCC3 could participate in the repair of EB monoadducts, but independently from 
HR pathway.  
NHEJ deficient cell lines, those that showed sensitivity to EB were in the following order: 
moderate sensitivity in Ku70-/- > LIGIV-/- >, and low sensitivity in DNAPKcs-/- [Table 4.6a]. EB 
DDR is potentially modulates repair by recognizing broken ends via Ku70, and sealing the ends 
by LIGIV. The low sensitivity in DNAPKcs suggests that NHEJ may be an alternative pathway 
for the repair of EB monoadducts. 
DNA Damage Sensor and Cell cycle checkpoint EB sensitivities were moderate in 
RAD17-/-, but > ATM-/- [Table 4.6b]. The DNA Damage Sensor RAD17 recruitment of the 9-1-1 
complex, and DNA binding of ATR kinase complex [ATR-ATRIP] to activate Chk1 to arrest 
cells at the G2/S phase to initiate DNA repair. 
EB DDR moderately requires RAD17 signaling for the recruitment of other downstream 
proteins involving repair and fork stalling prevention but its ATM independent.  
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4.4.2.4 EB DNA Damage Response Pathway 
4.4.2.4.1 EB Monoadducts 
We hypothesize that primary EB DDR will be to bypass monoadducts HB-Gua, HB-Ade 
and HB-Ura via TLS [Figure 4.13]. During replication, a high-fidelity polymerase can encounter 
EB monoadducts and stall at the replication fork. Exposed single-stranded DNA gets coated by 
protein RPA stimulating ubiquitin ligase-RAD18 to form complex RAD18/RAD6. This mono-
ubiquitylates polymerase clamp PCNA, enhancing its interaction with adaptor REV1 to facilitate 
the switch from a replication polymerases, to a TLS polymerases and bypass these lesions and 
AP-sites. REV1 is known to incorporates dCTP 10 opposite to AP-sites and adducted Gua (Nair, 
2005).  
EB predominantly generates mono-adducts; with Guanine (HB-Gua) at N2 and N7 
positions, with Adenine (HB-Ade) at the N3 and N6 positions, and one with Uracil (HB-Ura) at 
the N3 position. Adducts of HB-Gua at the N7 position are more abundant than those at the N2 
position, but the latter are more mutagenic11 and hydrolytically stable. N3-HB-Ura are 
exceptionally unstable and depurinate a lot quicker than the N7-HB-Gua. Adducts N2-HB-Gua 
and N3-HB-Ura have shown partial or complete block of Pol η (Chang, 2017).  After 48 hours of 
EB treatment, at least half of the original N7-HB-Gua adducts (half-life of 50 hours) will 
spontaneously depurinate, generating AP-sites (Boysen, 2009). Due to the unstable nature of the 
N3-HB-Ura we would also expect them to undergo depurination, leaving AP-sites. The resulting 
adducts and its AP-sites will mainly be processed by TLS. Here, REV1 incorporates dCTP 
without potentially creating mismatches, since Gua pairs with Cyt. Also, REV-1, would 
                                                 
10 dCTP: Deoxycytidine triphosphate (Cytosine nucleotide) 
11 N2-HB-Gua is more mutagenic for the S isomer. 
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incorporate dCTP opposite to N2-HB-Gua, and N6-HB-Ade to bypass these adducts by inserting 
a Cyt. This step won’t create a mismatch for adduct N2-HB-Gua, however it could generate a 
mismatch for adduct N6-HB-Ade. In, addition, REV1 incorporation of dCTP opposite to AP-
sites from N3-HB-Ura, will also generate a mismatch. This confirms that the primary DDR in the 
repair of EB DNA damage is via TLS bypass by REV1of adducts N7-HB-Gua, N2-HB-Gua, N3-
HB-Ade and N6-HB-Ade adducts and AP-sites. 
4.4.2.5 EB-diol DNA Damage Response 
BER deficient PARP1-/- cells were sensitive, Pol β-/- cells were moderately sensitive, and 
FEN-1-/- cells had low sensitivity [Table 4.3a]. EB-diol DDR requires BER via PAPR1 and Pol 
β. PARP1 seems essential in the recognition and repair of strand breaks, and AP-sites generated 
from the spontaneous depurination of THB-Gua. However, it can’t be excluded that this unique 
sensitivity in PARP1-/- mutant cells could reflect cellular stress in response to EB-diol exposure 
by depleting glutathione, leading to an indirect increase in reactive oxygen species. The 
depletion of glutathione for all BD epoxide isomers, including EB-diol isomers have been 
previously evaluated in vitro. In liver cytosol fractions from rat hepatocytes, EB-diol cytosol 
mediated removal of glutathione was 10-35%, without any differences in reactivity amongst 
isomers (Niesuma, 1998). Pol β is moderately involved in filling-in those AP-sites generated 
from removed bases by a glycosylase, or perhaps lost via spontaneous depurination of THB-Gua. 
Pol β participates in removing adducted nucleobases from the sugar-phosphate backbone, repairs 
AP-sites, and single strand breaks (Kim, 2012a). FEN1 typically plays an essential role in long 
patch BER repair by cleaving displaced oligonucleotides before the nick is sealed with a ligase 
(Robertson, 2009).  The lack of sensitivity in our experiments for FEN1 confirms that EB-diol 
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DDR responds preferentially via short patch, rather than long patch BER. EB-diol treatment 
seems to primarily induce DDR via short-patch BER to repair adducts THB-Gua or THB-Ade, 
AP-sites, any EB-diol induced strand breaks as sensed by PAPR1, as well as potential oxidative 
damage.  
NER deficient cell lines XPA-/- and XPG-/- presented moderate sensitivities [Table 4.3b]. 
EB-diol DDR in NER moderately requires both XPA and XPG. Our results suggest that post-
EB-diol treatment, (1) a DNA adduct is causing some helix distortion, perhaps a DNA-Protein 
crosslink (DPC) or (2) an intra-strand crosslink. The NER pathway readily removes intra-strand 
crosslinks (O'Donovan, 1994, Huang, 2013). The most predominant EB-diol monoadducts 
formed in vivo are N7 THB-Gua, N2 THB-Gua, and N6 THB-Ade. Although EB-diol 
monoadducts might not distort the DNA helix, they could affect its flexibility if the unbound 
trihydroxy group that’s available reacts with other proteins, resulting in a DPC. Overall, the 
moderate sensitivity of NER related proteins to EB-diol indicated that this pathway is an 
alternate pathway of repair. MMR cell line MSH3-/- sensitivity was similar to that of wt [Table 
4.4a], and thus EB-diol DDR does not involve MMR to recognize and repair mismatched bases 
via complex MutSβ.  
TLS mutant cell line REV1-/- had the highest sensitivity to EB-diol, followed by sensitivity 
to RAD18 -/-, moderate sensitivities in both Pol к-/- > Pol θ-/-, and Pol η-/- was as similar as wt 
[Table 4.4b]. EB-diol will trigger a DDR via TLS, relying on REV1 to bypass the DNA damage, 
initially via stimulation of ubiquitin ligase-RAD18. REV1 incorporates dCTP nucleotides 
opposite to AP-sites and/or THB-Gua adducts. In addition, TLS polymerases: Pol к may also 
participate in the bypass over Pol θ, but not Pol η.  
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Sensitivities in FA and HR pathway mutant cells against EB-diol were in the following 
order: highly sensitive RAD54-/- > BLM-/-, sensitive FANCD2-/- > XRCC2-/- > BRCA2-/-  > 
BRCA1-/-, moderately sensitive WER-/-  > XRCC3-/-  = RAD51c-/-, and low sensitivity RAD51d-/-  
[Table 4.5a and 4.5b]. EB-diol DDR requires these proteins to stabilize replication forks and 
repair an ICL and/or double strand break by a combination of pathways that includes the 
FA/BRCA as a primary pathway. In addition, EB-diol induces “BRCAness” as marked in both 
BRCA1-/- and BRCA2-/- mutant cells sensitivities. When combining results from previous EB-diol 
DDR sections, we see both HR and TLS pathways functioning downstream the FA pathway. It is 
strongly implied that EB-diol treatment triggers a DDR that responds to the repair of an 
unidentified ICL and or DSB breaks. This kind of DDR was unexpected for EB-diol using the 
existent BD DNA-adduct data. 
EB-diol DDR does not seem to require NHEJ for DNA repair. Ku70-/- > LIGIV-/- cells had 
moderate sensitivities, and DNAPKcs-/- cells had low sensitivity [Table 4.6a]. Its implied then 
that EB-diol modulates DSB repair (if any) by recognition of the broken ends via Ku70 
competitive binding against PARP1. Our previous results in PARP1 sensitivity for EB-diol were 
greater than the sensitivity of Ku70. The low sensitivity in LIGIV-/-, DNAPKcs-/- suggests that 
NHEJ could be an alternative pathway.  
EB-diol sensitivities are in the following order: RAD17-/- > RAD9-/- > ATM-/- [Table 4.6b]. 
EB-diol DDR relies heavily on RAD17 signaling for the recruitment of RAD9 as part of the 9-1-
1 complex, which activates DNA repair, and we speculate it potentially facilitate ATR-
phosphorylation of Chk1 to prevent fork stalling by inducing G2/S arrest.  
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Our results for lack of ATM sensitivity in EB-diol, suggests that ATR signaling is 
favored. EB-diol treatment is likely to induce stalled replication forks due to a possible EB-diol-
ICL. 
4.4.2.6 EB-diol DNA Damage Response Pathway 
4.4.2.6.1 EB-diol Monoadducts 
EB-diol generates monoadducts; at the N2 and N7 positions of Guanine (THB-Gua) and 
at the N6 position of Adenine (THB-Ade). Adducts of THB-Gua at the N7 position are more 
abundant than those at the N2 position, but the latter are more mutagenic12 and hydrolytically 
stable. In addition, N2-THB-Gua lesions have previously shown to partially block Pol η (Chang, 
2017). In our results, after 48 hours of EB-diol treatment, we expect that at least half of the 
original N7-THB-Gua to remain while the other half will leave behind AP-sites due to 
spontaneous depurination. Both the N7-THB-Gua adduct and the AP-site will rely on REV1 for 
the incorporation of dCTP without potentially creating mismatches, since G pairs with C. REV-
1, unlike any other polymerases, highly specializes in the incorporation of dCTP over any other 
nucleotide in adducted Guanines, particularly in N2-adducted-Gua, which have shown to 
obstruct replication (Nair, 2008, Choi, 2008). This also clarifies that those N2-THB-Gua adducts 
will also depend on REV1 for bypass via incorporation of Cyt opposite to the adducted-Gua 
without creating mismatches. However, if regular REV1 activity incorporates a dCTP opposite to 
an N6-THB-Ade adduct, a mismatch is expected.  
REV1 also participates with other DNA repair pathways. In stalled replication forks, 
REV1 participates to resolve ICL lesions as part of the Fanconi Anemia (FA) pathway (Ceccaldi, 
2016). Initially, REV1 forms a complex with B-family polymerase Pol ζ to perform the 
                                                 
12 For the S,S isomer 
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extension step during ICL repair. We did not perform tests for Pol ζ. Moreover, a specific 
component of the FA core complex (FAAP20), interacts and recruits REV1, in collaboration 
with ubiquitylated PCNA via RAD18, to promote TLS (Mirchandani, 2008, Kim, 2012, Kim & 
D’Andrea, 2012), without involving the FANC-ID complex (Budzowska, 2015). It has not yet 
been documented that EB-diol can induce an ICL, however the spectrum of DDR presented here 
strongly suggests that possibility (see FA/HR Pathway).  
In addition to REV1’s involvement in the repair of EB-diol related adducts, we also found 
that TLS polymerase Pol к and Pol θ (polymerase also involved in alternative end-joining), were 
sensitive and therefore part of the repair “team” but to a lesser extent than REV1 and RAD18. 
Some of the THB monoadducts could be detected as bulky adducts, and will partially require to 
be repaired/bypassed during replication via Pol к. Previous studies have noted the recruitment of 
Pol к upon DNA damage from benzo[a]pyrene diol epoxide (BPDE) as essential in the repair of 
bulky adduct benzpyrene diol epoxide-Gua (Suzuki, 2002, Avkin 2004). Pol κ can also 
accurately bypass benzopyrene-N2-Gua adducts via TLS (Ohashi 2000, Makridakis, 2012). Pol κ 
has demonstrated to accurately bypass a N2-Gua-N2-Gua ICL in vitro following mitomycin C 
exposure (Minko, 2008). In the event that a N2-Gua-N2-Gua ICL from EB-diol is formed, Pol κ 
could potentially ensue in its repair. Therefore, we speculate that Pol κ is cooperating with REV1 
in the bypass of N2-THB-Gua, N6-THB-Ade, N7-THB-Gua, including a possible not-yet-
identified EB-diol crosslink via TLS with or without involving the FA pathway.  
The moderate sensitivity of Pol θ-/- cells may suggest the repair of DSB via alt-EJ as 
playing as an important role in EB-diol repair. Pol θ efficiently incorporates an Ade opposite to 
AP-sites and extend past them (Seki, 2004, Knobel, 2011). Most AP-sites we expect to be 
generated consequently from N7-THB-Gua spontaneous depurination. It is therefore that this 
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could lead to mismatches due to mis-incorporation of Ade at the AP-site, instead of the 
corresponding Cyt. The lack of sensitivity in Pol η-/- cells to EB-diol points out that the 
generation of intrastrand-crosslinks (such as T-T dimers) are unlikely or that Pol η does not play 
an important role in EB-diol repair.  
Overall, we haven’t excluded the possibility of THB-monoadducts as precursors of DPCs 
via reaction of the unbound tri-hydroxy group. DPCs are considered bulky adducts, and future 
experiments should consider to test N2-Gua-THB, N7-Gua-THB and N6-Ade-THB as well as 
EB-diol with the hydroxy groups in distinct positions as precursors of these unidentified DPCs. 
Recent methods have been developed and applied for the isolation and analysis of DPCs from 
BD-epoxide DEB in vitro using HeLa cells (Tretyakova, 2015), however EB-diol was not 
included in their experiments. A new research project should considered future experiments that 
identify and characterize these target proteins from nuclear protein extracts of DT40 cells 
followed by proteomic analysis of DPCs. 
4.4.2.6.2 EB-diol ICL 
We hypothesize, that EB-diol is generating an un-identified ICL. The induced sensitivity 
in our panel of mutant cells have identified a combination of different DDR pathways that 
combine FA-TLS-HR.  
First, the “EB-diol ICL” is generated, leading to a replication forks stall. ATR is initially 
activated and recruited to DNA through RPA bound to single stranded DNA as a result of stalled 
replication forks, or from exposed single stranded 3ʹ overhangs after HR DNA resection. 
ATRIP13 then recruits ATR to single stranded DNA and activated by topoisomerase binding 
partner 1 (TOBP1), and into a complex with clamp loader Rad17-Rfc2-514, clamp formed by the 
                                                 
13 ATR-interacting protein 
14 Replication Factor C Subunit 2 
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9-1-1 complex, Claspin and RHINO15 (Brown, 2016). The adapter protein Claspin binds to 
BRCA1and kinase Chk1to facilitate the ATR phosphorylation of both, whereas RHINO binds to 
the 9-1-1 clamp and TOPBP1 to stabilize them (Lindsey-Boltz, 2015). CHK1 is then activated by 
ATR, inhibiting cyclin-dependent kinase (CDK) activity via phosphorylation of CDC25A to 
regulate the G2/S cell cycle arrest and preventing the replication fork to collapse.  
The sensitivity in and FANCD2-/- and RAD18-/- mutants denote how their corresponding 
proteins are important in the process of recognition of the ICL via FA as well as initiation of TLS 
[Figure 4.14 and 4.15]. First, the ICL is recognized by FANCM with FAAP24 by associating 
with the DNA-bound MHF complex (MHF1 and MFH2) to commence the assembly of the FA 
core complex. FANCM-FAAP-24 acts as a platform to recuit the rest of the core complex (10-
remaining proteins). Once assembled, it acts as a ubiquiting ligase. In paralell, sensor RAD18 
recruits PCNA via mono-ubiquitilation, initiating the convergence of TLS pathway and the FA 
pathway. Ubiquitilated PCNA promotes the recuitment of both FANCL and FANCD2. Here, 
phosphorilation of FANC-ID [FANCD2+FANCI] activates the complex and leads it to interact 
with the DNA-bound FA-core complex.  
The FA-core complex subunits FANCL and FANCT mono-ubiquitinates FANC-ID 
[FANCD2-FANCI] leading to its loading onto DNA and initiating the ICL-unhooking process. 
The FANCD2 protein allows FANC-ID to control the incision near the replication fork by its 
effector proteins. Recruited nucleases FANCP and FANCQ cut and release the ICL from one of 
the two parental strands, leaving (1) a strand with an anti-space (or DSB), and (2) another strand 
with the left-over lesion [Figure 4.15].  
                                                 
15 Rad9, Rad1, Hus1 interacting nuclear orphan 
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The bypass of the one-sided-left-over lesion will be carried on via TLS [Figure 4.16]. 
When the high-fidelity replication polymerase encounters this DNA damage, it stalls at the 
replication fork. Exposed single-stranded DNA gets coated by RPA, stimulating ubiquitin ligase-
RAD18 to form complex RAD18/RAD6. The complex mono-ubiquitylates PCNA polymerase 
clamp, to enhance its interaction with REV1, and recruiting TLS polymerases. Simultaneously, 
protein FAAP20 binds to the FA core complex forming FAAP20-FA core complex. Here, both 
RAD18 ubiquitinated PCNA, and now the FAAP20-FA core complex assesmble the TLS related 
complex PCNA-REV1 via ubiquitin-binding with REV1 (Mirchandani, 2008, Kim, 2012, Kim & 
D’Andrea, 2012). This interaction allows direct lesion bypass on the strand with the ICL leftover 
via TLS recruitment of REV1, and forming a complex with polymerase Pol ζ, or Pol к at the 
replication fork to perform the extension step. Once the extension is completed beyond the ICL 
(Räschle, 2008), the TLS polymerase is switched back to the replicative polymerase. The final 
product is one of the two strands being ligated to close the gap when it reaches an Okazaki 
Fragment (Buzowska, 2015).  
The bypassed ICL left over is excised by the NER pathway during either transcription or 
replication [Figure 4.17]. During transcription, the ICL leftover could lead polymerase RNAP2 
to stall (in TC-NER). Intermediate CSB recruits CSA and stabilizes the replication block by 
repositioning RNAP2 past the lesion. Alternatively, the damage is recognized upon binding by 
intermediate complexes, XPC/hHR23B, with or without DDB/XPE (in GG-NER). Either 
pathway will recruit helicase TFIIH to unwind the DNA helix, XPA and RPA to stabilize the 
helix opening, recruit endonuclease XPG and ERCC1-XPF and make incisions 5ʹ and 3ʹ 
respectively from the lesion. DNA replication proteins fill the single strand gap (RFC, PCNA, 
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RPA, and DNA polymerases δ, ε, or к) and nicks are then sealed by DNA ligases I or III (Giglia, 
2011).   
The induced sensitivity of EB-diol in PARP1-/- cells, and moderate sensitivity in Pol θ-/- 
cells suggests the alt-EJ pathway as minor contributor in DDR. Others have identified that Pol θ 
as a multifunctional polymerase/helicase that promotes alt-EJ (Wood, 2016), and PARP1 has 
been suggested as a facilitator protein in the recruitment such alt-EJ repair factors, including TLS 
polymerases (i.e. Pol θ) (Black, 2016, Ceccaldi, 2016). Both alt-EJ and HR share the initial DSB 
resection. Specifically, in HR, resection is extended and RAD51 proteins help in forming 
filaments on the 3ʹ overhangs, driving sister chromatid exchange, while in alt-EJ is thought that 
PARP1 mediates annealing using micro-homologies. Therefore, we are inclined to imply that the 
combination of FA-TLS pathways will distribute the next stage of repair between two sub-
pathways. Each pathway will be dependent on the TLS polymerase that performed the bypass. If 
Pol к performs the bypass then the following step will be HR and will be less likely to introduce 
errors. However if Pol θ performs the bypass then alt-EJ will follow but will be more likely to 
introduce errors. Our results for EB-diol showed Pol к-/- and Pol θ-/- cells as sensitive, however, 
the sensitivity in Pol к-/- cells was greater than that of Pol θ-/- cells.  
Our previously repaired one-sided ICL will now serve as template for repairing the 
opposite strand that has the unrepaired anti-space via HR [Figure 4.18]. Because an incision was 
made at the replication fork, it created a DSB as a by-product of DNA repair. First, HR initiates 
the repair of the DSB via DNA-binding of sensor PARP1. This leads to the recruitment of the 
nuclease active MRN-CtIP complex and the BRCA1/BARD1 for the resection of DSB ends. 
Exonucleases: EXO1, and DNA2, associate with DNA unwinding helicases BLM and WER to 
extend the resections several 1,000 base pairs. The product of the resected double strands are 3ʹ 
164 
 
single strand tails (or overhangs). In-tandem, RPA proteins coat these exposed 3ʹ single strand 
tail regions. Here, BRCA1/BRCA2/PALB2 assist RAD51 in replacing RPA proteins from the 3ʹ 
single strand tail regions by forming RAD51 single stranded nucleofilaments through its RAD51 
paralogues RAD51c, RAD51d, XRCC2, and XRCC3. These pre-synaptic filaments, binds 
duplex DNA to form the synaptic complex and “searches” for DNA homology in a duplex-sister-
chromatid obtained from the previously repaired one-sided ICL. This process is facilitated by 
several proteins that include Rad54, allowing single stranded DNA invasion of the homologous 
region in the duplex and forming a displacement loop (D-loop). Strand exchange occurs, and 
complementary DNA is synthesized by polymerases from the 3ʹ to 5ʹ using the sister chromatid 
as a template. We propose that the previous intermediate products from strand exchange, result 
in a double Holliday Junction that needs to be resolved by resolvase enzymes. These resolvases 
include both the activity of a complex formed in part by BLM helicase and Topoisomerase III α 
[BTR complex], and are arranged in a complex that promotes the dissolution of the double 
Holliday junction, resulting in the exclusive formation of non-crossover products (Kitano, 2014). 
Once the process is completed, FANCD-ID is de-ubiquitilated, the ends are sealed by a DNA 
ligase completing the EB-diol ICL repair (Chu, 2014, Sung, 2006, Chen, 2017, De Lorenzo, 
2013, Giglia, 2011).  
4.5 CONCLUSIONS 
Understanding the importance of BD-DNA adducts has been discussed regarding the 
genotoxicity of BD. However, limited information was available to date as to which DNA 
damage response pathways were essential for cells to counteract BD-epoxides damage. To this 
date, DT40 cells provide the most extensive collection of DNA repair mutant clones in vertebrate 
cells to assess DNA Damage Response using a high-throughput in vitro assay. The biological 
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significance of these DNA Damage Responses was established with by employing the 
DT40/XTT method to asses BD-epoxides, and their sensitivities. Effects were expressed by the 
Relative LD50, using DT40 parental cells and twenty seven DT40-/- mutants. These mutants 
were deficient in seven DNA repair pathways, including: BER, NER, MMR, TLS, FA, HR, 
NHEJ, with Damage Sensors, and Cell Cycle Checkpoints.   
Overall results showed that REV1-/- was the most senstive mutant cell line across BD-
epoxides. REV1 is not only an pivotal protein in TLS, but also represents the common link 
between DNA Repair pathway for FA and TLS. Irrespectively of differences on the 
corresponding DNA adducts formed by each epoxide, the primary form of response upon DNA 
damage is via bypass via TLS with the difference being the specific TLS bypass polymerases 
involved. The second common observation was that epoxides DEB and EB-diol had similar 
DDR signatures for certain pathways. For instance, in the FA pathway both DEB and EB-diol 
overlapped with sensitivity for mutant cells FANCD2-/- and BRCA2-/-. This was perharps one of 
the most striking and unexpected results to this date for EB-diol. There is extensive evidence that 
supports the generation of DEB crosslinks, but no documentation of EB-diol crosslinks (ICL) has 
been presented to this date. Also, both FA mutant cells BRCA1-/- and BRCA2-/- had induced 
sensitivity by EB-diol, and different from DEB where no sensitivity was seen in BRCA1-/- 
mutants. This indicates that the recognition and excision to unhook the ICL was similar for both 
epoxides. However, for EB-diol, sensitive BRCA1-/- cells signifies that the DSB needs to be 
processed via resection as part of the HR pathway. In contrast, EB did not induced FA or HR 
mutants sensitivity and DEB did not induced the latter.  One of the highlight findings was EB-
diol’s uniques DDR signature through six DT40 both highly sensitive and sensitive mutants, that 
were not sensitive for EB nor DEB. These unique EB-diol mutant cells were BLM-/-, RAD17-/-, 
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PARP1-/- and the combined sensitivity in both BRCA1-/- and BRCA2-/-. PARP1 is uniquely 
required for EB-diol DNA damage. In addition, BLM not only identified that EB-diol required 
HR as part of its DDR but also that strand exchage was mediated post resection, perhaps forming 
a dHJ that was resolved also by BLM to promote its dissolution; producing non-crossover 
products.   
The DT40/XTT allowed the elucidation of DDR for all three epoxides derived from BD. 
Results showed coupled DNA repair pathways as follows: EB’s DDR was primarily centered by 
TLS, EB-diol’s DDR is FA-TLS-HR, and DEB’s DDR is FA-TLS. Most of the Dt40 mutant 
cells results suggest that EB-diol treatment is inducing an ICL. This response to DNA damage 
was unaccounted for since we originally hypothesized to see EB-diol induced sensitivity in BER 
mutants as DDR. We cannot yet conclude or assume if the nature of the ICL is a DNA-DNA 
crosslink or a DNA-protein crosslink (DPC), or a combination of the two, and we think future 
work should be done to clarify this.  
Finally, the implication in the different DDR responses induced by BD-epoxides suggests 
that EB-diol is indeed a very important chemical that should continue to be examined, and not be 
underestimated in BD human risk assessment. EB-diol is the “Titan” of the BD-epoxides, due to 
its abundance across species. Our previous results in Chapter 3 solidifies this statement. 
Moreover, our measurements across species for BD-Hb adducts, IBD, and EB-Equivalency have 
proven that EB-diol is the most significant BD-epoxide across species, and particularly, the most 
influential in humans (Swenberg, 2011). The attributable carcinogenic potential of BD, 
particularly in mice has been directly influenced by the greater contribution of DEB, rather than 
EB and EB-diol as shown by the EB-equivalency (Swenberg, 2011). No doubt that DEB has 
been the BD-epoxide with the greatest genotoxic potential, because it has demonstrated to be 
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linked to induce tumor formation in mice. The formation of DEB is species dependent, where 
mice are more metabolically apt to favor the oxidation of EB into DEB. However, this just 
clarifies why there is a species differences in tumor formation between rats and mice, but does 
not reflect the importance of EB-diol in human risk assessment. In humans, DEB is a minor 
metabolite, since metabolism favor the hydrolytic pathway towards the formation of EB-diol. 
These observations have been clearly demonstrated with EB-diol as greatest contributor of THB-
Val Hb-adducts, THB-Gua DNA adducts, highest internal blood dose, and the greatest 
contributor in the EB-equivalency across species. In this report, we have strengthened the 
premise that DEB serves to understand its importance as a strong influence in mice 
carcinogenesis, but it is truly EB-diol that’s relevant for human risk assessment. We understand 
these results are contributing in our understanding and completion of existent data gaps for BD-
epoxides repair in BD.  
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4.7 TABLES: 
 
Pathway DT40 Cell Line 
Relative LD50  
(EB-diol) 
Mean SD (n) 
 Wild-Type DT40 1 0 8 
Checkpoint ATM-/- 0.89 0.09 4 
Sensor RAD17-/- 0.15 0.04 7 
HR 
RAD54-/- 0.25 0.08 7 
RAD51c-/- 0.73 0.05 2 
RAD51d-/- 0.86 0 2 
XRCC2-/- 0.33 0.03 7 
XRCC3-/- 0.73 - 1 
BRCA1-/- 0.49 0.09 6 
BRCA2-/- 0.34 0.08 6 
FANCD2-/- 0.32 0.08 8 
HEL BLOOM
-/- 0.26 0.03 4 
WERNER-/- 0.59  - 1 
NHEJ 
KU70-/- 0.54 0.05 3 
DNAPKcs-/- 0.83 0.05 3 
LIGIV-/- 0.76 0.06 2 
TLS 
RAD18-/- 0.34 0.05 6 
REV1-/- 0.07 0.02 8 
POLH-/- 1.26 0.28 2 
POLK-/- 0.51 0.1 4 
POLQ-/- 0.68 0.08 2 
BER 
POLB-/- 0.7 0.18 5 
FEN1-/- 0.77 0.19 4 
PARP1-/- 0.26 0.02 6 
NER XPA
-/- 0.57 0.08 4 
XPG-/- 0.66 0.06 3 
MMR MSH3-/- 0.96 0.13 4 
 
Table [4.1]: Relative LD50 of EB-diol in DT40 wt and DT40 mutants 
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Sensitivity Relative LD50 Categories 
High Sensitivity < 0.25 
Sensitivity 0.26 - 0.50 
Moderate Sensitivity 0.50 - 0.75 
Low Sensitivity 0.75 - 0.99 
No Sensitivity  1 and > 
 
Table [4.2] Relative LD50 Sensitivity Ranges: The LD50 of DT40 mutants divided by the 
LD50 DT40wt were used to determine the Relative LD50 to allow comparisons. We have 
subcategorized degrees of sensitivity by assigning categories and ranges to the Relative LD50. 
The five categories are: High Sensitivity (0.01-0.25), Sensitivity (0.26-0.50), Moderate 
Sensitivity (0.51-0.75), Low Sensitivity (0.75-0.99) and No Sensitivity (1.00 and above). 
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(a) 
Butadiene Epoxides Relative LD50  BER 
PARP1 -/- POLB -/- FEN1 -/- 
Epoxybutene (EB)  Low  Low  Low 
Diepoxybutene (DEB) L N  None  None 
Epoxybutene-diol (EB-diol)  Sen  Mod  Low 
 
(b) 
Butadiene Epoxides Relative LD50  NER 
XPA -/- XPG -/- 
Epoxybutene (EB) Low Low 
Diepoxybutene (DEB) Low None 
Epoxybutene-diol (EB-diol) Mod Mod 
 
Table [4.3] Relative Sensitivity of (a) Base Excision Repair and (b) Nucleotide Excision Repair to Butadiene Epoxides. 
 
 
 
 
 
 
  
  
171 
 
(a) 
 
 
 
 
(b) 
 
 
 
 
 
Table [4.4] Relative Sensitivity of (a) Mismatch Repair and (b) Translesion Synthesis to Butadiene Epoxide 
 
 
 
 
Butadiene Epoxides 
Mismatch 
Repair 
MSH3-/- 
Epoxybutene (EB) Low 
Diepoxybutene (DEB) None 
Epoxybutene-diol (EB-diol) Low None 
Butadiene Epoxides 
Translesion Synthesis 
PCNA RELATED y-Polymerases 
REV1-/- RAD18-/- POLK
-/- 
(Pol к) 
POLQ-/- 
(Pol θ) 
POLH-/- 
(Pol η) 
Epoxybutene (EB) Sen Mod L N L N N.T. 
Diepoxybutene (DEB) High High Low None Sen 
Epoxybutene-diol (EB-diol) High Sen Mod Mod None 
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(a) 
 
 
 
 
 
(b) 
 
Table [4.5] Relative Sensitivity of (a) Fanconi Anemia and (b) Homologous Recombination to Butadiene Epoxides. *N.T. means 
not tested. 
 
 
 
Fanconi Anemia Pathway 
 
ID Complex 
Downstream Effectors 
Butadiene Epoxides  
BRCA2-/-  is BRCA1-/- is   BRCA2-/-  is 
FANCD2-/- FANCD1-/- FANCD2-/- FANCD1-/- 
Epoxybutene (EB) L N L N L N L N 
Diepoxybutene (DEB) High  Sen None None 
Epoxybutene-diol (EB-diol)  Sen  Sen  Sen Mod 
Homologous Recombination 
Butadiene Epoxides  RAD54-/- BRCA2-/- BRCA1-/- XRCC2-/- BLM-/- WRN-/- XRCC3-/- RAD51c-/- RAD51d-/- 
Epoxybutene (EB) Mod L N L N Mod L N N.T.* Low L N Mod 
Diepoxybutene (DEB) None Sen None Mod None L N Mod None None 
Epoxybutene-diol (EB-diol) High Sen Sen Sen H S Mod Mod Mod Low 
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(a) 
Butadiene Epoxides Non-Homologous End-joining  
KU70-/-  LIGIV-/-  DNAPKcs-/- 
Epoxybutene (EB) Mod Mod Low 
Diepoxybutene (DEB) Mod Mod Low 
Epoxybutene-diol (EB-diol) Mod Low Low 
 
(b) 
 
 
 
 
 
Table [4.6] Relative Sensitivity of (a) Non-Homologous End Joining and (b) Sensors and Cell Cycle Check Points to Butadiene 
Epoxides. 
 
 
 
 
Butadiene Epoxides 
911 Complex Cell Cycle 
Checkpoint Sensor Sensor 
RAD17 -/- RAD9-/- ATM-/- 
Epoxybutene (EB) Mod N.T. Low 
Diepoxybutene (DEB) Mod N.T. None 
Epoxybutene-diol (EB-diol) High High Low 
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DT40 DNA 
Repair Pathways EB DEB EB-diol 
BER     PARP1 
TLS REV1 REV1, RAD18, Pol H REV1, RAD18 
FA-BRCA   FANCD2, BRCA2 FANCD2, BRCA1 and BRCA2 
HR RAD54 BRCA2, XRCC2 and XRCC3 
RAD54, BRCA1, BRCA2, 
XRCC2, BLM, WRN, 
XRCC3, Rad51c 
Sensors     RAD17 
DNA Damage HB-Gua THB-Gua and  DEB-Crosslinks 
THB-Gua and  
New EB-diol-Crosslink 
DNA Damage 
Response  TLS FA-TLS FA/HR-TLS 
 
Table [4.7] DNA Damage Response in DT40 Cells with a Relative LD50 < 0.5 
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4.8 FIGURES: 
  (a) 
 
  (b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure [4.1] Schematic Representations of the DT40/XTT Method: (a) Schematic 
representation of 24-well plate format for doses, controls and blanks. (b) Schematic 
representation of the general method: exposures of DT40wt and DT40 mutants, and XTT 
dye incubation/quantitation. 
XTT = sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-
carbonyl]-2H-tetrazolium inner salt 
XTT  Formazan Product  Quantifiable by Absorbance  
(450nm-650nm)  
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 (a)  
(b)  
Figure [4.2] Cytotoxicity of Butadiene epoxide EB-diol isomers (2R,3S, 2S,3R, 2S, 3S and 
2R,3R) in both (a) DT40wt cells and (b) TK6 cells. 
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(a) 
  
(b) 
 
(c) 
 
Figure [4.3] Sample Graphs from Dose-Response Curves for EB-diol exposures of DT40wt 
against DT40 mutants: (a) Sensors: R17-/- and R9-/- (b) Translesion Synthesis: Polη-/-, Polк-/-, 
and REV1-/- (c) BRCA proteins: BRCA1-/- and BRCA2-/-.  
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Figure [4.4]: EB-diol Relative LD50 in BER Repair DT40 mutants. 
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Figure [4.5]: EB-diol Relative LD50 in NER Repair DT40 mutants. 
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Figure [4.6]: EB-diol Relative LD50 in MMR Repair DT40 mutants.  
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Figure [4.7]: EB-diol Relative LD50 in TLS Repair DT40 mutants.  
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Figure [4.8]: EB-diol Relative LD50 in HR Repair DT40 mutants. 
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Figure [4.9]: EB-diol Relative LD50 in FA Repair DT40 mutants. 
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Figure [4.10]: EB-diol Relative LD50 in NHEJ Repair DT40 mutants. 
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Figure [4.11]: EB-diol Relative LD50 in Cells and Cell Cycle Checkpoints and Sensor DT40 mutants  
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Figure [4.12]: EB-diol DNA Damage Response as the Relative LD50 of DT40 mutants to DT40 wt. 
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Figure [4.13]: EB, DEB and EB-diol monoadducts or AP-sites DDR via TLS bypass. REV1 inserts a Cystosine opposite to 
adducted bases and or AP sites in order to bypass the damage and continue replication. Pink outline and white center ovals were DT40 
mutants that were tested.  
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Figure [4.14]: DEB and EB-diol crosslink DDR of FA ICL recognition, and ICL un-hooking. The FA core complex assembles 
and activates FANCID [FANCD2 and FANCI] to remove the ICL via nucleases FNACP and FANCQ. Pink outline and white center 
ovals were DT40 mutants that were tested.  
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Figure [4.15]: DEB and EB-diol crosslink DDR of FA and TLS proteins convergence into FA-TLS coupled repair. Pink outline 
and white center ovals were DT40 mutants that were tested.   
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Figure [4.16]: DEB and EB-diol crosslink DDR of TLS proteins from FA-TLS coupled repair bypassing the ICL left over 
lesion. Pink outline and white center ovals were DT40 mutants that were tested. 
X 
X 
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Figure [4.17]: EB-diol crosslink DDR of NER proteins participating in the excision of the ICL left over. Pink outline and white 
center ovals were DT40 mutants that were tested. 
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Figure [4.18] Diagram of HR in the Repair of DSB created by FA repair in EB-diol 
crosslinks. Pink outline and white center ovals were DT40 mutants that were tested.  
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CHAPTER V: CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 CONCLUSIONS 
5.1.1 Introduction 
1,3-Butadiene (BD) is a known multisite rodent carcinogen (NTP, 1984, Melnick 
1990, Melnick, 1993, NTP, 1993 and U.S. EPA, 1985, Owen 1990) and weak 
leukemogen in humans (IARC, 2008, NTP, 2005, U.S. EPA, 2002, NTP, 2005, ASTDR, 
1993). BD is bioactivated into three reactive epoxides: 1,2-epoxy-3-butene (EB), 1,2;3,4-
diepoxybutane (DEB) and 1,2-epoxy-butanediol (EB-diol).  
These epoxides have the capacity to bind to both DNA, and hemoglobin (Hb), 
forming epoxide-specific adducts at both endpoints. Earlier reports with rodents exposed 
to BD have identified species differences in the formation of BD-specific DNA and Hb 
adducts, ultimately indicating that metabolic activation of BD is species dependent. Mice 
generated greater amounts of the most mutagenic BD-epoxide (DEB) in blood, Hb 
adducts, and DNA adducts in rodents. However, these DEB epoxides in blood and Hb 
adducts are more similar in proportion in both rats and humans, than in mice. 
Understanding this difference was fundamental to explain why mice have been the most 
susceptible species, even more so than rats, as shown by tumor development at much 
lower levels of BD exposure. In addition to species differences, gender differences in 
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tumor formation for female mice have been observed at lower concentrations than that of 
male mice. 
The weight of evidence presented across rodent species has suggested sex specific 
differences in BD-DNA crosslinks, tumor formation, and mutagenicity. Therefore DNA 
repair efficiency rather than metabolism can be attributed to the observed sex-
dependence. Initial data interpretation in metabolic biomarkers and tumor formation 
presented species differences that were difficult to understand. Some of the questions that 
remained unclear were how BD was acting as a carcinogen, how we could use this data, 
and what these findings meant for human risk assessment. 
5.1.2 Contribution of this Thesis 
The goal of this project was to complete our dataset gaps in BD-epoxide metabolic 
activation and DNA repair. This will further improve our understanding of BD’s Mode of 
Action (MOA), and its relationship to BD-carcinogenesis. We hypothesized that through 
the development of new methods, incorporation of comprehensive data sets, and in vitro 
techniques, we would identify multispecies similarities and differences in BD-metabolic 
activation. Also, the integration of DNA-damage response as an endpoint would serve to 
strengthen BD carcinogenic MOA and identify relevant epoxide-specific differences in 
repair. Results are expected to contribute in the improvement of scientific risk 
assessment, public health, and further employed as an application to other known 
multispecies carcinogens.  
This dissertationintegrates and applies previously developed methods from our 
laboratory: (1) for the development and completion the set of BD Hb adducts peptide 
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standards, (2) to complete the quantitation of BD Hb adducts formation in our mice 
dataset, and (3) to evaluate DNA damage response pathways induced by selected BD-
epoxides. 
5.1.3 Thesis Chapters 
This dissertation was presented in three inter-related chapters (Chapters 2, 3 and 4). 
Chapter 2 describes a combination of methods that successfully generated a total of six 
unique EB-diol specific (1-11) THB-Val peptide standards. These included both analyte 
and internal peptide standards for Hb α (1-11) Human, Rat, and Mouse THB-Val. We 
employed direct alkylation of the Hb α (1-11) NTV peptide sequences with EB-diol. This 
was followed by chromatographic purification and characterization by LC-ESI+ MS/MS 
prior to amino acid quantitation by UPLC MS/MS-based amino acid analysis. THB-Val 
peptide standards were not previously available for the quantitation of EB-diol-specific 
Hb-adducts. Now, we were able to employ them in several downstream analytical 
applications. This included their integration in the validation of a simultaneous IA-
enrichment method prior to the analysis of a unique sample-set of rodents exposed to BD. 
All BD-epoxides react with the NTV of Hb upon BD exposure (Moll 1999) forming 
three epoxide specific adducts. The most abundant epoxide formed across species upon 
BD activation is EB-diol producing epoxide-specific Hb-adduct (N-(2,3,4-
trihydroxybutyl)-valine (THB-Val). Epoxide EB and DEB also bind to the NTV of Hb 
forming adducts N-(2-hydroxy-3-butenyl)valine (HB-Val) and N,N-(2,3-dihydroxy-1,4-
butadiyl)valine (pyr-Val) respectively. All three BD-Hb adducts have been used as 
surrogate markers of BD exposure, and helped in the identification of underlying 
differences in metabolism/metabolic activation through the estimation of their internal 
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dose in blood (IBD) (Fred 2008, Swenberg, 2011). In addition, species and sex-related 
differences in the formation of each individual epoxide were quantitatively assessed by 
the use of these biomarkers of exposure. Our final goal was to better understand the role 
of BD reactive epoxides and the metabolic species differences in toxicity, to ultimately 
determine which of the two rodent species is the most appropriate for human risk 
assessment. 
Chapter 3 describes quantitation all three BD Hb-adducts formed by epoxides 
EB, DEB, and EB-diol in B6C3F1 mice exposed to BD via inhalation for 10 days. Our 
goal was to integrate the use of species-specific (mouse) NTV(1-11) peptide standards 
with a recently improved immnoaffinity (IA) method coupled to UPLC-positive mode 
electrospray ionization-tandem mass spectrometry (UPLC-ESI+ -MS/MS). This approach 
allowed the simultaneous quantitative analysis of all three BD-Hb adducts from 
hemoglobin of mice exposed to BD. Proteolytic digestion with trypsin cleaved BD-Hb 
adducted peptides from globin proteins. Digests were processed by triple antibody IA 
enrichment and the adducted peptides eluted under acidic conditions were collected and 
quantitated by nano-UPLC-MS/MS analysis. The 13C15N5-labeled internal standard 
peptides facilitated the accurate quantitation, with a limit of detection as low as 5-10 
fmol, and with little globin (10 mg).  
Previously, this method was used for the analysis of BD-Hb adducts in rats 
(Bordeerat 2012). We now used it in the quantitation of samples from mice exposed via 
inhalation to BD, at concentrations that are relevant to human occupational exposures 
(0.5 ppm). The formation of BD-epoxide adducts increased with exposure, and the 
highest formation ratio of all three adducts per ppm BD was observed at lower levels of 
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exposures (0.5-1.5 ppm). The amounts of pyr-Val, HB-Val and THB-Val formation 
showed no signs of saturation at exposures up to 625 ppm for 10 days. Previous results 
obtained by this method in BD-exposed rats were integrated for comparisons, and we 
found that formation ratios for all BD-Hb adducts were higher in mice than in rats. 
Interestingly both species were more efficient in the formation of these adducts at lower 
levels of exposure, making this relevant due to similar levels of exposure in human 
occupational settings. However, results confirmed that there were no sex-specific 
differences in the formation of BD-Hb adducts.  
BD-Hb adducts results were integrated in the calculation of the Internal Blood 
Dose (IBD) of epoxides and transformed into the EB-equivalency for further 
comparisons. The IBD of BD-epoxides, and their corresponding EB-equivalencies, were 
calculated for mice using Fred’s 2008 Kval constants for BD-epoxides and mutagenic 
potency from Meng’s 2010 publication. The IBD was found to be highest at lower levels 
of exposure (0.5 ppm) and decreased with increasing concentrations. A collaborator of 
this project presented similar results but for rats (Bordeerat, 2012). There are undeniable 
species differences as reflected in the formation of BD-epoxides and their contribution to 
the EB-equivalency. Mice were more efficient in metabolic activation of BD-epoxides at 
lower levels of exposure than at higher levels, however no sex specific differences were 
noted. The carcinogenic potential of BD in mice is directly influenced by the greater 
contribution of DEB, rather than EB and EB-diol as shown by the EB-equivalency. DEB 
has been identified as the epoxide with the greatest genotoxic potential, and thus the most 
influential epoxide in tumor formation in mice.  
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These findings provide important information relevant to why mouse is the most 
susceptible species of the rodent models, and account for the specific species differences 
in BD metabolic activation as estimated by BD-Hb adducts. The current investigation has 
provided insights to our knowledge for BD risk assessment. Finally, in mice the greater 
DEB contribution in blood and corresponding biomarker of exposure pyr-Val does point 
out the reason for this species susceptibility to BD and tumor formation. Therefore, the 
rodent species that most appropriately represented the best animal model for BD risk 
assessment in human was rat, not mouse. This was accounted by the sharp contrast 
amongst species in the EB-equivalency per ppm, where mice had the greatest difference 
in the equivalency being ~50-fold greater than Rats and ~200-fold greater than Humans 
(Swenberg 2011). 
In Chapter 4, we identified the biological significance of DNA Damage Responses 
(DDR) by employing the DT40/XTT method to asses BD-epoxides, and their 
sensitivities. All three butadiene epoxides (EB, DEB, EB-diol) have the ability to react 
with DNA, and form covalent adducts. The formation of BD-DNA adducts are indicators 
of one or more genotoxic event(s) that leads to a non-mutational event, contributing in 
the initiation of mutagenesis. Therefore, BD-DNA adducts are considered a relevant 
event to BD-carcinogenic mode of action (MOA). Limited information was available 
regarding those DDR pathways involved in counteracting each specific BD-epoxide 
insults. Therefore, we identified that BD-DDR was a gap in knowledge in BDs current 
biomarkers of exposure-effect database.  
The DT40 cells used in this research have an extensive collection of DNA repair-
deficient mutant clones to assess in vitro DDR using a high-throughput assay. The 
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biological significance of these responses was established by employing the DT40/XTT 
system to asses BD-epoxides, and their sensitivities. Effects were expressed by the 
Relative LD50, using DT40 parental cells and DT40 mutants. These mutants were 
grouped by deficiencies in seven DNA repair pathways. These pathways included 
mutants in cell cycle checkpoint, base excision repair (BER), nucleotide excision repair 
(NER), homologous recombination (HR), non-homologous end-joining (NHEJ), 
mismatch repair (MMR), translesion synthesis (TLS), DNA damage sensors and Cell 
Cycle Checkpoints.  
Overall results showed that REV1-/- was the most senstive mutant cell line across 
BD-epoxides. REV1 is not only an pivotal protein in TLS, but also represents the 
common link between FA and TLS DNA Repair pathways. Irrespective of differences on 
the corresponding DNA adducts formed by each epoxide, the primary form of response 
upon BD DNA damage is via bypass by TLS polymerases employed. The second 
common observation was that epoxides DEB and EB-diol had similar DDR signatures for 
certain pathways. In the FA pathway, both DEB and EB-diol overlapped with sensitivity 
for mutants FANCD2-/- and BRCA2-/-. This was perharps one of the most striking and 
unexpected results to this date for EB-diol. There is extensive evidence that supports the 
generation of DEB crosslinks, but no documentation of EB-diol crosslinks (ICL) has 
been presented to this date. However, only EB-diol induced sensitivity in both DT40 
mutants BRCA1-/- and BRCA2-/-.This indicates that the recognition and excision to 
unhook the ICL was similar for both epoxides. However, for EB-diol, BRCA1-/- signifies 
that the DSB needs to be processed via resection as part of the HR pathway. In contrast, 
EB did not induced sensitivity in FA or HR mutants, and DEB did not induced the latter.  
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One of the highlight findings was EB-diol’s uniques DDR signature through six DT40 
both highly sensitive and sensitive mutants, that were not sensitive for EB nor DEB. 
These unique EB-diol mutants were BLM-/-, RAD17-/-, RAD9-/-, PARP1-/-  and the 
combined sensitivity in both BRCA’s [BRCA1-/-  and BRCA2-/-]. EB-diol induces a strong 
G2/S arrest in a ATR dependent manner as indicated by both RAD17-/-  and RAD9-/-  
sensitivites, whereas EB and DEB were ATM independent. The unique sensitivity in 
PARP1-/- mutant cells to EB-diol suggests that cellular stress as response to exposure due 
to glutathione depletion, leading to indirectly increasing reactive oxygen species. In 
addition, sensitivity in BLM-/- mutant cells not only identified that EB-diol required HR 
as part of its DDR, but also that strand exchage was mediated post resection, perhaps 
forming a dHJ that was resolved also by BLM to promote its dissolution; producing non-
crossover products.   
When looking at overall results, we noticed that DNA repair pathways were 
coupled to promote repair. For instance, results showed that EB’s DDR was primarily 
TLS, EB-diol’s DDR was FA-TLS-HR, and DEB’s DDR was FA-TLS. Our results 
unraveled that EB-diol induced a DDR that correspond to the repair of a crosslink (DNA-
DNA or DNA-protein crosslink). The most striking finding in this project was in EB-diol 
DDR. The FA pathway mainly coordinates the protection of replication forks by 
“unhooking ICL’s”. Also, the FA pathway coupled with other secondary pathways that 
included TLS, and HR to mediate repair. Overall, results from the DT40 mutant cells 
panel suggests that EB-diol treatment is inducing an ICL, posing a threat to the stability 
of replication forks. This response to DNA damage was unaccounted for, since we 
originally hypothesized EB-diol to induce sensitivity in BER-related mutants as DDR. 
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Finally, the implication in the different DDR responses induced by BD-epoxides suggests 
that EB-diol is indeed a very important chemical that should continue to be examined, 
and not be underestimated in BD human risk assessment. 
Overall, the research presented here completes selected gaps in knowledge of BD 
biomarkers of exposure (BD-Hb adducts) and biomarkers of effect (BD DDR). Our goal 
was to contribute to better understanding of BD exposure-response and improve risk 
assessment. DEB has been the BD-epoxide with the greatest genotoxic potential, because 
it has demonstrated to be linked to induce tumor formation in mice. The formation of 
DEB is species dependent, where mice are more metabolically apt to favor the oxidation 
of EB into DEB. The species differences in mice and rats tumor formation, does not 
reflect the importance of EB-diol in human risk assessment. In both rats and humans, 
DEB is a minor metabolite, since metabolism favors the hydrolytic pathway towards the 
formation of EB-diol. These observations clearly demonstrated that EB-diol is the 
“Titan” of BD-epoxides. It is also, the greatest contributor of THB-Val Hb-adducts, 
THB-Gua DNA adducts, highest IBD epoxide, and the most influential factor in the EB-
equivalency across species. In this report, we have strengthened the premise that DEB 
serves to understand its importance as a strong influence in mice carcinogenesis, but it is 
truly EB-diol that’s relevant for human risk assessment. These results have completed 
existent data gaps for BD-epoxides metabolic activation, and BD induced DNA repair as 
means to improve overall risk assessment.  
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5.2 FUTURE DIRECTIONS 
We believe that BD biomarkers of exposure, as represented by BD-Hb adducts 
won’t hold much potential for any additional future experiments with respect to BD. 
However, the methods here presented do provide an excellent platform to investigate 
other chemicals, pharmaceuticals, and even drugs that might present discrepancies in the 
effects of their bio activated reactive metabolites, using BD as a model.  
Where this project does promise potential for future experiments is in respect to 
our findings in relation to biomarkers of effect, as suggested by EB-diol’s DDR. Our 
results from the DT40 mutant cells panel suggests that EB-diol treatment is inducing 
Interstrand crosslinks (ICL). The nature of this DNA lesion has not been reported to date, 
and presents a new exciting opportunity to perform a study that identifies and 
characterizes the ICL. EB-diol stereoisomers with distinct positions of their hydroxy 
groups are currently being investigated by our group. These can be precursors of the 
unidentified lesion. In addition, an alternative could include the analysis of target proteins 
from nuclear protein extracts of DT40 cells followed by proteomic analysis of DPCs. 
Recent methods have been developed and applied for the isolation and analysis of DPCs 
from BD-epoxide DEB in vitro using HeLa cells (Tretyakova, 2015), however EB-diol 
was not included in their experiments. Additional research will be required to identify the 
possibility of THB-monoadducts as precursors of DNA protein crosslinks (DPC’s) via 
reaction of the unbound trihydroxy group. DPCs are considered bulky adducts, and future 
experiments should consider the in vitro formation of DPC’s using N2-Gua-THB, N7-
Gua-THB and N6-Ade-THB adducts as precursors.  
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